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ABSTRACT 
Dietary polyphenols are non-essential phytonutrients that are extensively metabolized upon 
consumption. Based on our previous studies, we hypothesized that the bioavailability of 
polyphenol metabolites is more important than unmetabolized polyphenols for the health-
promoting effects of polyphenol-rich foods. We tested this hypothesis with three objectives. First 
we developed a more complete polyphenol profile for almond, by characterizing its tannins and 
stilbenes. Tannins and stilbenes are extensively metabolized prior to or upon absorption. In 
almond, hydrolysable tannin content was 54.7 ± 2.3 mg ellagic acid and 27.4 ± 7.3 mg gallic acid 
per 100 g almond among varieties. The stilbene resveratrol-3-O-glucoside was identified in 
almond extracts, with 7.19–8.52 µg/100 g almond. These results suggested that almonds have a 
large pool of polyphenols that would be extensively metabolized in the colon prior to absorption. 
Second, we determined the efficiency by which aronia berry polyphenols are metabolized in an 
acute pharmacokinetic study in humans. In this experiment, polyphenol metabolites constituted 
at least 99% of the total polyphenol pool measured in plasma and urine. Third, we determined 
the association between aronia polyphenol metabolites and changes in key biomarkers of CVD 
risk in an intervention study. Former smokers, which were at greater risk for CVD, consumed 
aronia berry extract for 12 wk. Aronia consumption reduced fasting plasma total cholesterol (TC) 
level by 8% during the 12-week treatment compared with placebo group, and reduced plasma 
LDL-C level by 7% and 11% at both 6 wks and 12 wks compared with placebo group. In 
addition, participants in the aronia group who showed the largest decreases in TC had stronger 
correlations of urinary peonidin-3-O-galactoside and cyanidin-3-O-galactoside than those who 
did not respond to the intervention. These results suggested that increases in polyphenol 
metabolites were more highly correlated with reduced biomarkers of chronic disease than parent 
polyphenols. Thus, this study demonstrated that the cholesterol-lowering activity of polyphenol-
rich foods is associated in-part with its tissue metabolites.    
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Chapter 1: Introduction 
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1.1 Overview 
Increasing polyphenol consumption can improve dyslipidemia, inhibit inflammation, and 
reduce oxidative stress in individuals with increased cardiovascular disease (CVD) risk (Vita 
2005, Rahman, Biswas et al. 2006, Chiva-Blanch, Urpi-Sarda et al. 2012, Annuzzi, Bozzetto et al. 
2014). Polyphenols are extensively metabolized upon consumption, leading to a greater 
proportion of metabolites than parent compounds in tissues and circulation (Manach, Williamson 
et al. 2005). Even minor changes to a polyphenol structure can lead to a significant change in its 
biological activity (Heim, Tagliaferro et al. 2002).  Thus, it is important to determine the 
polyphenol profile of foods and their metabolic fate to explain the mechanisms by which 
polyphenol consumption reduces CVD risk. 
1.2 Central Hypothesis and Specific Aims 
The prevailing approach to determining polyphenol efficacy has been to screen 
polyphenols in vitro (e.g. antioxidant activity, enzyme inhibition) or in cell culture to determine 
it relative potency or mechanism(s) of action. However, this approach may need to be re-
evaluated for many dietary polyphenols. Polyphenols are extensively metabolized (e.g. 
flavonoids, phenolic acids) or have limited bioavailability (e.g. tannins). Thus, the overall 
hypothesis for this study was that the sum of polyphenol metabolites is more responsible than 
polyphenol parental compounds for exerting bioactivity after consumption (Figure 1.1). In order 
to test this hypothesis, we pursued three objectives: 1) characterize the polyphenol profile (e.g. 
metabolic availability) of almonds; 2) define polyphenol pharmacokinetics (e.g. metabolic 
efficiency) of aronia berry polyphenols; 3) determine the extent efficacy is associated with 
metabolism after chronic supplementation of aronia polyphenols.  
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Figure 1.1 The overall thesis hypothesis. 
1.2.1 Objective 1: Characterize the tannin and stilbene composition of 
almonds. 
Almond, among other nuts, is a rich source of dietary polyphenols containing phenolic 
acids, flavonoids, and lignans (Smeds, Eklund et al. 2007, Bolling, Dolnikowski et al. 2010). 
Despite extensive research on almond flavonoids, little is known about its other polyphenols, 
especially tannins and stilbenes. Proanthocyanidins (PACs) may be the most abundant class of 
polyphenols in almonds (Bolling, Chen et al. 2011). The PAC content of foods might be 
underestimated because solvent extraction does not completely liberate polyphenols covalently 
bound to cell walls (Arranz, Saura-Calixto et al. 2009). Flavonoids, phenolic acids, and PACs 
could be released by acid or alkaline hydrolysis from other plant materials (Arranz, Saura-
Calixto et al. 2009, White, Howard et al. 2010). Thus, more work is needed to determine the 
relative proportion of free and bound PACs in almonds. A previous study reported almond 
 4 
 
contained little to no gallotannins and ellagitannins following hydrolysis (Molyneux, Mahoney et al. 
2008). However, this study employed a moderate hydrolysis condition, which might not liberate these 
tannins. Furthermore, the content and distribution of stilbenes in almonds was unknown. Stilbenes have 
been reported to have a cardioprotective potential in in vivo studies (Baur and Sinclair 2006). The 
unknown content of tannins and stilbenes might comprise a potentially large pool of polyphenols that are 
extensively metabolized upon consumption.  
The hypothesis for Objective 1 was that most almond polyphenols are extensively metabolized 
prior to absorption (Figure 1.2). We developed qualitative and quantitative methods to more completely 
characterize almond tannins and stilbenes. Furthermore, we determined the compartmentalization of 
almond stilbenes, as almonds are consumed whole or blanched. Almond genotype also affects polyphenol 
profile (Milbury, Chen et al. 2006, Bolling, Dolnikowski et al. 2010). Thus, we characterized tannins and 
stilbenes in the top three cultivated California almond genotypes. This work is potentially applicable for 
other types of foods that contain a large portion of bound polyphenols. 
 
 
Figure 1.2 Objective 1 hypothesis 
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1.2.2 Objective 2: Determine the pharmacokinetics of aronia berry 
polyphenols and its metabolites. 
Previous studies on the pharmacokinetics of anthocyanin-rich extracts have provided 
limited information about the extent of polyphenol colonic catabolism. Chokeberry (aronia 
berry) is rich in polyphenol antioxidants, such as PACs and anthocyanins (Taheri, Connolly et al. 
2013). PACs and anthocyanins may be extensively metabolized by phase II conjugation 
reactions (e.g. glucuronidation, sulfation, methylation) or catabolized to smaller phenolic 
compounds by gut microbiota. The hypothesis for Objective 2 was that the rate of first-pass 
metabolism and microbiota catabolism creates a larger pool of metabolites than bioavailable 
parent compounds from aronia berry extract in vivo (Figure 1.3). To test this hypothesis, we 
quantitated the major aronia berry polyphenols and metabolites in plasma and urine following 
consumption of aronia berry extract. We then determined pharmacokinetic parameters for 
metabolites and parent compounds.  
 
Figure 1.3 Objective 2 hypothesis 
P 
 
M 
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from	aronia	berry	extract	in	vivo.		
Objec ve	2:	Determine	the	pharmacokine cs	of	aronia	
berry	polyphenols	and	its	metabolites.	
 6 
 
1.2.3 Objective 3: Determine the extent to which polyphenol metabolites are 
associated with changes in plasma cholesterol in former smokers after 12 wk 
of chronic consumption of aronia berry extract. 
Smoking increases CVD risk (Ambrose and Barua 2004). Although smoking cessation may 
curve the risk, CVD risk remains elevated for 10-15 years in former smokers compared with 
never-smokers (Kawachi, Colditz et al. 1993, Iso, Date et al. 2005). Consumption of a 
polyphenol-rich aronia berry extract might be a promising intervention for reducing CVD risk in 
former smokers. Prior human intervention studies indicated aronia berry consumption lowers 
cholesterol and reduces oxidative stress in other populations with increased CVD risk 
(Naruszewicz, Łaniewska et al. 2007, Broncel M 2010). Despite these studies, the compounds 
responsible for these effects remain uncharacterized. 
We hypothesized that following consumption of aronia berry polyphenols, increases in 
polyphenol metabolites will more strongly correlate to reductions in plasma total cholesterol than 
increases in unmetabolized polyphenols. Thus, the metabolites would be more responsible for 
reduction in CVD risk in former smoker than parent compounds.  Protocatechuic acid, a 
principal metabolite of anthocyanins could reduce serum total cholesterol level in diabetic mice 
(Lin, Huang et al. 2009). Protocatechuic acid was suggested to reduce serum total cholesterol 
level by increasing the hepatic LDL receptor, apo E, lecithin-cholesterol acyltransferase and 
hepatic triglyceride lipase expression in rats (Tamura, Fukushima et al. 2004). Thus, our working 
hypothesis for this objective was that plasma and urinary protocatechuic acid will be highly 
correlated to reductions in total cholesterol after aronia berry supplementation. To test this 
hypothesis, we determined metabolites and polyphenols in plasma and urine of former smokers 
consuming aronia berry extract or a placebo. We used the methods developed in Objective 2 to 
determine metabolites of PACs and anthocyanins in urine and plasma of participants consuming 
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aronia berry extract. With these data, we determined the association between metabolites of 
PACs and anthocyanins and biomarkers of lipid metabolism.  
 8 
 
1.3 References 
Ambrose, J. A. and R. S. Barua (2004). "The pathophysiology of cigarette smoking and 
cardiovascular disease: An update." Journal of the American College of Cardiology 43(10): 
1731-1737. 
 
Annuzzi, G., L. Bozzetto, G. Costabile, R. Giacco, A. Mangione, G. Anniballi, M. Vitale, C. 
Vetrani, P. Cipriano, G. Della Corte, F. Pasanisi, G. Riccardi and A. A. Rivellese (2014). "Diets 
naturally rich in polyphenols improve fasting and postprandial dyslipidemia and reduce 
oxidative stress: a randomized controlled trial." The American Journal of Clinical Nutrition 
99(3): 463-471. 
 
Arranz, S., F. Saura-Calixto, S. Shaha and P. A. Kroon (2009). "High Contents of 
Nonextractable Polyphenols in Fruits Suggest That Polyphenol Contents of Plant Foods 
Have Been Underestimated." Journal of Agricultural and Food Chemistry 57(16): 7298-
7303. 
 
Baur, J. A. and D. A. Sinclair (2006). "Therapeutic potential of resveratrol: the in vivo 
evidence." Nat Rev Drug Discov 5(6): 493-506. 
 
Bolling, B. W., C.-Y. O. Chen, D. L. McKay and J. B. Blumberg (2011). "Tree nut 
phytochemicals: composition, antioxidant capacity, bioactivity, impact factors. A systematic 
review of almonds, Brazils, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios 
and walnuts." Nutrition Research Reviews 24(02): 244-275. 
 
Bolling, B. W., G. Dolnikowski, J. B. Blumberg and C. Y. O. Chen (2010). "Polyphenol content 
and antioxidant activity of California almonds depend on cultivar and harvest year." Food 
Chemistry 122(3): 819-825. 
 
Broncel M, K. M., Duchnowicz P, Koter-Michalak M, Sikora J, Chojnowska-Jezierska J (2010). 
"Aronia melanocarpa extract reduces blood pressure, serum endothelin, lipid, and 
oxidative stress marker levels in patients with metabolic syndrome." Med Sci Monit 16(1): 
CR28-34. 
 
Chiva-Blanch, G., M. Urpi-Sarda, R. Llorach, M. Rotches-Ribalta, M. Guillén, R. Casas, S. 
Arranz, P. Valderas-Martinez, O. Portoles, D. Corella, F. Tinahones, R. M. Lamuela-Raventos, 
C. Andres-Lacueva and R. Estruch (2012). "Differential effects of polyphenols and alcohol of 
red wine on the expression of adhesion molecules and inflammatory cytokines related to 
atherosclerosis: a randomized clinical trial." The American Journal of Clinical Nutrition 
95(2): 326-334. 
 
Heim, K. E., A. R. Tagliaferro and D. J. Bobilya (2002). "Flavonoid antioxidants: chemistry, 
metabolism and structure-activity relationships." The Journal of Nutritional Biochemistry 
13(10): 572-584. 
 9 
 
 
Iso, H., C. Date, A. Yamamoto, H. Toyoshima, Y. Watanabe, S. Kikuchi, A. Koizumi, Y. Wada, T. 
Kondo, Y. Inaba, A. Tamakoshi and t. J. S. Group (2005). "Smoking Cessation and Mortality 
from Cardiovascular Disease among Japanese Men and Women: The JACC Study." American 
Journal of Epidemiology 161(2): 170-179. 
 
Kawachi, I., G. A. Colditz, M. J. Stampfer, W. C. Willett, J. E. Manson, B. Rosner, D. J. Hunter, C. 
H. Hennekens and F. E. Speizer (1993). "Smoking Cessation in Relation to Total Mortality 
Rates in Women: A Prospective Cohort Study." Annals of Internal Medicine 119(10): 992-
1000. 
 
Lin, C.-Y., C.-S. Huang, C.-Y. Huang and M.-C. Yin (2009). "Anticoagulatory, 
Antiinflammatory, and Antioxidative Effects of Protocatechuic Acid in Diabetic Mice." 
Journal of Agricultural and Food Chemistry 57(15): 6661-6667. 
 
Manach, C., G. Williamson, C. Morand, A. Scalbert and C. Rémésy (2005). "Bioavailability and 
bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies." The American 
Journal of Clinical Nutrition 81(1): 230S-242S. 
 
Milbury, P. E., C.-Y. Chen, G. G. Dolnikowski and J. B. Blumberg (2006). "Determination of 
Flavonoids and Phenolics and Their Distribution in Almonds." Journal of Agricultural and 
Food Chemistry 54(14): 5027-5033. 
 
Molyneux, R., N. Mahoney, J. H. Kim and B. Campbell (2008). "Bioassay-directed isolation 
and identification of antiaflatoxigenic constituents of walnuts." Bioactive natural products: 
detection, isolation, and structural determination/edited by Steven M. Colegate, Russell J. 
Molyneux. 
 
Naruszewicz, M., I. Łaniewska, B. Millo and M. Dłużniewski (2007). "Combination therapy of 
statin with flavonoids rich extract from chokeberry fruits enhanced reduction in 
cardiovascular risk markers in patients after myocardial infraction (MI)." Atherosclerosis 
194(2): e179-e184. 
 
Rahman, I., S. K. Biswas and P. A. Kirkham (2006). "Regulation of inflammation and redox 
signaling by dietary polyphenols." Biochemical Pharmacology 72(11): 1439-1452. 
 
Smeds, A. I., P. C. Eklund, R. E. Sjöholm, S. M. Willför, S. Nishibe, T. Deyama and B. R. 
Holmbom (2007). "Quantification of a Broad Spectrum of Lignans in Cereals, Oilseeds, and 
Nuts." Journal of Agricultural and Food Chemistry 55(4): 1337-1346. 
 
Taheri, R., B. A. Connolly, M. H. Brand and B. W. Bolling (2013). "Underutilized Chokeberry 
(Aronia melanocarpa, Aronia arbutifolia, Aronia prunifolia) Accessions Are Rich Sources of 
Anthocyanins, Flavonoids, Hydroxycinnamic Acids, and Proanthocyanidins." Journal of 
Agricultural and Food Chemistry 61(36): 8581-8588. 
 
 10 
 
Tamura, A., M. Fukushima, K.-i. Shimada, K.-H. Han, M. Sekikawa, S. Watanabe, M. Nakano, 
M. Matsumoto, H. Chiji, O. U. o. A. Department of Animal Science, M. Veterinary and H. J. 
Obihiro (2004). "Cholesterol metabolism in rat is affected by protocatechuic acid." Journal 
of nutritional science and vitaminology 50(1): 13-18. 
 
Vita, J. A. (2005). "Polyphenols and cardiovascular disease: effects on endothelial and 
platelet function." The American Journal of Clinical Nutrition 81(1): 292S-297S. 
 
White, B. L., L. R. Howard and R. L. Prior (2010). "Release of Bound Procyanidins from 
Cranberry Pomace by Alkaline Hydrolysis." Journal of Agricultural and Food Chemistry 
58(13): 7572-7579. 
 
 
 11 
 
Chapter 2: Literature Review 
 
 
 
 
 
 
 
 12 
 
2.1 Introduction 
Polyphenols are a class of organic compounds characterized by phenol structural units. 
Polyphenols are abundant in tea, fruits, vegetables, and grains. Increased polyphenol 
consumption may reduce chronic inflammation, improve antioxidant defenses, modulate lipid 
metabolism, and inhibit cell-signaling pathways. Epidemiological and intervention studies have 
associated increased consumption of polyphenol-rich foods or beverages with lower risk of 
chronic disease, such as cancer, cardiovascular diseases (CVD), Alzheimer's, diabetes and 
metabolic syndrome. Polyphenol bioactivity is limited by their absorption, distribution, 
metabolism and excretion (ADME). In this chapter, dietary polyphenols and their ADME will be 
presented with a focus on linking these to their putative ability to reduce biomarkers of CVD 
risk.  
2.2 Polyphenol variety and consumption 
More than 8000 naturally occurring polyphenols have been identified, many which are 
present in foods. The main classes of dietary polyphenols include phenolic acids, flavonoids, 
stilbenes, lignans, and tannins, among others (Figure 2.1). Phenolic acids can be divided into 
hydroxybenzoic acids and hydroxycinnamic acids. Flavonoids can be divided into 6 classes, 
which are anthocyanins, flavonols, flavones, flavanones, isoflavones, and flavan-3-ols. Tannins 
include both hydrolysable and condensed tannins which are also known as proanthocyanidins 
(PACs).  
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Figure 2.1 Chemical structure of representative polyphenol.  
 
Dietary polyphenols are widely distributed in plant foods, such as fruits and vegetables, and 
beverages, such as coffee and tea (Table 2.1). For example, black chokeberry ranks 2 of the top 
100 polyphenol rich food per serving, and almonds ranks 62 (Perez-Jimenez, Neveu et al. 2010). 
The average intake of total polyphenols in the adult diet is ~1 g/day (Table 2.2) (Hertog, 
Hollman et al. 1993, Kimira M 1998, Kirk, Patterson et al. 1999, Wu, Beecher et al. 2006, Chun, 
Chung et al. 2007, Ovaskainen, Törrönen et al. 2008, Wang, Chung et al. 2011, McCullough, 
Peterson et al. 2012). Phenolic acids may be the most abundant dietary polyphenols (Table 2.2). 
Flavonoids, are second largest contributor to polyphenol intake followed by condensed tannins, 
hydrolyzable tannins and lignans. Among flavonoids, flavones and isoflavones contribute the 
least to daily polyphenol intake in western diets. The quantity of polyphenol consumption in 
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Table 2.2 is estimated based on the polyphenols reported in fruits and vegetables, which include 
non-extractable and non-digestible polyphenols. For example, among the total of 95 mg/day 
condensed tannins intake, only monomers (22%) and dimers (16%) are absorbed (Wang, Chung 
et al. 2011). Thus, the amount of total polyphenols absorbed after consumption is likely less than 
the estimated intake. A significant portion of unabsorbed metabolites would be catabolized by 
gut microbiota. Dietary polyphenol intake is also influenced by cultural dietary habits. For 
example, Japanese have the largest consumption of isoflavones, 40 mg/day, because soy food 
products are more popular in Japan than in western countries (Kimira M 1998).  
 
Table 2.1 Main classes of dietary polyphenols and their sources (Manach, Scalbert et al. 2004). 
Classes Subclass Food sources 
Phenolic acids Derivatives of benzoic acid red fruits, black radish, onions, and tea 
Derivatives of cinnamic acid most fruits, coffee, cereals, and grains 
Flavonoids Anthocyanins fruits, red wine, certain cereal, and certain leafy and 
root vegetables 
Flavonols most foods and beverages 
Flavones parsley, celery, and citrus 
Flavanones tomatoes, aromatic plants, and citrus 
Isoflavones leguminous plants and products 
Flavan-3-ols many types of fruits, red wine, tea, and chocolates 
Stilbenes  wine, nuts, certain fruits 
Lignans  certain cereal, grains, fruits and vegetables 
Tannins Hydrolyzable tannins red fruits 
Condensed tannins astringent fruits and beverages, and chocolates 
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Table 2.2 Estimates of dietary polyphenol intake (Hertog, Hollman et al. 1993, Kimira M 1998, 
Kirk, Patterson et al. 1999, Wu, Beecher et al. 2006, Chun, Chung et al. 2007, Ovaskainen, 
Törrönen et al. 2008, Wang, Chung et al. 2011, McCullough, Peterson et al. 2012). 
Classes Subclass Intake (Country) 
Phenolic acids Derivatives of benzoic acid 33 mg/day (Finnish)1 
Derivatives of cinnamic acid 608 mg/day (Finnish) 
Total 23 mg/day (Netherland) 
6-987 mg/day (Germany) 
641 mg/day (Finnish) 
Flavonoids Anthocyanins 47 mg/day (Finnish) 
12.5 mg/day (USA) 
3.8-22.2 mg/day (USA) 
Flavonols 5.4 mg/day (Finnish) 
21 mg/day (Netherland) 
6.9-27.2 mg/day (USA) 
Flavones 2 mg/day (Netherland) 
0.4-3.0 mg/day (USA) 
Flavanones 27 mg/day (Finnish) 
3.5-49.9 mg/day (USA) 
Isoflavones 0.9 mg/day (Finnish) 
0.024-0.713 mg/day (USA) 
Flavan-3-ols 7.0-63.7  mg/day (USA) 
Total 189.7 mg/day (USA) 
94.5-512.5 mg/day (USA) 
Stilbenes -- -- 
Lignans -- 0.9 mg/day (Finnish) 
Tannins Hydrolyzable tannins 12 mg/day (Finnish) 
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Condensed tannins 
(≥2 degree of polymerization) 
74 mg/day (USA) 
53.1-379.4 mg/day (USA) 
Total -- 863 mg/day (Finnish) 
1 g/day (USA) 
1
The results are presented as average daily intake or range of the daily intake 
 
2.3 Polyphenol absorption 
The absorption of polyphenols occurs in two major locations, the small intestine and colon. 
The small intestine mainly absorbs polyphenol aglycones or glycosides with low-molecular-
weights (<800 Daltons) (e.g. anthocyanins, phenolic acids, and flavonoids) through passive 
transport or active transport (Tamai, Sai et al. 1999, Day, Cañada et al. 2000, Kay 2006, Crozier, 
Del Rio et al. 2010). In the colon, gut microbes catabolize unabsorbed small (e.g. curcumin) and 
large molecular-weight polyphenols (e.g. proanthocyanidins, ellagitannins and flavonoid 
rutinosides) into simple phenolics (Rios, Gonthier et al. 2003, Crozier, Del Rio et al. 2010, 
González-Barrio, Edwards et al. 2011). A portion of quercetin, anthocyanins and phenolic acid 
may also be absorbed through stomach, although this pathway has been poorly characterized 
(Crespy, Morand et al. 2002, Konishi, Zhao et al. 2006, Fernandes, de Freitas et al. 2012).  
In the small intestine, polyphenol glycosides can be transported from the lumen by 
sodium–glucose co-transporters (SGLT) into small intestine cells, remaining intact (Figure 2.2) 
(Day, Cañada et al. 2000, Kay 2006). Alternatively, polyphenol glycosides can be hydrolyzed at 
the brush-border of the small intestine epithelial cells, and the aglycone transported to the small 
intestine cell. Once inside small intestine epithelial cells, polyphenol glycosides are 
transpoported to the portal circulation or hydrolyzed by broad-specificity cytosolic β-glucosidase 
(CBG) within the epithelial cell to the polyphenol aglycone (Németh, Plumb et al. 2003). Then, 
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polyphenol aglycones are glucuronidated, methylated or sulfated by phase II enzymes, such as 
UDP-glucuronosyltransferase (UDP-GT), catechol-O-methyltransferase (COMT), or 
sulfotransferase (SULT), and transported into the portal circulation. For other low-molecular-
weight polyphenols, such as flavan-3-ol, are transported into the small intestine epithelial cells 
intact by active transport, subjected to phase II metabolism, and then transported into portal 
circulation (Kuhnle, Spencer et al. 2000, Spencer 2003, Crozier, Del Rio et al. 2010). Phenolic 
acids can be absorbed into the small intestine epithial cells through the monocarboxylic acid 
transporter (MCT) by active transport (Tamai, Sai et al. 1999). 
 
 
Figure 2.2 Potential mechanisms of polyphenol glycoside absorption in small intestine. 
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High-molecular-weight polyphenols or substituted with irregular glycosides (e.g. 
rutinosides, quinic acid) cannot be absorbed intact and may be catabolized before absorption. 
Proanthocyanidins are oligomers or larger polymers of flavan-3-ols. Previous studies have 
suggested that proanthocyanidin oligomers having degrees of polymerization ≤ 4 can be rapidly 
absorbed across differentiated Caco-2 cells, a model of intestinal absorption (Deprez, Mila et al. 
2001, Ou, Percival et al. 2012). In the colon, proanthocyanidins with degrees of polymerization 
> 4  are degraded by microbes into low-molecular-weight phenolic acid compounds, and 
subsequently absorbed into the large intestine cells (Déprez, Brezillon et al. 2000, Ou and Gu 
2013). Human colonic MCT may be largely responsible for microbial-derived phenolic acid 
absorption  (Iwanaga, Takebe et al. 2006). The major proanthocyanidin metabolites observed in 
human urine or plasma after consumption are 3-(3’-hydroxyphenyl) propionic acid, 3’-
hydroxyphenylacetic acid, 3’,4’-hydroxyphenylacetic acid, 3-hydroxybenzoic acid, hippuric acid, 
ferulic acid and phenolic acid (Rios, Gonthier et al. 2003, Urpi-Sarda, Monagas et al. 2009).  
Ellagitannins are glucose-bound hexahydroxydiphenic acids. In the colon, ellagitannins are 
catabolized by colonic microflora to ellagic acid (González-Barrio, Edwards et al. 2011). 
Subsequently, ellagic acids are transformed to urolithins by microbes and then aborbed into large 
interstine cells.  
The stomach also has a limited role in absoption of dietary polyphenols. Low molecular 
weight aglycone compounds, such as quercetin or phenolic acid, can be absorbed directly by 
gastric cells (McCullough, Peterson et al. 2012). Quercetin, but not quercetin-glycoside was 
absorbed across the gastric lining of rats with ligated sphincters  to prevent gastro-esophagus 
reflux (Crespy, Morand et al. 2002). Similary, quercetin can quickly appear (15 min) in human 
plasma after consumption, suggesting stomach absorption  (Kaushik, O’Fallon et al. 2012). 
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However, the transporters responsible for gastric polyphenol absorption are not well-defined. 
Tamai, et al. suggested that stomach MCT might contribute to the gastric absorption of phenolic 
acids in rats, similar to the small intestinal mechanism (Crespy, Morand et al. 2002). However, 
MCT has not yet been reported in the human stomach. Further, it is unknown if pheolic acids can 
be absorbed through the human stomach. The earliest appearance of phenolic acids in human 
plasma is 1 h after consumption, which suggests this is plausible (Caccetta, Croft et al. 2000).  
In contrast to other polyphenols, glycosylated anthocyanidins (e.g. anthocyanins) can be 
absorbed by the human stomach. Anthocyanins are absorbed intact by human cultured stomach 
cells in a time dependent manner, likely via a saturable transport mechanism (Fernandes, de 
Freitas et al. 2012). Passamonti, et al proposed that bilitranslocase could transport anthocyanins 
across gastric epithelial cells (Passamonti, Vrhovsek et al. 2002). In this study, the anthocyanin-
bilitranslocase interactions were modeled using rat plasma membrane vesicles. Anthocyanins, 
including cyanidin-3-glucoside, behaved as competitive inhibitors of bilitranslocase transport 
activity, which suggested anthocyanins have high affinities for bilitranslocase. Similar results 
were also reported by using human plasma membrane vesicles (Ziberna, Tramer et al. 2012). 
However, bilitranslocase has only been characterized in the rat stomach (Battiston, Macagno et 
al. 1999), and not been confirmed in the human stomach. Previous study indicated that cyanidin-
3-glucoside can be detected by 30 min in human plasma after consumption (Miyazawa, 
Nakagawa et al. 1999). Thus, a limited number of low molecular-weight polyphenols including 
anthocyanins and aglycone phenolic acids or flavonols may be absorbed through the human 
stomach.   
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2.4 Polyphenol distribution  
After absorption from the gastrointestinal tract, polyphenols are transported to the liver 
through portal circulation (Figure 2.3), then distributed to tissues or excreted out of the body 
(Scalbert, Morand et al. 2002). Polyphenols have been detected in the blood, urine, feces, and 
tissue in vivo (Morton, Chan et al. 1997, Pan, Huang et al. 1999, Zhao and Agarwal 1999, Hong, 
Kim et al. 2002, Maubach, Bracke et al. 2003, de Boer, Dihal et al. 2005, Garcea, Berry et al. 
2005, Hoh, Boocock et al. 2006, Czank, Cassidy et al. 2013). Isoflavones and lignans have been 
detected in human urine, plasma, prostate gland and breast tissue (Morton, Chan et al. 1997, 
Hong, Kim et al. 2002, Maubach, Bracke et al. 2003). Curcumin and its metabolites, curcumin 
sulfate and curcumin glucuronide, were detected in the colorectal tissue of colorectal cancer 
patients supplemented with 450 to 3600 mg curcumin daily for 7 days (Garcea, Berry et al. 2005). 
Silibinin, a flavonolignan from milk thistle, was detected in plasma, colorectal tissue and liver 
tissue of patients with colorectal adenocarcinoma receiving silibinin at dosages of 360, 720, or 
1,440 mg silibinin daily for 7 days (Hoh, Boocock et al. 2006). Resveratrol and resveratrol-3-O-
glucuronide were also recovered from colorectal tissue in colorectal cancer patients consuming 
supplemental resveratrol (Patel, Brown et al. 2010). In animals, polyphenols can be found in 
heart, brain, skin, lung, prostate, pancreas, liver, intestine, spleen, kidney and adipose tissues, 
which suggest polyphenol may be transported to a broad range of tissues (Pan, Huang et al. 
1999, Zhao and Agarwal 1999, de Boer, Dihal et al. 2005, Suresh and Srinivasan 2010).  
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Figure 2.3 Pathway of polyphenol distribution (Scalbert, Morand et al. 2002). 
2.5 Polyphenol metabolism 
Polyphenols are extensively metabolized after absorption. For example, 70% to 80% of a 
single cyanidin-3-glucoside dose was recovered as metabolites after consumption (Czank, 
Cassidy et al. 2013). The human intestine and liver are the two major sites of polyphenol 
metabolism, although other tissues may also contribute to this process. In the small intestine, 
lactase phlorizin hydrolase (LPH) at the brush-border can hydrolyze polyphenol β-glycosides of 
glucose, arabinose, and galactose to its aglycone form. Inside small intestine epithelial cells, 
polyphenol β-glycosides can be hydrolyzed to aglycones by CBG. Subsequently, polyphenol 
aglycone hydroxyl groups can be sulfated, methylated, and/or glucuronidated by UDP-GT, 
COMT, and/or SULT.  
In the liver, polyphenols can be metabolized by both phase I and II enzymes. Phase I 
enzymes are a family of cytochrome P450 monooxygenases (CYPs) that catalyze oxidation, 
reduction, hydroxylation or demethylation reactions (Hodek, Trefil et al. 2002). For example, 
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galangin and kaempferide are oxidized to kaempferol by both CYP1A2 and CYP2C9 by human 
liver microsomes (Otake and Walle 2002). Isoflavones, curcumin, and hesperetin are also readily 
metabolized by phase I enzymes (Kulling, Honig et al. 2001, Duarte Silva, Rodrigues et al. 1997, 
Silva, Rodrigues et al. 1997, Ireson, Orr et al. 2001, Ireson, Jones et al. 2002, Garcea, Jones et al. 
2004, Roberts-Kirchhoff, Crowley et al. 1999, Doostdar, Burke et al. 2000). The phase I 
isoflavone metabolites, 6,7,4’-trihydroxyisoflavone, 7,3’,4’-trihydroxyisoflavone, 7,8,4’-
trihydroxyisoflavone, 7,8,3’,4’-tetrahydroxyisoflavone, and 6,7,3’,4’-tetrahydroxyisoflavone, 
were present in the urine of human consumed ~70 mg of soy isoflavones (Kulling, Honig et al. 
2001).  
Polyphenols and/or their phase I metabolites can be further metabolized by hepatic phase II 
glucuronidation, sulfation, and/or methylation. Curcumin glucuronides and sulftates were 
identified from a human hepatocyte suspension from livers of patients with hepatic metastases 
(Ireson, Orr et al. 2001, Ireson, Jones et al. 2002, Garcea, Jones et al. 2004). Anthocyanins are 
primarily methylated or glucuronidated after consumption (Wu, Cao et al. 2002, Czank, Cassidy 
et al. 2013).  
Other tissues have phase I and II enzymes, and potential capacity for polyphenol 
metabolism. Rat kidney microsomes have ethoxyresorufin-O-deethylase (EROD), 
methoxyresorufin-O-demethylase (MROD), p-nitrophenol hydroxylase (PNPH), glutathione S-
transferase (GST), UDP-glucuronosyltransferase (UDP-GT) and NAD(P)H:quinone 
oxidoreductase (NQO1) activity (Krajka-Kuźniak and Baer-Dubowska 2003). The extent to 
which non-hepatic and GI tissue contribute to polyphenol metabolism is an ongoing area of 
interest. 
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2.6 Polyphenol excretion 
Polyphenols and their metabolites are mainly excreted through breath, urine or feces 
(Scalbert, Morand et al. 2002, Czank, Cassidy et al. 2013). Fecal polyphenols include absorbed 
polyphenols secreted back to the intestine from bile and unabsorbed dietary polyphenols 
(Scalbert, Morand et al. 2002). In healthy subjects that ingested a single dose of 500 mg 13C 
cyanidin-3-O-glucoside, 13C cyanidin-3-O-glucoside and 13C cyanidin-3-O-glucoside metabolites 
were found in the feces, which suggested unabsorbed cyanidin-3-O-glucoside remain intact 
through the feces (Czank, Cassidy et al. 2013). A fraction of polyphenols is excreted in bile. 
After infusion of 14C genistein into the duodenum of rats for 1 h, cumulative 14C genistein as its 
7-O-β-glucuronide conjugate was found in the bile (Sfakianos, Coward et al. 1997). Many 
polyphenols have enterohepatic recirculation, including isoflavones (Setchell, Brown et al. 2001, 
Zubik and Meydani 2003). Many transport proteins contribute to polyphenol excretion. In the 
small intestine, ATP-binding cassette (ABC) transporters contribute to polyphenol efflux 
(Vaidyanathan and Walle 2003, Juan, González-Pons et al. 2010). For example, (-)-epicatechin-
3-gallate (ECG) is transported by multidrug-associated protein 1 (MRP1, ABCC1), multidrug-
associated protein 2 (MPR2, ABCC2), and P-glycoprotein (ABCB1) (Vaidyanathan and Walle 
2003). MRP1 and MRP2, but not P-glycoprotein contribute to EGCG efflux (Hong, Lambert et 
al. 2003). In addition, MRP2 and breast cancer resistance protein (BCRP, ABCG2) have been 
associated with the efflux of trans-resveratrol glucuronide and trans-resveratrol sulfate (Juan, 
González-Pons et al. 2010). However, P-glycoprotein does not efflux of trans-resveratrol and its 
conjugates. The fraction of polyphenols excreted varies by route. In a tracer study, 5.37 ± 0.67% 
of the 13C of cyanidin-3-glucoside was excreted through urine, 6.91 ±  1.59% was excreted 
through breath, and 32.13 ± 6.3% was excreted through feces (Czank, Cassidy et al. 2013). In 
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the breath, 13C was present as CO2. In the urine, 
13C was present as cyanidin-3-glucoside (11%) 
and its metabolites (89%). 
2.7 Polyphenols and CVD Risk 
Epidemiological studies, animal studies and human intervention studies suggest that 
polyphenol consumption may reduce CVD risk (Arts and Hollman 2005, Chong, Macdonald et 
al. 2010). According to WHO, CVD is defined as a group of disorders of the heart and blood 
vessels, which include coronary heart disease, cerebrovascular disease, peripheral arterial 
disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis and pulmonary 
embolism (WHO 2015). In 2012, CVD led to about 17.5 million deaths globally, and was the 
primary cause of non-communicable disease deaths world world-wide (WHO 2014). 
Atherosclerosis is the major cause of CVD. Endothelial dysfunction is a characteristic feature 
throughout the pathogenesis of atherosclerosis, and it is an independent predictor for future 
cardiovascular risk (Gonzalez and Selwyn 2003). Endothelial dysfunction is initiated by plaque 
formation (Libby, Ridker et al. 2002). At the beginning of plaque formation, low-density 
lipoprotein (LDL) penetrates into the intima, binds to the proteoglycan matrix, and undergoes 
oxidative modification to form oxidized LDL (ox-LDL) (Berliner J 1997). Monocytes and 
macrophages then will uptake ox-LDL and develop into foam cells, which leads to intimal 
thickening, plaque formation, and vessel narrowing (Gonzalez and Selwyn 2003). Cytokines and 
growth factors secreted by activated monocytes, macrophages, endothelial cells and T cells can 
promote the migration and proliferation of smooth muscle cells (SMCs). SMC enzymes can 
digest the arterial extracellular matrix by hydrolyzing elastin and collagen (Libby, Ridker et al. 
2002). The degradation of the arterial extracellular matrix permits the penetration of the SMCs 
and a fibrous cap develops to cover the plaque (Libby, Ridker et al. 2002). Subsequently, 
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thrombosis is triggered as a result of increased accumulation of lipid and foam cells, and fibrous 
cap rupture leads to infarction (Fuster V 1990).  
During the pathogenesis of atherosclerosis, ox-LDL can activate nuclear factor-κB (NF-κB) 
in monocyte and macrophage (Brand, Eisele et al. 1997). NF-κB activation promotes the 
endothelial cell monolayer to secret adhesion molecules, such as L-selectin, vascular cell 
adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) (Takei, Huang 
et al. 2001). NF-κB activation can also induce migration of blood monocytes, macrophages, 
dendritic cells, T cells and some B-cells into the intima (Frostegård, Nilsson et al. 1990, J A 
Berliner 1990, Frostegård, Wu et al. 1992, Atout R 2012). NF-κB can also active the expression 
of pro-inflammatory cytokines and growth factors (Hoesel and Schmid 2013). Pro-inflammatory 
cytokines and growth factors, such as IL-1, IL-6, monocyte chemotactic protein-1 (MCP-1) and 
tumor necrosis factor-α (TNF-α) accelerate atherosclerosis. For example, IL-6 can stimulate the 
liver to produce C-reactive protein (CRP) which can further stimulate inflammation (Saito, 
Ishimitsu et al. 2003). Patients with CVD have increased plasma levels of VCAM–1, ICAM–1, 
IL-6, oxidative stress, NF-κB, and CRP (Gonzalez and Selwyn 2003). Thus, the pathogenesis of 
CVD is partially a consequence of chronic cardiovascular inflammation.  
Free radicals also contribute to the pathogenesis of atherosclerosis. Nitric oxide (NO) is 
synthesized by the endothelial nitric oxide synthase (eNOS), which is important for maintaining 
vasodilation (Cannon 1998). Ox-LDL and reactive oxygen species stimulate the expression of 
inducible nitric oxide synthase (iNOS) in aortic endothelial cells (Hirata, Miki et al. 1995, Cai 
and Harrison 2000). iNOS overproduction promotes the formation and activation of peroxynitrite 
(Buttery LD 1996). Peroxynitrite can down-regulate the eNOS production, ultimately reducing 
endothelial NO (Buttery LD 1996).  
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Furthermore, oxidative stress and inflammation activate protein kinase intracellular 
signaling molecules such as extracellular signal-regulated kinases (ERK), jun amino-terminal 
kinases (JNK) and p38 mitogen-activated protein kinases (MAPKs) (González-Gallego, 
Sánchez-Campos et al. 2007) (Figure 2.4). These will activate Nrf2 and NF-κB, key 
transcription factors modulating antioxidant and inflammatory responses. Activated protein 
kinase intracellular signaling molecules disrupt the bonding between Nrf2 and keap1, leading to 
nuclear translocation of Nrf2. In the nucleus, Nrf2 binds to the specific DNA sequence 
(antioxidant response element, ARE) in the upstream promoter region of many antioxidative 
genes, such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-
Px), and initiates their transcription and expression. While in an inactivated state, NF-κB is 
located in the cytosol complexed with the inhibitory protein IκBα. Activated protein kinase 
intracellular signaling molecules can activate the enzyme IκB kinase (IKK). IKK, in turn, 
phosphorylates the IκBα protein, which results in dissociation of IκBα from NF-κB. The 
activated NF-κB is then translocated into the nucleus where it binds to specific sequences of 
DNA (response elements, RE) and initiate transcription and expression of gene coding 
cyclooxygenase (COX-2), iNOS, CRP, cytokines and adhesion molecules, which increase 
inflammation.  
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Figure 2.4 The mechanism of polyphenol against CVD in mRNA level (González-Gallego, 
Sánchez-Campos et al. 2007) 
 
Previous observational cohort studies and clinical trial suggested diet rich in polyphenols, 
such as anthocyanins and proanthocyanidins, could prevent the risk of CVD (Rasmussen, 
Frederiksen et al. 2005, Wallace 2011, Estruch, Ros et al. 2013). 
2.7.1 Anthocyanins 
Preventing chronic inflammation is a promising approach to reduce CVD risk. During the 
pathogenesis of atherosclerosis, NF-κB was responsible for initiating the inflammatory response 
(Brand, Eisele et al. 1997). Deactivation of NF-κB could suppress the expression of pro-
inflammatory chemokines, growth factors, and adhesion molecules in the treatment of 
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inflammatory and chronic disease (Yamamoto and Gaynor 2001). In in vitro studies, 
anthocyanins were observed to directly inhibit the LPS-induced NF-κB transactivation in human 
monocytes (Karlsen, Retterstøl et al. 2007). In human studies, reduced plasma level of NF-κB 
and IL-8 were found in human subjects with anthocyanins-rich red wine intake (Blanco-Colio, 
Valderrama et al. 2000). It has been suggested that ox-LDL can stimulate CD40 production 
through the function of lipoprotein receptor-1 (LOX-1), a major receptor of ox-LDL (Li, Liu et 
al. 2003). Up-regulation of CD40 was associated with the pathogenesis of atherosclerosis (Mach, 
Schonbeck et al. 1998, Lutgens, Cleutjens et al. 2000, Schönbeck, Sukhova et al. 2000). The 
function of CD40 was to activate NF-κB and induce the release of pro-inflammatory chemokines 
and cytokines through up-regulating the expression of TNF receptor-associated factor 2 (TRAF-
2). TRAF-2 could induce the distribution of cholesterol in lipid rafts of membrane in endothelial 
cells. Anthocyanin could reduce CD40-mediated activation of NF-κB by disrupting the function 
of TRAF-2 in human endothelial cells. (Xia, Ling et al. 2007).  
Activated monocytes, macrophages, endothelial cells and T cells could secrete cytokines 
and growth factors, such as IL-1, IL-6, MCP-1 and TNF-α. The secretion of cytokines and 
growth factors may increase the inflammatory response in the pathogenesis of atherosclerosis 
(Libby, Ridker et al. 2002). MCP-1 was secreted by activated macrophages and endothelial cells. 
MCP-1 overproduction can induce macrophages to form plaque. Anthocyanins have the capacity 
to inhibit the production of MCP-1 induced by TNF-α. In an in vitro study, TNF-α-mediated 
MCP-1 production by primary human endothelial cells was inhibited by anthocyanin treatment 
(García-Alonso, Rimbach et al. 2004). Anthocyanin-rich blueberry and cranberry extracts can 
reduce the levels of IL-8, MCP-1 and ICAM-1 induced by TNF-α when applied to human 
endothelial cells (Youdim, McDonald et al. 2002). In healthy humans, plasma MCP-1 was 
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reduced by a single 12 g dose of red wine anthocyanins (Garcia-Alonso, Minihane et al. 2009). 
Red-wine consumption also reduced MCP-1 in high cholesterol-fed rabbits (Feng, Chen et al. 
1999). Anthocyanins can also down-regulate TNF-α expression directly in other in vivo CVD 
models  (Mao, van de Water et al. 2002, Kim, Tsoy et al. 2006).  
Anthocyanins can also inhibit the production of adhesion molecules and CRP which 
stimulate the inflammatory response during the pathogenesis of atherosclerosis (Takei, Huang et 
al. 2001, Saito, Ishimitsu et al. 2003). TNF-α increased human umbilical vein endothelial ICAM-
1 and VCAM-1 expression and increased nuclear GATA-4, GATA-6, and IRF-1 level 
(Nizamutdinova, Kim et al. 2009). Pretreatment of endothelial cells with anthocyanins inhibited 
VCAM-1, GATA-4, GATA-6 and IRF-1 expression, but not ICAM-1 expression. Also, 
pretreatment of cells with a specific Jak/STAT inhibitor elicited a similar response, suggesting 
anthocyanins reduce inflammation by down-regulating the adhesion molecules activated by 
Jak/STAT pathway. Anthocyanins can also inhibit expression of CD40-mediated adhesion 
molecules. Pretreatment of endothelial cells with CD40 ligand (CD40L) significantly increased 
cellular VCAM-1 and ICAM-1 (Xia, Ling et al. 2009). However, pretreatment of endothelial 
cells with anthocyanins inhibited the production of VCAM-1 and ICAM-1 (Xia, Ling et al. 
2009). According to previous observational cohort studies, serum CRP was significantly 
inversely associated with anthocyanin intakes by adults in the U.S. (Chun, Chung et al. 2008). In 
a clinical trial, consumption of anthocyanin-rich cherries in healthy people reduced plasma CRP 
level but not plasma IL-6 level after 4 weeks (Kelley, Rasooly et al. 2006). Thus, anthocyanins 
might reduce the inflammatory level during the pathogenesis of CVD by inhibition the 
production of adhesion molecules and CRP.  
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SMCs are activated by inflammatory mediators, which stimulate the production of matrix 
metalloproteinase (MMP) which can hydrolyze the extracellular matrix during atherosclerosis 
(Libby, Ridker et al. 2002). Direct application of anthocyanins reduces CD40L-mediated MMP-1 
and MMP-9 expression in human endothelial cells (Xia, Ling et al. 2009). Vascular endothelial 
growth factor (VEGF), a pro-atherosclerotic factor, is increased in SMCs during CVD 
development. Anthocyanins also inhibit VEGF release in vascular SMCs by inhibiting p38-
MAPK and JNK pathways (Oak, Bedoui et al. 2006).  
Thus, anthocyanins might prevent the CVD risk by reducing chronic inflammation in the 
vascular system. The anti-inflammatory mechanisms involve inhibiting the initiation of 
inflammatory response and inflammation-induced extracellular matrix break down. 
Anthocyanins may also reduce CVD risk through antioxidant mechanisms. NO is a key 
molecule in the pathogenesis of CVD, because it has anti-hypertension, anti-thrombosis, anti-
atherosclerosis, and anti-smooth muscle proliferation functions (Förstermann and Sessa 2012). 
Anthocyanins increase NO and improve endothelial function in models of CVD. Aronia and 
bilberry anthocyanins increased NO-mediated vasorelaxation when applied to pig coronary 
artery endothelial cells (Bell and Gochenaur 2006). Black currant concentrate also had a 
vasorelaxing effect when applied to rat coronary artery endothelial cells, which was specific to 
NO (Nakamura, Matsumoto et al. 2002). Delphinidin, but not malvidin or cyanidin, improved 
endothelium-dependent vasorelaxation in the rat artery endothelial cells (Andriambeloson, 
Magnier et al. 1998). In contrast, cyanidin inducing eNOS expression and NO production via a 
Src-ERK1/2-Sp1 signaling pathway in bovine artery endothelial cells (Xu, Ikeda et al. 2004). 
Thus, the ability of anthocyanins to mediate NO pathways appear to depend on its chemical 
structure. Anthocyanins also modulate NO in vivo. Healthy rat fed wild blueberries had better 
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endothelium-dependent vasorelaxation in the arterial endothelium after 7 weeks (Kalea, Clark et 
al. 2009).   
Anthocyanin consumption can also increase serum antioxidant capacity. Following 
consumption of 12 g of anthocyanins from freeze-dried blueberries, a serum anthocyanins and ex 
vivo antioxidant capacity were correlated (Mazza, Kay et al. 2002). Previous studies have 
suggested that anthocyanin consumption may indirectly increase antioxidant function (Youdim, 
McDonald et al. 2002, Acquaviva, Russo et al. 2003, Broncel M 2010). Adults with metabolic 
syndrome that consumed aronia extract had reduced CAT, increased SOD, and increased GSH-
Px in the blood, which suggested improved antioxidative enzyme function (Broncel M 2010). 
Anthocyanins can also protect membrane fatty acids of endothelial cells from oxidation and 
DNA cleavage induced by elevated inflammatory level (Youdim, McDonald et al. 2002, 
Acquaviva, Russo et al. 2003). Similarly aronia berry extract consumption reduced ox-LDL in 
patients that previously suffered a myocardial infarction (Naruszewicz, Łaniewska et al. 2007).  
In conclusion, anthocyanins might have the potential in CVD prevention by reducing 
chronic inflammation and improving antioxidant capacity in cardiovascular. However, 
mechanistic data were mainly from cell studies.  
2.7.2 Proanthocyanidins 
Other than anthocyanins, clinical evidence for the anti-CVD effect of proanthocyanidins 
has also been suggested. However, the mechanism might be different from other polyphenols 
(Kruger, Davies et al. 2014). In in vitro studies, proanthocyanidins inhibited IL-1β-induced NF-
κB transactivation in human monocytes (Gentile, Allegra et al. 2012). In patients with diabetes 
mellitus or had ≥3 of cardiovascular disease risk factors, the intake of 40 g proanthocyanidin-rich 
cocoa powder for 4 wks decreased the expression of very late activation antigen-4 (VLA-4, 
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CD49d), CD40, and CD36 in monocytes and the serum levels of P-selectin and ICAM-1 
(Monagas, Khan et al. 2009). Also, proanthocyanidins can directly down-regulate TNF-α 
expression in in vitro CVD models (Mao, van de Water et al. 2002).  
Other than preventing the initiation of chronic inflammation, proanthocyanidins can also 
prevent the expression of adhesion molecules and CRP which are responsible for stimulating 
inflammatory response during the pathogenesis of atherosclerosis. A grape seed 
proanthocyanidin extract inhibited TNF-α-induced expression of VCAM-1 and ICAM-1 in 
human umbilical vein endothelial cells, independent of a NF-κB-dependent pathway (Sen and 
Bagchi 2001). (+)-Catechin metabolites also inhibited U937 cell adhesion to IL-1 beta-stimulated 
human aortic endothelial cells and ROS generation in U937 cells (Koga and Meydani 2001). 
Since (+)-catechin is one of the building blocks of proanthocyanidins, it is possible that 
proanthocyanidin metabolites have similar bioactivity as (+)-catechin metabolites. Healthy adults 
that consumed 30 g/d of a proanthocyanidin-rich red wine for 28 d had reduced plasma VLA-4 
compared with gin (low polyphenol) consumption (Badía, Sacanella et al. 2004). Also, in ex vivo 
analysis, red wine consumption decreased TNF-α-induced adhesion of human monocytes to 
endothelial cells (Badía, Sacanella et al. 2004). In a prospective randomized crossover trial, 
healthy adults that consumed 30 g/d proanthocyanidin-rich red wine consumption for 28 d had 
reduced expression of VLA-4 and MCP-1, as well as reduced serum concentrations of hs-CRP, 
VCAM-1 and ICAM-1 (Estruch, Sacanella et al. 2004). In patients with systemic sclerosis that 
consumed of 100 g grape seed-derived proanthocyanidins extract for a month had reduced 
plasma malondialdehyde formation and adhesion molecules (ICAM-1, VCAM-1 and E-selectin) 
(Kalfin, Righi et al. 2002).  
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Also, consumption of proanthocyanidins also may improve antioxidant function. In an ex 
vivo study, the plasma from rats fed a proanthocyanidins-rich extract from longan flower had 
increased the resistance to Cu2+-induced LDL oxidation (Tsai, Wu et al. 2008). The direct anti-
oxidative mechanisms of proanthocyanidins were explained by da Silva Porto, et at., which 
suggested the antioxidant activity increases with degree of polymerization (da Silva Porto, 
Laranjinha et al. 2003).  
Animal and human studies have demonstrated that proanthocyanidins may reverse vascular 
endothelial function by increasing NO (Duffy and Vita 2003). Healthy rats that consumed a 
proanthocyanidin-rich red wine for 7 days had progressively lower systolic blood pressure after 4 
days relative to the control (Diebolt, Bucher et al. 2001). NO appeared to mediate these effects 
(Diebolt, Bucher et al. 2001). Adults with impaired endothelial function that consumed a 
proanthocyanidin-rich purple grape juice had improved flow-mediated vasodilation (FMD), 
which might because a reduction in ox-LDL (Stein, Keevil et al. 1999). 
Also, the protective effects of proanthocyanidin-rich food, such as red wine, cranberry 
products, grape skin extracts, cocoa, and chocolate, have been observed in human intervention 
studies, which suggests its potential capacity for reducing CVD risk (Blanco-Colio, Valderrama 
et al. 2000, Garcia-Alonso, Minihane et al. 2009). However, most studies have not used pure 
proanthocyanidins to investigate their mechanisms of CVD risk reduction. Thus, it is not 
possible to directly attribute these effects to proanthocyanidins alone. Also, proanthocyanidins 
have a low bioavailability, which might limit the bioactivity of proanthocyanidins (Manach, 
Scalbert et al. 2004).  
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2.8 Conclusion 
Polyphenols have promise for CVD prevention. Polyphenols appear to reduce CVD risk by 
anti-inflammatory or antioxidant mechanism. For anti-inflammatory effects, polyphenols may 
reduce the level of many pro-inflammatory mediators, such as adhesion molecules, cytokines and 
growth factors. It is unclear whether the function of polyphenols is to inhibit the initiation of 
inflammatory response, the aggravation of inflammatory response or both. For antioxidant 
function, polyphenols can promote the function of NO, and elevate the serum antioxidant 
capacity. At the mRNA level, polyphenols can promote the Nrf2 translocation and expression of 
antioxidative genes, as well as inhibit the NF-κB translocation and expression of gene amplify 
inflammatory response (González-Gallego, Sánchez-Campos et al. 2007).  
A limitation of the previous studies is that most evidence found were based on cell or 
animal studies. Cell or animials models treated with polyphenols might not refelct the metabolic 
profile of polyphenols in human. It is essential to determine whether polyphenol metabolites is 
responsible for the changes in biomarker of CVD risk in human. 
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composition of almonds 
 48 
 
This chapter has been published in Journal of Agricultural and Food Chemistry.  
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3.1 Abstract 
Background: Almond, among other nuts, is a rich source of dietary polyphenols containing 
phenolic acids, flavonoids, and lignans. However, less is known about the content of bound 
proanthocyanidins and hydrolysable tannins in almonds.  
Objectives: To quantify the extractable and bound proanthocyanidins and hydrolysable tannins 
content in almond.  
Design: Extractable and bound proanthocyanidins and hydrolysable tannins in almond were 
characterized in Nonpareil, Carmel, and Butte almond varieties from California, with n  = 3 
samples/variety. 
Results: Bound proanthocyanidins were recovered from extracted defatted almond residue by 
hydrolysis with 4 N sodium hydroxide and represented 3− 21% of the total proanthocyanidin 
content among varieties. The bound proanthocyanidins were recovered primarily as monomers 
and dimers. In contrast, acid hydrolysis of extracted almond residue did not yield bound 
proanthocyanidins. Hydrolysable tannins were characterized in aqueous acetone extracts of 
defatted almond using two-dimensional TLC and further quantitated by HPLC following acid 
hydrolysis. Almond hydrolysable tannin content was 54.7 ± 2.3 mg ellagic acid and 27.4 ± 7.3 
mg gallic acid per 100 g almond among varieties. The tannin contents of Nonpareil, Carmel, and 
Butte almond varieties were not significantly different. 
Conclusion: Bound proanthocyanidins and hydrolysable tannins significantly contribute to 
almond polyphenol content. 
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3.2 Introduction 
Almonds (Prunus dulcis) are a rich dietary source of polyphenols (Pérez-Jiménez, Neveu et 
al. 2010). The most abundant class of polyphenols in almonds is proanthocyanidins, followed by 
flavonoids and phenolic acids (Bolling, Chen et al. 2011). Almond flavonoids include flavonols, 
flavanones, and flavanols, while almond proanthocyanidins are composed of flavan-3-ols with 
varying degrees of polymerization (Gu, Kelm et al. 2003, Gu, Kelm et al. 2004, Prior and Gu 
2005, Garrido, Monagas et al. 2008, Urpi-Sarda, Monagas et al. 2009). However, while 
proanthocyanidins have been characterized in almond, data about its distribution among varieties 
is lacking (Gu, Kelm et al. 2004). Less is known about the content of hydrolysable tannins in 
almonds.  
Tannins and other polyphenols may contribute to the health-promoting potential of 
almonds. Almond flavonoids and proanthocyanidins are bioavailable and extensively 
metabolized in vivo by phase II enzymes or intestinal microbiota (Urpi-Sarda, Garrido et al. 
2009). These polyphenols and their metabolites may contribute to the antioxidant and anti-
inflammatory effects of almonds observed in animal studies (Chen, Milbury et al. 2005, 
Mandalari, Bisignano et al. 2011).  
A growing body of research suggests that the polyphenol content of foods could be 
underestimated because solvent extraction does not completely liberate polyphenols covalently 
bound to cell walls (Arranz, Saura-Calixto et al. 2009, Arranz, Silván et al. 2010). Previously, 
non-covalently bound phenolic acids and flavonoids (e.g. free or extractable) from almond skin 
extracts were quantified by HPLC-MS (Bolling, Dolnikowski et al. 2009, Bolling, Blumberg et 
al. 2010, Bolling, Dolnikowski et al. 2010). However, Mandalari and colleagues reported a 
portion of almond phenolic acids, mainly p-hydroxybenzoic acid, vanillic acid and ferulic acid, 
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was covalently bound and released by acid hydrolysis (Mandalari, Tomaino et al. 2010). 
Flavonoids, phenolic acids, and proanthocyanidins can also be released by acid or alkaline 
hydrolysis from other plant materials (Arranz, Saura-Calixto et al. 2009, White, Howard et al. 
2010). Thus, more work is needed to determine the relative proportion of free and bound 
polyphenols in almonds. The objectives of this study were to further characterize almond tannins 
by 1) quantifying extractable and bound proanthocyanidins, and 2) screening for hydrolysable 
tannins. We utilized Nonpareil, Carmel and Butte almonds, as these are the top three cultivated 
California almond varieties.  
3.3 Materials and Methods 
3.3.1 Reagents and Materials 
         Methanol, dichloromethane, and acetic acid were HPLC grade from Fischer Scientific (Fair 
Lawn, NJ). Water was ultrapure grade. All other chemicals and reagents were acquired from 
Sigma-Aldrich (St. Louis, MO). Samples of whole, unpasteurized Butte, Carmel, and Nonpareil 
California almonds from harvest year 2011 were provided by the Almond Board of California. 
Each variety had 3 unique samples representing different orchards, for a total of n = 9 samples. 
Almonds were stored at -20°C until analysis. 
3.3.2 Extraction of Proanthocyanidins 
         Frozen almonds were finely ground using an IKA A11 basic grinder (Wilmington, NC). 
Almond powder (4 g) was homogenized in 40 mL hexane using an IKA Ultra-Turrax T18 
homogenizer for 2 min at a power setting of 4. The homogenate was centrifuged and the 
supernatant was removed. The residue was similarly homogenized twice, and the resulting 
supernatants were combined and dried under a nitrogen gas stream. The mass of the extracted, 
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dried lipids were recorded to determine almond lipid content. The defatted almond residue was 
then extracted with acidified aqueous acetone (70:29.5:0.5 mixture of acetone, distilled water, 
and acetic acid), according to methods described by Prior et al. with modifications (Prior and Gu 
2005). Acidified aqueous acetone (40 mL) was added to the defatted nut residue and vortexed for 
30 to 40 s, and sonicated for 10 minutes at 37C (Fisher Scientific, Utrasonic cleaner, FS30). The 
sample was then agitated on a tube rocker for 50 min at 23 C, centrifuged, and the supernatant 
was filtered through a 0.2 µm nylon filter. The pelleted almond residue was dried under a 
nitrogen gas stream and stored at -20 C until hydrolysis. The filtered supernatant was dried 
under a nitrogen gas stream to remove acetone, frozen at -80 C, lyophilized to a powder, and 
stored at -80 C.  
3.3.3 Acid and Alkaline Hydrolysis  
Residual defatted or defatted, extracted almond powder was subjected to acid or alkaline 
hydrolysis. Acid hydrolysis was based on previously described methods (Singleton, Orthofer et 
al. 1998, Prior and Gu 2005). Almond residue was resuspended in 20 mL of 1.2 N hydrochloric 
acid in methanol:water (80:20, v/v) and 0.5 g/L tert-butylhydroquinone and heated at 75 °C in a 
dry bath for 3 h. Incubates were then cooled over ice brought to pH 5.5 with 3.7 M ammonium 
acetate. The hydrolysis solution was centrifuged, and the supernatant was dried of residual 
methanol under nitrogen gas at 40 °C. The resulting aqueous solution was stored at -80C until 
further analysis.  
  Base hydrolysis was performed according to a previously described method (White, 
Howard et al. 2010). Defatted and extracted almond residue was resuspended in 20 mL of 4 N 
aqueous sodium hydroxide. Resuspended residue was and incubated in a water bath at 60 °C for 
15 min with 30 s vortexing every 3 min. The hydrolyzed sample was cooled over ice and 
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neutralized with 4 N hydrochloric acid. The neutralized sample was centrifuged, and the 
supernatant was frozen at -80 C, lyophilized to a powder, and stored at -80 C until further 
testing.  
3.3.4 Isolation of Tannins  
         Tannins were isolated by stepwise elution from Sephadex LH-20 columns, as described 
previously (Prior and Gu 2005). Neutralized aqueous hydrolysis solutions or dried almond 
extracts were reconstituted in 2 to 4 mL of 30% methanol in water, and were loaded on 1 cm 
diameter column containing ~4 g Sephadex LH-20. Sugars and salts were eluted with 50 mL 
methanol:water (30:70 v/v), and discarded. Proanthocyanidins were eluted with 100 mL 
acetone:water (70:30 v/v). The proanthocyanidin fraction was dried of residual acetone by a 
nitrogen gas stream at 37 °C. The resulting aqueous residue was frozen at -80 °C and lyophilized 
to a powder prior to HPLC analysis. 
3.3.5 HPLC Analysis of Proanthocyanidins  
         Proanthocyanidins were quantified based a modified method of Prior and colleagues using 
a Dionex Ultimate 3000 HPLC equipped with a refrigerated autosampler, column oven, diode 
array detector, and fluorescence detector (Sunnyvale, CA) (Prior and Gu 2005). 
Proanthocyanidin isolates were reconstituted in 100 µL methanol:dichloromethane (1:1) and 20 
µL was injected on a 260 × 4.60 mm Hypersil silica column (ThermoFisher, Bellefonte, PA). 
Samples were resolved by a 1 mL/min gradient of 100% dichloromethane (A) and 100% 
methanol (B) with a constant 4% of acetic acid:water (50:50, v/v). The gradient increased 
linearly from 14% B at 0 min to 28.4% B at 30 min, to 39.6% B at 45 min, to 86 % B at 55 min 
and held until 60 min, then decreased to 14% B until 75 min. Proanthocyanidins were quantified 
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by fluorescence, with excitation at 276 nm and emission at 316 nm, using (+)-catechin, (-)-
epicatechin, and proanthocyanidin B2 as standards. A check standard of cocoa 
proanthocyanidins purified in-house was used to control for intraday variation.   
3.3.6 Colorimetric Determination of Total Phenols and Proanthocyanidins 
The total phenol content of almond extract and hydrolyzed residue was determined 
according to the method of Singleton et al., adapted to a microtiter plate (Singleton, Orthofer et 
al. 1998). Results were expressed as mg gallic acid equivalents (GAE) per 100 g whole almonds. 
Proanthocyanidin content was determined by the 4-(dimethylamino)cinnamaldehyde (DMAC) 
method.(Payne, Hurst et al. 2010) Samples or standards were reconstituted in 70 μL 50% 
aqueous methanol and mixed with 210 μL of 0.1% DMAC (w/v) in 1: 1: 6 (v/v/v) 37% 
hydrochloric acid:water:ethanol in a microtiter plate. The plate was incubated at 25 °C in a 
spectrophotometer (Synergy HT Multi-Mode Microplate Reader, BioTek, Winooski, VT) and 
absorbance was monitored at 640 nm in 1 min intervals for 30 min. Results were expressed as 
mg (+)-catechin equivalents (CE) per 100 g whole almonds.  
3.3.7 Thin-layer Chromatography (TLC) of Hydrolyzable Tannins 
Almond hydrolyzable tannins were characterized by two-dimensional TLC (White, 
Howard et al. 2010). Duplicate cellulose plates (20 × 20 cm, 100 µm, Selecto Scientific Inc., 
Suwanee, GA) were spotted with 50 μL of the almond tannin fraction reconstituted in 100% 
methanol. Plates were developed in glass chambers saturated with 100 to 150 mL of a 14:1:5 
(v/v/v) mixture of butan-2-ol/acetic acid/water until the solvent front was at least 18 cm. Plates 
were then removed from the chambers and dried at ambient temperature. Plates were then rotated 
90° and placed into a glass chamber saturated with 100 to 150 mL of a 2:98 (v/v) mixture of 
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acetic acid/water. The plates were dried at ambient temperature. Plates were sprayed with a 
saturated potassium iodate solution to detect gallotannins or 4% sodium nitrite (w/v) in 50% 
aqueous acetic acid (v/v) to detect ellagitannins.  
3.3.8 Gallotannin and Ellagitanin Hydrolysis 
Defatted almond was hydrolyzed according to a previously described method (Lei, Jervis et 
al. 2001). Defatted almond powder (20 mg) was reconstituted in 2 mL methanol in 50 mL glass 
screw-top test tubes. Sulfuric acid (18% in water, 100 µL) was slowly added to samples in two 
aliquots, manually swirling the solution between additions. Samples were then incubated in a dry 
bath at 85 °C for 20 h, cooled over ice, and neutralized by carefully adding 4 aliquots of 50 µL 
ethanolamine to each sample. Caffeic acid or trans-stilbene (5 µg/mL) were used as internal 
standards for analysis of gallic acid or ellagic acid, respectively. Solutions were brought to 2 mL 
with water and centrifuged. Supernatants were passed through a 0.2 µm nylon syringe filter if 
cloudy or used directly for HPLC analysis. 
3.3.9 HPLC Analysis of Gallic Acid and Ellagic Acid 
HPLC was performed using the previously described Dionex Ultimate 3000 system. 
Diluted, neutralized hydrolysis solutions or standards (20 µL) were injected onto a 50 × 2.10 mm 
Dionex 2.2 µm 120Å Acclaim RSLC PolarAdvantage column (ThermoScientific, Sunnyvale, 
CA). Gradients of 1% aqueous acetic acid (A) and methanol (B) and were used to resolve 
samples at 0.2 mL/min. For gallic acid, 10% B was held to 3 min, followed by a linear gradient 
to 40% B at 7 min, returning to 10% B at 12 min and held for 5 min. For ellagic acid, 10% A was 
held for 3 min, followed by a linear gradient to 100% B at 10 min, returning to 10% B at 12 min 
and held for 8 min. Gallic acid and ellagic acid were used as external standards for 
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quantification. Caffeic acid and trans-stilbene were internal standards for gallic acid and ellagic 
acid, respectively. Gallic acid and ellagic acid were identified in hydrolysis solution by 
comparison of UV spectra analysis and retention time (RT) to authentic standards. Methyl gallate 
eluted at 4.4 min but was not detected below 0.12 ng on-column in hydrolysis solutions. Gallic 
acid and caffeic acid were quantified at 280 nm, and ellagic acid and trans-stilbene were 
quantified at 320 nm and 250 nm, respectively. Inter- and intra-assay RSD for gallic acid 
analysis were 14.55 and 7.36 %, respectively. Inter- and intra-assay RSD for ellagic acid analysis 
were 1.06 and 2.98 %, respectively. Gallic acid, caffeic acid, ellagic acid and trans-stilbene 
eluted at 1.9, 8.7, 12.4, and 15.2 min, respectively.  
3.3.10 Statistics and Data Analysis  
Data are mean ± standard deviation of at least duplicate samples. Statistical significance 
was determined by two or one-way ANOVA as indicated, followed by Tukey’s multiple 
comparison test using GraphPad Prism 5.01 software (GraphPad Software, Inc., La Jolla, CA). 
Differences were considered significant at P < 0.05.  
3.4 Results 
Tannins are the most abundant class of polyphenols in almonds (Bolling, Chen et al. 2011). 
Little is known about the abundance of bound proanthocyanindins and hydrolyzable tannins in 
almonds or their distribution between varieties. Therefore, we characterized and quantified 
extractable and bound proanthocyanidins and hydrolyzable tannins in Nonpareil, Carmel, and 
Butte almond varieties.  
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3.4.1 Extractable Proanthocyanidins  
         The extractable proanthocyanidins from almond consisted of (+)-catechin and (-)-
epicatechin, three dimer peaks, including proanthocyanidin B2, as well as trimers and greater 
oligomers (Figure 3.1A). Among the three almond varieties, Nonpareil had ~2-fold more 
extractable proanthocyanidins (107.27 mg/100 g almond) than Butte (25.35 mg/100 g almond) 
and Carmel (28.09 mg/100 g almond) because of increased oligomer content (Table 3.1). 
Nonpareil had 2-fold the monomers of Butte and 3-fold the monomers than Carmel. Nonpareil 
had 3-fold the dimers of Butte and Carmel, and 4-fold the trimers of Butte and Carmel. Besides, 
Nonpareil also had ~3 fold the oligomers (4-7) and 8mers and greater polymers than Butte and 
Carmel almonds. The extractable proanthocyanidin profiles, e.g. proportion to the sum of 
proanthocyanidin, varied among the three almond genotypes (Figure 3.3A). 8 mers and greater 
polymers were the most abundant proanthocyanidins among the three almond genotypes, ranging 
from 27.2 to 33.3 % of extractable proanthocyanidins, with the greatest polymer proportion in 
Carmel. Nonpareil had the greatest relative proportion of dimer 2, trimers and 4mers. Butte had 
the highest proportion of (+)-catechin (0.9%), (-)-epicatechin (6.8%), dimer 1(2.4%) and dimer 3 
(15.9%). Carmel had the highest proportion of 5mers, 6mers and 7mers, which were 10.8%, 7.5% 
and 7.4%, respectively. 
3.4.2 Bound Proanthocyanidins  
The recovery of proanthocyanidins from defatted almond residue was greatest at 3 h, as 
quantified by the DMAC assay (Figure 3.5A). Alkaline hydrolysis of unextracted was 
maximized at 4 N sodium hydroxide by the DMAC assay (Figure 3.5B). Alkaline hydrolysis 
yielded 23 to 98% of the extractable proanthocyanidins, with the highest recovery in Carmel 
(Figure 3.2) (P = 0.0002 for extraction method, P = 0.4105 for genotype, and P = 0.4004 for 
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their interaction). In contrast, acid hydrolysis yielded minimal proanthocyanidin content, with < 
0.2 mg catechin equivalents (CE)/100 g almond.  
Following almond extraction with acidic aqueous acetone, acid hydrolysis of the residue 
did not yield additional proanthocyanidins by HPLC fluorescence analysis (<0.02 mg/100 g 
almond). Proanthocyanidins recovered from alkaline hydrolysis of extracted almond residue 
were quantified by HPLC (Figure 3.1B). Only proanthocyanidin monomers, dimers, and 
oligomers with polymerization of 8 and greater were recovered after hydrolysis (Table 3.1). 
Alkaline hydrolysis of extracted almond residue yielded an additional 3.4, 6.8, and 6.4 mg 
proanthocyanidin B2 equivalents (PE)/100 g almond in Nonpareil, Butte, and Carmel almonds, 
respectively (Table 3.1). These yields added 22 to 66% toward monomer content and 45 to 81% 
to dimer 1 content. Nonpareil almonds had the lowest recovery of bound proanthocyanidins, 
despite having the highest yield of extractable proanthocyanidins among almond varieties.  
3.4.3 Total Proanthocyanidins  
The sum of extractable and bound proanthocyanidins almonds reflects the total 
proanthocyanidin content and profile (Table 3.1, Figure 3.2B) of almonds. Nonpareil almonds 
had the most proanthocyanidins with 110.6 mg/100 g, representing 3.4- and 3.2-fold of Butte and 
Carmel varieties. Butte almonds had greatest relative proportion of monomers and dimers 
contributing ~50% to the total proanthocyanidin content. In contrast, trimers and greater 
oligomers contributed more than 70% of the proanthocyanidin content of Nonpareil and Carmel 
almonds. Base hydrolysis yielded an additional 3 to 27% of the sum of extractable 
proanthocyanidins (Table 3.1).  
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3.4.4 Hydrolysable tannins  
Extractable almond tannin fractions were resolved by 2-dimensional TLC to screen for the 
presence of gallotannins and ellagitannins (Table 3.3). In each almond variety, at least 5 to 6 
unique spots reacted with potassium iodate, indicating potential gallotannin content. Nonpareil 
and Butte almonds each had 4 orange-brown spots after a sodium nitrate spray, indicating the 
presence of ellagitannins (Mueller-Harvey 2001). Carmel almonds had a unique ellagitannin 
profile, with 3 orange-brown and 3 pink spots after the sodium nitrate spray. Low retention 
factors in the second TLC dimension tentatively indicated the presence of large molecular-
weight ellagitannin and gallotannins (Mueller-Harvey 2001). 
Gallic acid and ellagic acid were present in hydrolysis solutions of defatted almonds 
(Figure 3.4). Nonpareil, Butte, and Carmel almond contained 19.64 to 34.11 mg gallic acid/100 
g, and 43.28 to 57.36 mg ellagic acid/100 g with no significant differences between varieties (n = 
3/variety) (Table 3.2).  
3.5 Discussion 
3.5.1 Extractable Proanthocyanidins  
Normal-phase HPLC resolution of proanthocyanidins in California almond varieties was 
similar to Spanish almonds (Prodanov, Garrido et al. 2008). Almond proanthocyanidins have 
(epi)afzelechin, (epi)catechin and (epi)gallocatechin as constituent units, with both A-type and 
B-type linkages and an average degree of polymerization of 12.7 (Gu, Kelm et al. 2003, 
Monagas, Garrido et al. 2007, Prodanov, Garrido et al. 2008). Almond proanthocyanidins with 
polymerization of 6 or more have only B-type linkages (Prodanov, Garrido et al. 2008).  
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Proanthocyanidins and hydrolyzable tannins contribute a significant portion of the 
polyphenol content of almonds and other tree nuts.  Almonds have more extractable 
proanthocyanidins than walnuts, but less than hazelnuts, pecans and pistachios (Gu, Kelm et al. 
2004). Gu and colleagues reported 184.1 mg extractable proanthocyanidins/100 g almond in a 
commercial almond sample using similar extraction conditions (Gu, Kelm et al. 2004). While the 
distribution of proanthocyanidin polymers is similar to this study, the content was higher than the 
25 to 107 mg PE/100 g obtained in the present study. The use of proanthocyanidin B2 
equivalents may contribute to this difference. Also, pre-harvest factors such as climate and 
environment and post-harvest factors, such as storage and processing may contribute to 
differences among almond samples (Bolling, Chen et al. 2011). However, our values appear 
greater than a previous study by Garrido and colleagues, adjusted by the relative proportion of 
almond skins to 100 g almonds (Garrido, Monagas et al. 2008). 
DMAC values of extractable proanthocyanidins were 75.1% to 89.9% less than HPLC. 
DMAC reacts with terminal flavan-3-ols, so this method underestimates polymeric 
proanthocyanidins (Prior, Fan et al. 2010). The present work is also limited by a lack of suitable 
analytical standards for HPLC analysis. Further work is needed to purify proanthocyanidins of 
similar composition, linkages, and with varying polymerization to validate methods for 
quantification of almond proanthocyanidins.  
The differences in extractable proanthocyanidins between Nonpareil, Carmel, and Butte 
almonds are greater than other reported polyphenols. In the present study, Nonpareil had more 
extractable proanthocyanidins than Butte and Carmel, while there were no differences in 
flavonoid and phenolic acid between these varieties (Bolling, Dolnikowski et al. 2010). 
Nonpareil almonds had significantly greater (-)-epicatechin content than the same study, with 3.4 
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mg/100 g almonds.(Bolling, Dolnikowski et al. 2010) It is unclear if this difference is due to 
yearly variation in polyphenol content or due to different extraction conditions. 
3.5.2 Bound Proanthocyanidins  
Acid hydrolysis was insufficient to release additional bound proanthocyanidins in almond, 
despite previous studies that have used acid hydrolysis prior to analysis of catechins (Merken and 
Beecher 2000, Harnly, Doherty et al. 2006). Alkaline hydrolysis yielded additional bound 
proanthocyanidins from extracted almond residue, as monomer and dimers. This is consistent 
with a previous study in cranberry pomace, where alkaline hydrolysis liberated 4-fold the 
monomer to hexamer proanthocyanidins than conventional extraction (White, Howard et al. 
2010). Alkaline hydrolysis of cranberry polymeric proanthocyanidins yielded primarily 
monomers and dimers (White, Howard et al. 2010). 
 According to our results, bound proanthocyanidin yielded 3.1 to 26.8% of the extractable 
proanthocyanidins (Table 3.1). This proportion was less than that of apple, peach and nectarine, 
which bound proanthocyanidin were 6 to 20-fold of the extractable proanthocyanidins measured 
by HPLC (Arranz, Saura-Calixto et al. 2009). Other bound polyphenols were 2 to 6-fold of the 
extractable polyphenols in apple, peach and nectarine measured by LC-MS (Arranz, Saura-
Calixto et al. 2009). However, the bound polyphenol content of tree nuts may be less than other 
fruits and vegetables. In walnuts and heartnuts, bound total phenolic contents were for 20 to 77 % 
of extractable total phenolic contents measured by Folin-Ciocalteu assay (Li, Tsao et al. 2006). 
In a study of 29 kinds of food, bound phenolic compounds accounted nearly the same or more 
antioxidant capacity than free phenolic compounds measured (Pellegrini, Serafini et al. 2006). 
Thus, the proportion of bound polyphenols may depend on plant varieties, genotypes, and 
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polyphenol composition. Further work is needed to define the contribution of bound polyphenols 
to almond bioactivity. 
3.5.3 Total Proanthocyanidins  
The proanthocyanidin profile of Butte and Carmel almonds changed after summing 
extractable and bound proanthocyanidins. This was due to the high content of monomers, dimers 
and trimers in Butte and Carmel almonds following alkaline hydrolysis of their extracted residue. 
For oligomers (>3) and polymers, the total proanthocyanidins profile reflected the extractable 
proanthocyanidin profile.  
3.5.4 Hydrolyzable Tannins  
Hydrolyzable tannins vary according to their polymeric level of gallic acid and ellagic acid 
(Chung, Wong et al. 1998). TLC analysis indicated the presence several different gallotannins 
and ellagitannins in almonds. A number of ellagitannins have been identified in walnut, 
including pedunculagin, glansrins, casuarictin and others (Fukuda, Ito et al. 2003, Cerdá, Tomás-
Barberán et al. 2005). Thus, almonds may also contain a diverse ellagitannin profile. Precaution 
should be taken when selecting almond tannin TLC bands for further analysis, since potassium 
iodate also reacts with catechins (Table 3.3). Further work is needed to isolate and identify these 
compounds from almonds. 
Walnuts and pecans contain hydrolyzable tannins (Daniel, Krupnick et al. 1989). In 
comparison to previous studies, almond ellagitannins are 3 to 10-fold less than walnut, which 
have 150 to 546 mg of ellagic acid/100 g (Cerdá, Tomás-Barberán et al. 2005, Li, Tsao et al. 
2006). A previous study reported almond contain little to no gallotannins and ellagitannins 
following hydrolysis (Molyneux 2008). However, this study employed a more moderate 
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hydrolysis condition than the present study. Thus, almond hydrolysable tannin content may have 
been previously underestimated. Ellagic acid consumption in the United States is estimated to be 
3.4 to 15.1 mg/1000 kcal energy in adult females, varying by whether they meet fruit and 
vegetable intake recommendations (Murphy, Barraj et al. 2012). Therefore, consuming a 43 g 
(1.5 oz) serving of almond could more than double the estimated ellagic acid intake.  
While originally recognized as anti-nutrients, a number of putative health effects are 
attributed to tannins. Gallic acid is antioxidant and apoptotic to SH-SY5Y and U 937 cancer cells 
in vitro (Saeki, Yuo et al. 2000, Lu, Nie et al. 2006). Likewise, ellagic acid has in vitro 
antioxidant potential, anti-inflammatory, estrogenic and/or anti-estrogenic roles and 
antimicrobial and prebiotic effects (Landete 2011). However, ellagic acid is not bioavailable 
from ellagitannins, and is metabolized to the bioavailable urolithins, which may be a marker for 
nut intake (Tulipani, Urpi-Sarda et al. 2012). Almond proanthocyanidins are bioavailable, and 
tend to be metabolized to (epi)catechin conjugated metabolites by phase II enzymes after 2 to 6 h 
consumption in healthy adults (Garrido, Urpi-Sarda et al. 2010). There is a need to characterize 
the bioaccessability of bound phenolics in almonds and other polyphenol-rich foods. Thus, future 
studies characterizing the effects of almond polyphenol consumption, should consider of 
hydrolyzable tannins and bound proanthocyanidins.  
3.6 Conclusion 
In conclusion, almonds are a source of diverse polyphenols, including phenolic acids, 
flavonoids, proanthocyanidins, ellagitannins, gallotannins, and likely other uncharacterized 
constituents. Base hydrolysis yielded additional polyphenols from extracted almond residue, 
increasing total proanthocyanidin content 3 to 21 % in California almonds. Almonds were also 
found to contain 27.43 mg gallic acid and 54.69 mg ellagic acid/100 g following hydrolysis. 
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Database values and future analytical research efforts should consider the presence of “bound” 
polyphenols, ellagitannins, and gallotannins in California almonds.  
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3.7 Chapter 3 Tables and Figures 
Table 3.1 Proanthocyanidin content and the extractable proanthocyanidin proportion of California almond cultivars  
PACs 
Nonpareil Butte Carmel 
Extractable 
Base  
hydrolysis Total Extractable 
Base 
hydrolysis Total Extractable 
Base 
hydrolysis Total 
(+)-catechin 0.33 ± 0.10 0.10 ± 0.05 0.43 ± 0.13 0.14 ± 0.13 0.18 ± 0.06 0.32 ± 0.10 0.10 ± 0.03 0.22 ± 0.10 0.31 ± 0.08 
(-)-epicatechin 3.44 ± 0.50 1.17 ± 0.89 4.61 ± 1.20 1.24 ± 1.25 2.64 ± 1.14 3.88 ± 1.08 0.76 ± 0.31 1.80 ± 1.03 2.56 ± 1.16 
PAC dimer 1 1.99 ±1.60 1.45 ± 0.93 3.43 ± 1.38 0.43 ± 0.40 1.80 ± 0.54 2.23 ± 0.14 0.37 ± 0.06 1.89 ± 1.22 2.26 ± 1.29 
PAC B2 8.29 ± 2.88 0.03 ± 0.03 8.31 ± 2.90 1.53 ± 1.83 0.79 ± 1.32 2.32 ± 1.52 1.17 ± 0.46 0.05 ± 0.03 1.22 ± 0.47 
PAC dimer-3 8.39 ± 2.17 0.02 ± 0.01 8.41 ± 2.18 2.49 ± 2.01 0.21 ± 0.25 2.69 ± 1.83 2.43 ± 0.18 0.11 ± 0.06 2.55 ± 0.20 
trimers 14.03 ± 3.26 
 
14.03 ± 3.26 2.97 ± 3.84  2.97 ± 3.84 2.68 ± 1.46  2.68 ± 1.46 
4-mers 15.10 ± 3.53 
 
15.10 ± 3.53 3.15 ± 4.00  3.15 ± 4.00 3.34 ± 2.09  3.34 ± 2.09 
5-mers 10.87 ± 4.10 
 
10.87 ± 4.10 2.23 ± 2.86  2.23 ± 2.86 3.08 ± 1.88  3.08 ± 1.88 
6-mers 7.23 ± 2.33 
 
7.23 ± 2.33 1.61 ± 2.09  1.61 ± 2.09 2.22 ± 1.57  2.22 ± 1.57 
7-mers 6.33 ± 2.11 
 
6.33 ± 2.11 1.65 ±2.14  1.65 ± 2.14 2.21 ± 1.63  2.21 ± 1.63 
8-mers and 
greater 31.28 ± 8.87 0.61 ± 0.07 31.89 ± 8.81 7.91 ±10.45 1.18 ± 0.98 9.09 ± 10.12 9.74 ± 6.72 2.29 ± 0.33 12.03 ± 7.04 
Sum 107.27 3.37 110.6 25.35 6.80 32.15 28.09 6.37 34.46 
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Table 3.2 Hydrolyzable tannin content of California almond cultivars determined by methanolysis and HPLC analysis.  
Hydrolyzable Tannin  Value Almond Cultivar 
  Nonpareil Butte Carmel 
mg gallic acid/100 g mean 34.11± 2.36 28.54 ± 10.45 19.64 ± 5.00 
 range 32.6-32.8 22.4-40.6 14.1-23.8 
mg ellagic acid /100 g mean 57.36 ± 6.44 53.28 ± 1.45 53.44 ± 5.36 
 range 50.5-63.2 54.6-54.3 48.7-59.3 
Data are mean ± standard deviation, n = 3/cultivar. Statistical significances among almond cultivars by ANOVA were P = 0.1016 for 
gallotannins, and P = 0.5490 for ellagitannins. 
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Table 3.3 Two dimensional TLC profiles of almond tannins. 
Genotype Sample Spray Reagent 
  Gallotannins (KIO3) Ellagitannins (NaNO2) 
  Rf1
 Rf2 Color
b Rf1 Rf2 Color
 
Nonpareil 2079 0.234 (B a) 0 brown 0.435 (B) 0 orange-brown 
  0.208 (B) 0.138 brown -- -- -- 
  0.734 0.225 brown -- -- -- 
 2080 0.833 (B) 0 brown 0.723 (B) 0 orange-brown 
  0.303 (B) 0.180 brown 0.730 0.222 orange 
  0.877 0.066 brown -- -- -- 
  0.809 0.216 brown -- -- -- 
 2081 0.950 (B) 0 brown 0.712 (B) 0 orange-brown 
  0.256 (B) 0.129 brown 0.600 0.216 orange 
  0.844 0.082 brown 0.689 0.252 orange 
  0.750 0.224 brown -- -- -- 
Butte 2082 0.862 (B) 0 brown 0.700 (B) 0 orange-brown 
  0.745 0.083 brown 0.680 0.222 orange 
  0.655 0.232 brown -- -- -- 
 2083 0.258 (B) 0 brown 0.323 (B) 0 orange-brown 
  0 
0.136 
(B) 
brown 0.194 (B) 0.205 orange-brown 
  0.182 0.178 brown 0.684 0.211 orange-brown 
  0.711 0.201 brown -- -- -- 
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 2084 0.312 (B) 0 brown 0.388 (B) 0 orange-brown 
  0.243 (B) 0.139 brown 0.273 (B) 0.151 orange-brown 
  0.832 0.208 brown 0.792 0.235 orange 
Carmel 2085 0.205 (B) 0 brown 0.440 ( B) 0 pink 
  0.325 (B) 0 brown 0.217 (B) 0 orange-brown 
  0.723 0.224 brown 0.464 0.135 pink 
  -- -- -- 0.512 0 pink 
  -- -- -- 0.602 0 pink 
 2086 0.823 (B) 0 brown 0.351 (B) 0 orange-brown 
  0.253 0.194 brown 0 0.136 orange-brown 
  -- -- -- 0.225 (B) 0.183 orange-brown 
 2087 0.477 (B) 0 brown 0.433 (B) 0 orange-brown 
  0 
0.151 
(B) 
brown 0 
0.128 
(B) 
orange-brown 
  0.305(B) 0.205 brown 0.293 (B) 0.151 orange-brown 
For standard compounds, potassium iodate spray gave an orange spot for (+)-catechin (0.739, 
0.269), a brown spot for gallic acid (0.816, 0.313), and brown-pink spots for tannic acid (0.365-
0.825, 0), (0.745, 0.176), (0.650, 0.364), (0.380, 0.339) and (0.277, 0.461). Sodium nitrite spray 
gave a brown-pink spot with ellagic acid (0.5347, 0). 
aB: band observed 
bReactivity of spot with spray reagent 
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Figure 3.1 A. Representative HPLC fluorescence chromatogram of solvent-extractable almond 
proanthocyanidin fraction. B. Representative HPLC fluorescence chromatogram of base 
hydrolyzed almond proanthocyanidin fraction. 
0 20 40 60
0
10000000
20000000
30000000
40000000
fl
u
o
re
s
c
e
n
c
e
 in
te
n
s
ity
 (
c
o
u
n
ts
)
(+)-catechin
(-)-epicatechin
dimer 1
dimer 2
dimer 3
trimers
4-mers
5-mers
6-mers
7-mers
8-mers and greater polymers
A
Time (min)
0 20 40 60
0
10000000
20000000
30000000
40000000
fl
u
o
re
s
c
e
n
c
e
 in
te
n
s
ity
 (
c
o
u
n
ts
)
dimer 3
(+)-catechin
(-)-epicatechin
dimer 1
dimer 2
8-mers and greater polymers
B
Time (min)
 70 
 
 
Figure 3.2 A. Relative extractable proanthocyanidin profile of California almond genotypes. 
Data are mean ± SEM of Nonpareil, Butte, and Carmel almonds (n=3/genotype). By 2-way 
ANOVA, P =0.2921 for genotype, P <0.0001 for proanthocyanidin type, with P =0.0087 for their 
interaction. B. Relative total proanthocyanidin profile of California almond genotypes. Data are 
mean ± SEM of Nonpareil, Butte, and Carmel almonds (n=3/genotype). By 2-way ANOVA, P 
=0.5959 for genotype, P <0.0001 for proanthocyanidin type, with P =0.0019 for their interaction. 
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Figure 3.3 Proanthocyanidin content of extracted and hydrolyzed residues from California 
almond genotypes determined by the DMAC (4-(dimethylamino)cinnamaldehyde) assay. CE: 
catechin equivalents. By 2-way ANOVA, P = 0.0002 for extraction method, P = 0.4105 for 
genotype, and P = 0.4004 for their interaction. 
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Figure 3.4 A. Representative HPLC fluorescence chromatogram of almond gallic acid fraction. 
B. Representative HPLC fluorescence chromatogram of almond ellagic acid fraction. 
0 5 10 15
-600
-400
-200
0
gallic acid
caffeic acid
A
Time (min)
A
b
s
 2
8
0
 n
m
0 5 10 15
0
50
100
150
200
ellagic acid
trans-stilbene
B
Time (min)
A
b
s
 2
5
0
 n
m
 73 
 
 
Figure 3.5 Recovery of proanthocyanidins following A. acidic and B. alkaline hydrolysis of 
defatted almond powder. Data are mean ± standard deviation of triplicate determinations, where 
P=0.6514 for acidic and P = 0.0189 for alkaline hydrolysis, by one-way ANOVA.  
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4.1 Abstract 
Background: Stilbene polyphenols are present in some fruits and nuts, but their abundance in 
many foods, such as almonds, is unknown.  
Objectives: To develop UHPLC-MS methods to quantitate and characterize stilbenes content in 
almond.  
Design: Stilbenes in almond were characterized in Nonpareil, Carmel, and Butte almond 
varieties from California, with n  = 3 samples/variety. 
Results: Stilbenes were isolated from ethanolic almond extracts by solid phase extraction and 
identified with UHPLC–MS by comparison of retention times (RTs), mass spectra, insource CID 
spectra, and enzymatic hydrolysis to authentic standards. Polydatin was identified in almond 
extracts, with 7.19–8.52 µg/100 g almond. Piceatannol + oxyresveratrol was tentatively 
identified in almond blanch water, at 0.19–2.55 µg/100 g almond. Polydatin was concentrated in 
almond skins, which contained 95.6–97.5% of the total almond content. 
Conclusion: Almonds contain the stilbene class of polyphenols in addition to the previously 
identified proanthocyanidin, hydrolysable tannin, flavonoid, and phenolic acid classes.
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4.2 Introduction 
Almonds (Prunus dulcis) contribute to dietary polyphenol intake, and are ranked as one of 
the top 40 richest food sources of polyphenols (Perez-Jimenez, Neveu, Vos, & Scalbert, 2010). 
Clinical and preclinical studies have demonstrated that almonds have antioxidant, anti-diabetic, 
and hypocholesterolemic actions (Li, Jia et al. 2007, Li, Liu et al. 2011, Foster, Shantz et al. 
2012).  
The most abundant class of polyphenols in almonds is proanthocyanidins, followed by 
hydrolysable tannins, flavonoids and phenolic acids (Bolling, Chen et al. 2011, Xie, Roto et al. 
2012). Almond phenolic acids and flavonoids have been well-characterized, and are enriched in 
almond skins (Milbury, Chen et al. 2006, Mandalari, Tomaino et al. 2010). Some almond 
polyphenols are readily extractable, while a smaller proportion requires hydrolysis of the 
extracted residue to be liberated from the food matrix (Xie, Roto et al. 2012).  
The polyphenol diversity of many foods have been reported and indexed in databases such 
as Phenol-Explorer (Neveu, Perez-Jiménez et al. 2010). Despite these efforts, a significant 
portion of dietary polyphenols may be underestimated simply because previous analytical studies 
have not targeted particular polyphenol classes for certain foods. A more complete 
characterization almond polyphenols is desirable to relate almond bioactivities to its chemical 
composition. For example, we recently reported that almonds contain ellagitannins and 
gallotannins (Xie, Roto et al. 2012). Likewise, stilbenes are not well-characterized in nuts. 
Stilbenes have been reported in peanuts and pistachios, but have yet to be identified in almonds, 
Brazil nuts, hazelnuts, macadamias, pine nuts, or walnuts (Sobolev and Cole 1999, Tokuşoǧlu, 
Ünal et al. 2005).   
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Stilbenes are synthesized in plants through the shikimate and phenylalanine/polymalonate 
pathways (Jeandet, Delaunois et al. 2010). The reported stilbene content of foods is generally 
less than other polyphenols, e.g. flavonoids and tannins. Trans-resveratrol or its glucoside is the 
most abundant stilbene in wine, grapes, peanuts and Vaccinium species (Cassidy, Hanley et al. 
2000, Rimando, Kalt et al. 2004). Stilbenes may contribute to the health-promoting potential of 
polyphenol-rich foods, through antioxidant or phytoestrogen activities (Cassidy, Hanley et al. 
2000).  
The content and distribution of stilbenes in almonds is unknown. Therefore, the objectives 
of this study were to 1) develop a UHPLC-MS method for determining stilbenes in almonds; 2) 
identify and quantitate stilbenes in Nonpareil, Carmel, and Butte California almonds, as these are 
the top three cultivated varieties of California almonds; and 3) determine the 
compartmentalization of stilbenes in almonds.  
4.3 Materials and methods  
4.3.1 Chemicals and plant materials 
Methanol and formic acid were LC-MS grade and acetyl acetate was HPLC grade from 
Fischer Scientific (Fair Lawn, NJ). Ethanol was absolute, anhydrous, ACS/USP grade from 
Pharmco-AAPER (Brookfield, CT). Water was Type II ultrapure grade produced by Picopure®2 
(Hydro Service and Supplies, Inc). β-D-glucosidase (49290-1G), and all other chemicals and 
reagents were acquired from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. Samples of 
whole, unpasteurized Butte, Carmel, and Nonpareil California almonds from harvest year 2011 
were provided by the Almond Board of California. Each variety had 3 unique samples 
representing different orchards, for a total of n = 9 samples. Samples were not matched by 
orchard location or geography. Almond samples were stored at -20 °C in darkness until analysis.  
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4.3.2 Extraction of almond stilbenes.  
Whole, frozen almonds were ground to a powder using an IKA A11 Basic Grinder (St. 
Louis, MO). Extraction was based on methods previously described, with modifications (Sanders, 
McMichael et al. 2000). First, 10 g of almond powder was homogenized in 20 mL of ethanol and 
water (80:20, v/v) at 4 °C for 5 min using an IKA T-18 Basic Ultra-Turrax homogenizer at 
power level 4 (Staufen, Germany). The homogenate was then centrifuged for 10 min at 4 °C and 
3000 × g, and the supernatant was removed from the residue. The residue was homogenized and 
supernatant removed as above, for a total of three extractions. The supernatants were then 
combined and stored at -20 °C in darkness before clean-up. Before the clean-up step, 
supernatants were spiked with internal standard 1 (IS1, trans-resveratrol).  
For compartmentalization studies, almond skins were separated by hot water blanching 
(Bolling, Dolnikowski et al. 2009). A sample of ~100 g whole almond was placed in a beaker 
filled with 175 mL boiling water for 2 min. The blanch water was decanted, and its volume was 
recorded. The blanched almond skins were manually removed from the seed, and the meat and 
skins were dried at room temperature overnight. Almond meat, skins, and blanch water were 
stored at -20 °C until analysis. For extraction, almond skins (1 g) or meat (10 g) was powdered 
by a lab mill and homogenized in 20 mL of extraction solvent as described above. Blanch water 
was filtered through a 2.0 µm nylon membrane, spiked with the appropriate internal standard 2 
(IS2, pterostilbene), and analyzed directly by UHPLC-MS. 
4.3.3 Clean-up of extract 
The combined supernatant from whole-almond homogenate was cleaned-up by solid phase 
extraction (SPE) (Sanders, McMichael et al. 2000). First, a 1 cm diameter column was packed 
with 1 g of 1:1 (w/w) 50-200 µm neutral alumina and 40-63 µm, 60Å, endcapped C18 silica gel 
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(Sorbent Technologies, Norcross, GA). The column was successively preconditioned with 10 mL 
each of water, ethanol, and ethanol:water (80:20, v/v). The extract supernatant (3 mL) was 
applied to the column and collected by vacuum (2 to 3 drops per second). An additional 6 mL of 
80% ethanol was applied to the column and the eluate was collected. Both elutes were combined, 
dried under nitrogen gas at 23 °C, then held at -80 °C until UHPLC-MS analysis.  
4.3.4 UHPLC-MS analysis of stilbenes 
The dried residue from SPE was reconstituted with 50 µL of methanol and spiked with the 
appropriate internal standard (IS2) in 1 µL methanol. UHPLC-MS analysis was conducted using 
a Shimadzu Nexera UHPLC equipped with DGU-20A5 Prominence Degasser, SIL-30AC Nexera 
Auto Sampler, SPD-M20A Prominence Diode Array Detector, CTD-30A Nexera column oven, 
and two LC-30AD pumps (Kyoto, Japan) equipped with a Phenomenex Kinetex PFP column 
(1.7 µm, 100 Å, 2.1 × 50 mm, Torrance, CA, USA). The following gradient of water/formic acid 
(99.05:0.5, v/v) (A) and methanol (B) was used: 0 min, 70% A and 30% B; 6 min, 10% A and 90% 
B; 7 min, 10% A and 90% B; 8 min, 70% A and 30% B and held until the stop time at 10 min. 
The flow was maintained at 0.2 mL/min and the sample injection volume was 1 µL. Absorbance 
was monitored at 320 nm. Mass spectrometry analyses were performed using a Shimadzu 
LCMS-2020 mass spectrometer equipped with ESI, APCI, and DUIS (dual ionization) modes. 
The data were acquired in full-scan DUIS mode (MS) from m/z 100 to 500 in both positive and 
negative polarity modes, with instrument settings as follows: detector voltage was 1.1 kV, 
interface voltage was 4.5 V, nebulizing gas flow was 1.5 L/min, drying gas flow was 15.0 L/min, 
desolvation line was 250°C, heat block was 500°C, and Q-array DC was varied according to 
compounds of interest (Table 4.1). Signal (S) to noise (N) ratios were determined experimentally 
using area under the curve (AUC) values of external standards. The limit of detection (LOD) 
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(S/N > 3) and limit of quantification (LOQ) (S/N > 10) for standard compounds were determined 
experimentally by at least 3 injections of 2-fold serial dilutions of the calibration curve, where 
S/N = AUC/standard deviationAUC (Long and Winefordner 1983). Recovery was determined 
using IS1, whereas IS2 was used to normalize AUC values for quantitation. Quantification was 
based on MS AUC responses. 
4.3.5 Enzymatic hydrolysis of stilbene glucosides  
Almond extract was hydrolyzed as previously described (Rimando and Barney 2005) with 
modification. Briefly, 10 mL of almond extract (Section 2.2) was dried to ~1 mL by a nitrogen 
gas stream at 23 °C to remove ethanol. The pH of the extract was adjusted to 6 by using 0.1 M 
sodium hydroxide. The solution was hydrolyzed by incubating 30 units of β-D-glucosidase for 
18 h at 37 °C. The resulting solution was extracted three times with 6 mL ethyl acetate. The ethyl 
acetate extracts were combined and dried under a nitrogen gas stream at 23 °C. The dried ethyl 
acetate extract was resuspended in 3 mL ethanol:water (80:20, v/v) and subjected to SPE clean-
up as above (Section 2.3).  
4.3.6 Statistical analysis 
Data are presented as mean ± standard deviation of triplicate analyses of n samples 
indicated in tables and figures. Statistical significance was determined by two or one-way 
ANOVA, followed by Tukey’s multiple comparison test using GraphPad Prism v 5.01 software 
(GraphPad Software, Inc., La Jolla, CA). Differences were considered significant at P ≤ 0.05.  
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4.4 Results  
4.4.1 Method validation 
As shown in Table 4.1, 11 standards of stilbenes and stilbenes analogous were screened. 
Among them, trans-stilbene and E-resveratrol trimethyl ether could not be ionized under the 
given condition. 5 of them, polydatin, piceatannol, trans-resveratrol, dienestrol and 
oxyresveratrol, were ionized under negative model. Piceatannol and oxyresveratrol were eluted 
under the same RT and m/z ratio. The other 4 standards, pterostilbene, cis-resveratrol, hexestrol 
and d4-resveratrol were ionized under positive model. The condition of Q-array DC was also 
optimized, which too high may breakdown the ionized structure, and too low may insufficient to 
ionize the molecular. The on column LOD and LOQ of 4 common stilbenes: polydatin, 
piceatannol, trans-resveratrol and pterostilbene were also determined. They were ranged from 
0.38 pg/column to 24.41 pg/column, and from 1.53 pg/column to 146.48 pg/column. 
Pterostilbene, the most sensitive standard, had a 64-fold greater LOD sensitivity and a 96-fold 
greater LOQ sensitivity than trans-resveratrol. Comparing with its precursor, trans-resveratrol 
had a 16-fold lesser LOD sensitivity and a 24-fold lesser LOQ sensitivity than polydatin.  
The recovery rates for polydatin, piceatannol, trans-resveratrol, and pterostilbene were 
determined by spiking homogenates with standards prior to SPE clean-up (Table 4.2). Stilbene 
recoveries from SPE were 61 to 73%, except for piceatannol, which was not recovered. 
Piceatannol is rarely reported in botanical analysis, because the alumina/C18 SPE methods 
typically employed for stilbene clean-up give inadequate recovery of piceatannol (Sanders, 
McMichael et al. 2000, Rudolf, Resurreccion et al. 2005). Piceatannol analysis requires either 
direct injection or use of a C18 SPE clean-up method (Lin, Lien et al. 2007).   
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The intraday and interday variation of IS1 and IS2 were 7.5% and 8.3%, and 3.6% and 
1.4%, respectively.  
Dienestrol, cis-resveratrol, hexesterol, and d4-resveratrol could not be used as internal 
standards because of their incomplete resolution from compounds with the same m/z in almond 
extracts. Oxyresveratrol was not a suitable internal standard, as it co-eluted with piceatannol at 
an identical m/z ratio, and may be present in almonds (Section 3.2). Thus, none of these five 
stilbenes was a suitable internal standard. Trans-resveratrol was not observed in any preparations 
or samples run while characterizing almond stilbene content, and pterostilbene was not recovered 
from almond extracts (Table 4.2). Therefore, we used trans-resveratrol (IS1), to determine 
variance introduced by SPE and drying, and pterostilbene (IS2) to determine variance introduced 
by UHPLC-MS.  
4.4.2 Identification of almond stilbenes 
Based on the mass spectra of almond extract (Figure 4.1), only polydatin was identified 
based on the RT and m/z ratio. The other stilbene components were under the LOD.  
Due to the limitation of the clean-up step, piceatannol might present in almonds. However, 
it could not be determined based on the method used in this paper.  
         In contrast to almond extracts, which required SPE cleanup prior to UHPLC-MS analysis, 
almond blanch water was analyzed directly after filtration. Therefore, we examined if 
piceatannol was present in blanch water. Indeed, a peak corresponding to piceatannol was 
identified at 3.5 min and [M-H]- m/z 243 (Figure A.4.1). Piceatannol and oxyresveratrol co-
eluted in our UHPLC-MS method, so we could not exclude its presence in almonds. Therefore 
the piceatannol+oxyresveratrol content of almond varieties was 0.91-2.55 µg/100 g as 
quantitated by a piceatannol standard (Table 4.3). When accounting for the blanch water 
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recovery of piceatannol+oxyresveratrol, the total stilbenes content in almond were 8.33-9.60 
µg/100 g almonds. 
4.4.3 Polydatin identification and quantitation in almond.  
As shown in Figure 4.7.1, both specific RT which equaled to 2.9 and m/z ratio at 389 can 
testify the presentation of polydatin. However, other evidence should also be provided to rule out 
the possibility of other similar components. Due to the content of polydatin in almonds were 
insufficient for visible absorbance detection under 320 nm. A hydrolysis method was developed 
for polydatin identification.  
A β-D-glucosidase was chosen for hydrolyzing the β-D-glucosidic linkage between trans-
resveratrol and glucoside on polydatin. As shown in Figure 4.2, an ionized peak at 4.0 min (RT) 
and 227 m/z was shown on the chromatography of almond after hydrolysis. The peak had the 
similar RT and m/z ratio as the ionized trans-resveratrol. In contrary, a smaller ionized polydatin 
peak was also found, which indicated the polydatin in almond was hydrolyzed to trans-
resveratrol.  
By quantitative analysis of whole-almond ethanolic extracts, the polydatin content of 
Nonpareil, Butte and Carmel almonds was 7.19-8.52 µg/100 g almond and not significantly 
different between varieties (P = 0.8519) (Table 4.2). 
4.4.4 Compartmentalization of almond stilbenes 
Following almond blanching, the blanch water contained 96 to 98% of the total polydatin 
content, which were markedly higher than what was recovered in the dried skin (2 to 3%) and 
meat (~1%) after extraction (P <0.0001). When compartmentalized by blanching, polydatin 
content was highest in Butte and Carmel skins and meat and Nonpareil blanch water (Table 4.3).   
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4.5 Discussion 
A UHPLC-MS method was developed to quantitate stilbenes in almonds. Commercially 
available stilbenes or potential internal standards were examined for suitability for UHPLC-MS 
analysis (Table 4.1).  In our preliminary evaluation of standards by UHPLC-MS, pterostilbene, 
cis-resveratrol, hexestrol and d4-resveratrol had better S/N responses in positive ionization than 
negative ionization mode. In contrast, polydatin (resvatrol-3-O-β-glucoside), piceatannol, trans-
resveratrol, dienestrol and oxyresveratrol had better S/N in negative ionization than positive 
ionization mode. Other LC-MS quantitative methods for stilbenes have employed solely positive 
or negative ionization of stilbenes by ESI analysis (Kammerer, Claus et al. 2004, Counet, 
Callemien et al. 2006, Burkon and Somoza 2008).  
The Q-array DC voltage was also optimized for available commercial standard compounds 
(Table 4.1). In the Shimadzu LCMS2020, the Q-array is set after the ion source before the 
quadrupole and can apply a voltage that focuses ions entering the quadrupole. Increasing Q-array 
voltage may induce fragmentation of ions entering the quadrupole. The optimal Q-array voltages 
to maximize S/N varied between stilbenes.  Both cis- and trans-resveratrol along with polydatin 
gave better responses at a Q-array of -30 V. Cycling Q-array voltage from -100 to 100 V did not 
significantly improve detection of other stilbenes. Trans-stilbene and E-resveratrol trimethyl 
ether were not ionized under a range of conditions tested (Q-array DC from -100 to 100 V). 
Trans-stilbene was previously ionized by atmospheric-pressure chemical-ionization mass 
spectrometry using benzene as a carrier solvent (Macha, McCarley et al. 1999). E-resveratrol 
trimethyl ether cations were ionized by ESI using a methanol-water mixture with 10 mM 
ammonium acetate and 0.2% formic acid (Ma, Liu et al. 2007).    
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In ethanolic extracts of whole almonds, the stilbenes piceatannol, trans-resveratrol, and 
pterostilbene were below the LOD (Figure 4.1). These stilbenes have previously been reported 
in foods. For example, piceatannol was 0.14−0.42 µg/g dry weight in two Vaccinium species 
(Rimando, Kalt et al. 2004, Rimando and Barney 2005). Trans-resveratrol was reported in 
pistachio (0.09-1.67 µg/g), cocoa products (0.4-0.5 µg/g), peanut products (0.06-5.14 µg/g), 
Vaccinium species (0.01-5.88 µg/g dry weight), and grape skins (11.1-123.0 µg/g dry weight) 
(Sobolev and Cole 1999, Kammerer, Claus et al. 2004, Rimando, Kalt et al. 2004, Rimando and 
Barney 2005, Tokuşoǧlu, Ünal et al. 2005, Counet, Callemien et al. 2006). Pterostilbene was also 
reported in two Vaccinium species, at 0.1-0.5µg/g dry weight (Rimando, Kalt et al. 2004, 
Rimando and Barney 2005). Therefore, in most stilbene-containing foods, trans-resveratrol 
appears to be more abundant and widely distributed than other stilbenes.  
Polydatin was identified in whole almond ethanolic extracts based on RT (2.9 min) and the 
presence of the pseudomolecular ion [M-H]- at m/z 389, together with a peak corresponding to 
the resveratrol daughter ion [M-H-glucose]- at m/z 227 matching with a reference standard 
(Figure 4.1). We performed Q-array experiments to further confirm this peak as polydatin, as 
MS scan spectra were not definitive due to the presence of co-eluting compounds. Based on the 
presence of the m/z 227 (-) daughter ion at the same RT as polydatin, we assessed the 
relationship of these peaks by increasing Q-array DC voltage. Increasing the Q-array DC reduced 
the polydatin, and increased [M-glucose]- at m/z 227 at the same RT (Figure 4.2). A similar 
result was obtained when increasing the Q-array voltage during injections of almond extracts 
(Figure A.4.2). Therefore Q-array fragmentation and enzymatic hydrolysis of whole almond 
extract corroborate peak the peak at 2.9 min as polydatin. A similar approach could be used to 
screen for other polyphenol glucoside-conjugates by UHPLC-MS.  
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We utilized a β-D-glucosidase hydrolysis method to identify other putative stilbene 
glucosides in almond extracts. Enzymatic hydrolysis of almond extract reduced polydatin and 
catalyzed the formation of trans-resveratrol, and eliminated putative resveratrol-containing peaks 
at 1.2, 3.4, 5.2 and 5.7 min (Figure 4.2). Due to the presence of co-eluting peaks, MS scan data 
did not provide further insight into the identity of these compounds. Further work utilizing 
MS/MS methods is necessary to determine if these unidentified peaks are composed of 
resveratrol glucosides. For example, grape cell suspension cultures produced resveratrol 
diglucoside (Decendit, Waffo-Teguo et al. 2002) and stilbene dimers and dimer diglucosides 
were isolated and characterized from wine (Baderschneider and Winterhalter 2000). Thus, 
almond stilbene content may be more abundant and diverse than reported in the present study. 
Polydatin was also previously quantitated in peanut (7-38 µg/100 g), cocoa (100-120 µg/g), 
and pistachio (620 to 820 µg/100 g) (Counet, Callemien et al. 2006, Grippi, Crosta et al. 2008, 
Potrebko and Resurreccion 2009). In previous studies resveratrol content varied 31% among 12 
pistachio samples and ~90-fold among 15 peanut cultivars (Sanders, McMichael et al. 2000, 
Grippi, Crosta et al. 2008). Further work is needed to determine the relationship of almond 
stilbene content to climactic, genotype, seasonal, and geographical variance, as these variables 
can influence polyphenol content of tree nuts (Bolling, Chen et al. 2011).  
Polydatin was primarily present in almond skin, and readily extracted by hot water. Like 
almonds, stilbenes are also concentrated in grape and peanut skins (Sanders, McMichael et al. 
2000, Kammerer, Claus et al. 2004). For example, grape skins contained 86 and 77% 
respectively, of total grape resveratrol and polydatin content (Kammerer, Claus et al. 2004).  
In comparison to almond, the total stilbene content of peanuts and pistachios were 2.5-100 
times more than almonds (Sanders, McMichael et al. 2000, Grippi, Crosta et al. 2008). In 
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almonds, stilbenes appear to be less abundant than flavonoids, phenolic acids, ellagitannins, and 
proanthocyanidins, which are present in milligram quantities (Bolling, Chen et al. 2011, Xie, 
Roto et al. 2012). It should be noted that stilbenes have synergistic bioactivities with other 
polyphenols present in almonds. Resveratrol was synergistic with ellagic acid and quercetin at 
inducing caspase-3 activity in cultured human leukemia cells (Mertens-Talcott and Percival 
2005). Resveratrol was also synergistic with epigallocatechin gallate and γ-tocotrienol in the 
induction of quinone reductase activity in cultured MCF-7 breast cancer cells (Hsieh and Wu 
2008). Almond extracts also induce quinone reductase activity in murine hepatocytes (Chen and 
Blumberg 2008). In vivo, polydatin is metabolized to resveratrol-sulfate, resveratrol-disulfate 
resveratrol glucuronide, and resveratrol diglucuronide (Burkon and Somoza 2008). Considering 
the extensive metabolism of stilbenes and other polyphenols in vivo, further studies are needed to 
determine relevant synergies between almond stilbenes and other polyphenols. 
4.6 Conclusions 
Polydatin was identified in almond extracts, and concentrated primarily in almond skins. 
Piceatannol + oxyresveratrol was tentatively identified in almond blanch water, and less 
abundant than polydatin. Further work is warranted to determine the identity of components in 
almond extract with putative resveratrol daughter ions. Stilbene content was not significantly 
different among extracts of Nonpareil, Butte, and Carmel California almond varieties. The 
diversity of polyphenols in almonds and other polyphenol-rich foods suggests that attention 
should be given to the contribution of less abundant constituents to the synergy or antagonism of 
polyphenols. 
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4.7 Chapter 4 Tables and Figures 
Table 4.1 UHPLC-MS chromatography of various stilbene standards including instrument settings, limits of detection (LOD), and 
limits of quantification (LOQ). 
Standard Type Stilbene RT m/z Q-array DC LOD LOQ 
  (min) (ionization) (V) (pg/column) (pg/column) 
external polydatin 2.9 389 (-) -30 1.53 6.10 
external piceatannol 3.4 243(-) 0 1.53 12.21 
external trans-resveratrol 4.0 227 (-) -30 24.41 146.48 
external pterostilbene 6.2 257 (+) 0 0.38 1.53 
external cis-resveratrol 3.4 229 (+) +30 -- -- 
internal dienestrol 6.2 265 (-) 0 -- -- 
internal hexestrol 5.4 271 (+) 0 -- -- 
internal oxyresveratrol 3.4 243 (-) 0 -- -- 
internal d4-resveratrol 4.0 233 (+) +20 -- -- 
 
RT: Retention time 
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Table 4.2 Stilbene content of whole almonds and recovery of spiked standards determined by 
UHPLC-MS analysis. 
Compound Content in Almond Variety 
(µg/g) 
% recovery 
from clean-up 
 Butte Carmel Nonpareil  
polydatin 8.52 ± 3.47 7.44 ± 3.44 7.19 ± 2.19 73.0% 
piceatannol+oxyresveratrol NDA ND ND 0.0 % 
trans-resveratrol <LODB <LOD <LOD 67.0% 
pterostilbene <LOD <LOD <LOD 60.5% 
Data is mean ± standard deviation of three independent samples from each almond variety (n = 
9), P = 0.8519 for polydatin content between varieties by one-way ANOVA analysis. Recovery 
of stilbenes was determined by spiking almond homogenate with internal standard prior to solid 
phase extraction clean-up. AND, not determined as present method not suitable for quantitation; 
Bcontent in almond extract below the limit of detection of 0.25 pg trans-resveratrol/g almond and 
0.0039 pg pterostilbene/g almond.  
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Table 4.3 Stilbene content and proportion of California almond cultivars. 
Data are mean ± standard deviation of a composite sample representing three orchards for each 
almond cultivar. Within rows, values bearing different letters are significantly different by 
ANOVA and Tukey’s multiple comparison test (P ≤ 0.05). Two-way ANOVA analysis of 
almond stilbene content by almond compartment and cultivar is P < 0.0001 for compartment, 
variety, and for their interaction. AQuantitated as piceatannol equivalents.  
 
 
Almond 
compartment 
Compound 
Content in almond variety (µg/100 g almonds) 
Nonpareil Butte Carmel 
skin polydatin 0.15 ± 0.01b 0.22 ± 0.01a 0.22 ± 0.00a 
meat polydatin 0.06 ± 0.00b 0.08 ± 0.00a 0.08 ± 0.00a 
blanch water polydatin 8.43 ± 0.27a 6.75 ± 0.07b 6.33 ± 0.20b 
 
piceatannol + 
oxyresveratrolA 
0.91 ± 0.12c 2.55 ± 0.22a 1.71 ± 0.06b 
sum  9.55 ± 0.37a 9.60 ± 0.16a 8.33 ± 0.19b 
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Figure 4.1 Representative UHPLC-MS chromatograms of whole almond extract following solid 
phase extraction clean-up or standard compounds following a 1 µL injection. A: resveratrol 
standard at m/z 227 (-); B: piceatannol standard at m/z 243 (-); C: pterostilbene standard at m/z 
257 (+); D: polydatin standard at m/z 389 (-); E: almond sample at m/z 227 (-); F: almond 
sample at m/z 243 (-); H: almond sample at m/z 257 (+); G: almond sample at m/z 389 (-).  
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Figure 4.2 Representative UHPLC-MS chromatogram of a 1 µL injection of almond extract 
following solid phase extraction clean-up and before or after enzymatic hydrolysis with β-
glucosidase: A. m/z 227 (-) prior to hydrolysis; B. resveratrol [M-H]- m/z 227 after hydrolysis. 
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Figure 4.3 Representative UHPLC-MS chromatograms at m/z 389 (-) and 227 (-) of 0.4 ng 
polydatin on column at increasing Q-array DC voltages. 
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Chapter 5: Bioavailability of anthocyanins and 
colonic polyphenol metabolites following 
consumption of aronia berry extract
 103 
 
5.1 Abstract 
Background: Aronia berries are a rich food source of anthocyanins and other polyphenols, 
which likely contribute to their putative health benefits.  
Objectives: To develop UHPLC-MS methods to quantitate aronia berry polyphenols and their 
metabolites in plasma and urine samples. To determine the bioavailability and pharmacokinetics 
of aronia berry polyphenols in human.  
Design: A single-dose pharmacokinetic trial was conducted in 6 adults to evaluate the acute 
absorption and urinary excretion of anthocyanins and colonic polyphenol metabolites after 
consumption of 500 mg encapsulated aronia berry extract.  
Results: While anthocyanins were bioavailable, catabolites of phenolic acid by microbiota, 
including phenylacetic acid, hippuric acid, ferulic acid, and benzoic acids, increased ~10-fold 
more than total anthocyanins in plasma and urine. Among the anthocyanins, cyanidin-3-O-
galactoside was rapidly metabolized to peonidin-3-O-galactoside, and cyanidin-3-O-glucoside 
was present in plasma and urine at greater concentrations than other unmetabolized glycosides. 
Aronia polyphenols were absorbed and extensively metabolized with tmax of anthocyanins and 
other polyphenol catabolites from 1.0 h to 6.33 h in plasma and urine. Despite significant inter-
individual variation in pharmacokinetic parameters, concentrations of polyphenol metabolites in 
plasma and urine at 24 h were positively correlated with total AUC in plasma and urine (r = 
0.9275, and r = 0.9828, respectively). 
Conclusion: The results suggested that blood and urine collections after supplemental aronia 
extract consumption could be used to estimate its polyphenol bioavailability and metabolism.
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5.2 Introduction 
Aronia berries are a rich source of dietary polyphenols, including anthocyanins, 
hydroxycinnamic acids, and proanthocyanidins (Taheri, Connolly et al. 2013). Studies have 
suggested that aronia berry consumption improves dyslipidemia, inhibits inflammation, and 
reduces oxidative stress associated with chronic diseases in humans (Naruszewicz, Łaniewska et 
al. 2007, Skoczyńska, Jedrychowska et al. 2007, Porȩba, Skoczyńska et al. 2009, Broncel, 
Koziróg et al. 2010) and animals (Skoczyńska, Jedrychowska et al. 2007, Valcheva-Kuzmanova, 
Kuzmanov et al. 2007, Kujawska, Ignatowicz et al. 2011, Kim, Ku et al. 2013). Polyphenols are 
extensively metabolized and have apparently low bioavailability (Manach, Scalbert et al. 2004). 
Therefore, further data are needed to reconcile aronia polyphenol bioavailability with its 
apparent health effects.  
The most abundant aronia polyphenols, i.e., anthocyanins and proanthocyanins, have less 
than 6% bioavailability of the initial dose ingested (Miyazawa, Nakagawa et al. 1999, Cao, 
Muccitelli et al. 2001, Wu, Cao et al. 2002). When considering colonic metabolites, the 
bioavailability of anthocyanin and proanthocyanidins may range from 12% to 18% (Gonthier, 
Donovan et al. 2003, Czank, Cassidy et al. 2013). Anthocyanins can be absorbed in the intestine, 
and further subjected to phase II metabolism in the gut or liver (Wu, Cao et al. 2002, Kay 2006). 
Also, spontaneous degradation or microbial catabolism of anthocyanins may lead to the 
formation of phenolic acids, such as protocatechuic acid (Czank, Cassidy et al. 2013). Aronia 
proanthocyanidins are primarily polymeric, which limits absorption to its microbial catabolites 
(Déprez, Brezillon et al. 2000, Ou and Gu 2013). These catabolites include valerolactones, 
hydroxyphenyl propionic acids, hydroxyphenyl acetic acids, and hydroxybenzoic acids that are 
absorbed from the colon (Rios, Gonthier et al. 2003, Urpi-Sarda, Monagas et al. 2009).  
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The bioavailability and excretion of aronia anthocyanins and its phase II metabolites 
following juice and extract consumption has been prevoiously described (Kay, Mazza et al. 
2004, Kay, Mazza et al. 2005, Woodward, Kroon et al. 2009, Wiczkowski, Romaszko et al. 
2010). However, the bioavailability of major colonic catabolites has not been well-defined. The 
catabolism of aronia polyphenols converges on several key intermediates, including hippuric 
acid, protocatechuic acid, and phenylproprionic acids (Figure 5.1) (Wu, Cao et al. 2002, Prior 
2003, Wu, Pittman et al. 2004, El Mohsen, Marks et al. 2006, Monagas, Urpi-Sarda et al. 2010, 
Stalmach, Edwards et al. 2013). Therefore, the objectives of this study were to quantitate aronia 
anthocyanins and colonic polyphenol catabolites in humans following consumption of aronia 
extract. Furthermore, we describe the validation of analytical methods used to generate these 
data.  
5.3 Materials and methods  
5.3.1 Reagents and materials 
Methanol was LC-MS grade from Fischer Scientific (Fair Lawn, NJ, USA). Anthocyanin 
standards with ≥98% purity were purchased from Wuxi App Tec Co. (Shanghai, China). All 
other chemicals and reagents, including LC-MS grade formic acid and tribluoroacetic acid, were 
acquired from Sigma-Aldrich (St. Louis, MO, USA). Aronia berry extract was purchased from 
Artemis International (Fort Wayne, IA, USA) and packaged into opaque cellulose capsules 
containing 250 mg extract ± 10% per capsule (Beehive Botanicals, Hayward, WI, USA). 
5.3.2 Study participants and institutional approval 
Baseline characteristics of healthy 18 to 60 year old adults participated in the study are 
described in Table 5.1 Participants were part of a larger study evaluating the function of aronia 
 106 
 
berry supplementation in reducing cardiovascular disease risk in former smokers. All participants 
consented to the study and the research protocol was approved by the University of Connecticut 
Institutional Review Board as protocol #H11-311, and registered at ClinicalTrials.gov as 
NCT01541826. 
5.3.3 Inclusion criteria for study participants 
Former smokers, defined as people whom previously smoked ≥10 cigarettes/day for at 
least 1 year, and cessation for at least 6 months. The exclusion criteria used to screen for their 
eligibility included: 1) previous diagnoses of CVD, diabetes, or arthritis (except for 
osteoarthritis), 2) currently being treated for cancer (i.e., chemotherapy, radiation therapy), 3) 
women with prescribed estrogen replacement therapy, 4) having slimming diets, 5) practicing 
vegetarian diet, 6) currently taking vitamin or mineral supplements or plant pills, 7) alcohol 
consumption exceeding the definition of moderate drinking (2 drinks/day or a total of 12/week 
for men or 1 drink/day or a total of 7/week for women). 
5.3.4 Study design 
The participants were advised to consume a low polyphenol diet for at least 3 days before 
the study began. Participants avoided polyphenol-rich foods and beverages (green or black tea, 
fruit or vegetable juice, grape products, berries, and certain fruits) and dietary supplements. After 
an overnight fast, baseline plasma and urine samples were collected from participants. The 
participants then consumed two capsules of aronia extract with water, providing ~500 mg of 
extract. Subsequent blood samples were taken at 0.5, 1, 2, 4, 6, 9, 12, and 24 h post-consumption 
of the extract. Urine samples were also collected at 2, 4, 6, 9, 12, and 24 h post-consumption of 
the extract. Over the course of the following 24 h, low polyphenol diets were provided to 
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participants. Breakfast was provided after the consumption of the aronia capsules. Lunch was 
provided between hours 4 to 6 and dinner was provided between hours 6 to 9 after consumption 
of the aronia extract. Snacks were provided between meals. The low polyphenol diet and snacks 
consisted of dairy products, tuna, chicken, banana, potato chips, white bread, and plain bagels. 
Blood samples (20 mL) were drawn from a brachial vein into EDTA vacutainer tubes (BD, 
Franklin Lakes, NJ, USA). The blood samples were immediately placed on ice, and then 
centrifuged at 1,500 ×g for 15 min at 4°C to recover plasma. The plasma and urine samples were 
then acidified to 0.5% HCl and centrifuged at 2,500 ×g for 15 min at 4 °C to recover polyphenols 
(Woodward, Kroon et al. 2009). The supernatant was collect and stored at -80°C until analysis.  
5.3.5 Analysis and composition of aronia extract 
The polyphenol content of the aronia supplement was analyzed using methods previously 
reported by our group (Taheri, Connolly et al. 2013). Briefly, anthocyanins, flavonols, and 
hydroxycinnamic acids were quantitated by UHPLC-MS, proanthocyanidins by normal-phase 
HPLC, and total phenols by the Folin-Ciocalteu assay.  
5.3.6 Sample clean-up 
The extraction of anthocyanins and polyphenol metabolites from plasma and urine was 
adapted from the methods reported by others (Kay, Mazza et al. 2004). Solid phase extraction 
(SPE) of biofluid was performed using HyperSep C18 cartridges (500 mg/3 mL, Thermo 
Scientific, Waltham, MS) attached to a vacuum manifold. The SPE cartridge was preconditioned 
with 6 mL each of 0.5% formic acid in methanol (v:v) (A), and then 0.5% formic acid in water 
(v:v) (B). Plasma (1.5 mL) or urine (4 mL) was then applied to the cartridge. An additional 6 mL 
of B was then applied to wash the cartridge. Subsequently, the elute was collected with 6 mL of 
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A and dried under nitrogen gas at 23°C. The dried residue was held at −80°C until UHPLC–MS 
analysis. 
5.3.7 UHPLC-MS analysis  
Dried residue from SPE clean-up of urine or plasma was reconstituted with 100 µL 
methanol. UHPLC–MS analysis was conducted using a Shimadzu Nexera UHPLC equipped 
with DGU-20A5 Prominence degasser, SIL-30AC Nexera autosampler, CTD-30A Nexera 
column oven, two LC-30AD pumps (Shimadzu, Kyoto, Japan), LCMS-2020 mass spectrometer, 
and a Kinetex PFP column (1.7 µm, 100 Å, 2.1 × 50 mm; Phenomenex, Torrance, CA). The 
following chromatographic methods were developed to optimize resolution and detection of 
aronia polyphenols and metabolites in the reconstituted samples: 
3,4-Dihydroxybenzoic acid, 3,4-dihydroxyphenylacetic acid, hippuric acid, and ferulic 
acid: A gradient of water with formic acid (99.5:0.5, v/v) (A) and methanol (B) started at: 92% A 
and 8% B; increased to 10% B at 8 min; increased to 20% B at 9.6 min; increased to 30% B at 14 
min; increased to 40% B at 18 min; increased to 100% B at 25 min; returned to 8% B at 39 min, 
and was held until the stop time at 40 min. The flow was maintained at 0.2 mL/min and the 
sample injection volume was 1 μL.  
3-(4-Hydroxyphenyl)propionic acid: A gradient of water (A) and methanol (B) started at 
95% A and 5% B; increased to 100% B at 12 min; and returned to 5% at 16 min, and held until 
the stop time at 20 min. The flow was maintained at 0.2 mL/min and the sample injection 
volume was 1 μL.  
Cyanidin-3-O-glucoside, cyanidin-3-O-galactoside, cyanidin-3-O-arabinoside, and 
peonidin-3-O-galactoside: A gradient of water with trifluoroacetic acid (99.9:0.1, v/v) (A) and 
methanol (B) started at 80% A and 20% B; increased to 40% B at 9 min; increased to 100% B at 
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12 min; returned to 20% B at 18 min, and was held until the stop time at 20 min. The flow was 
maintained at 0.2 mL/min and the sample injection volume was 5 μL.  
For all chromatographic methods, the mass spectrometer was set to a nebulizing gas flow 
of 1.5 L/min, a drying gas flow of 15.0 L/min, the desolvation line at 250 °C, the heat block at 
500 °C, and the interface temperature at 350 °C. Other detector parameters were set to optimize 
the response of individual compounds of interest (Table 5.7.2).  
Signal (S) to noise (N) ratios, limits of detection (LOD), limits of quantification (LOQ) 
were determined for each compound based on methods previously described (Xie and Bolling 
2014). Quantitation was based on MS area under the curve (AUC) responses and comparison to 
authentic standards.  
5.3.8 Determination of recovery 
Recovery was determined according to the method of previous study (Wiczkowski, 
Romaszko et al. 2010). Briefly, blanks of plasma and urine samples were spiked with standard 
compounds to concentrations within the expected ranges of anthocyanins and metabolites (0.01-
42.2  µmol/L) that have been previously observed in human samples following anthocyanin 
consumption (Kay, Mazza et al. 2004, Kay, Mazza et al. 2005, Wiczkowski, Romaszko et al. 
2010, Czank, Cassidy et al. 2013). Polyphenol concentrations of spiked samples were determined 
by SPE clean-up and UHPLC-MS analysis as described above.  
5.3.9 Creatinine analysis 
The urine creatinine content was measured by an urinary creatinine colorimetric assay kit 
(Cayman Chemical, Ann Arbor, MI).  
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5.3.10 Pharmacokinetic and Statistical Analysis 
Cmax, tmax, and AUC of anthocyanins and metabolites in plasma and urine were determined 
as previously described (McKay, Chen et al. 2015). The results of plasma and urine variables 
included 6 subjects and are presented as means ± SEM, unless otherwise noted. Pearson 
correlation analysis with Fisher’s z transformation was conducted by SAS (9.4, SAS Institute, 
Inc., Cary, NC). Other statistical analysis was performed using GraphPad Prism (GraphPad 
Software, San Diego, CA, USA). Statistical significance was defined as P-value <0.05.  
5.4 Results  
5.4.1 Analysis of supplement 
The supplement constitute were reported in the Table 5.4. Anthocyanins and 
proanthocyanins were the most abundant polyphenol classes in aronia extract, accounting for 
34% and 31% of the total polyphenol content, respectively. Anthocyanins were primarily 
cyanidin-3-O-galactoside, cyanidin-3-O-glucoside, cyanidin-3-O-arabinoside, and cyanidn-3-O-
xyloside. Proanthocyanidins were 0.2% monomers, 7.1% dimers, 32.2% trimers, and 60.4% 
degree of polymerization (DP) >4. In total, a 500 mg dose of aronia berry extract provided 45.07 
mg anthocyanins, 41.9 mg proanthocyanidins as catechin equivalents, 9.9 mg flavonols, 36.9 mg 
hydroxycinnamic acids, and 306 mg total phenols as gallic acid equivalents. 
5.4.2 UHPLC-MS conditions for polyphenols in plasma and urine  
Mobile phase composition was essential for polyphenol detection and resolution in plasma 
and urine. Acid modifiers suppressed 3-(4-hydroxyphenyl)propionic acid ionization in both 
positive and negative operating modes. The use of 0.5% formic acid was adequate to resolve 
most polyphenols, but 0.1% trifluoroacetic acid was required to resolve cyanidin-3-O-galactoside 
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and cyanidin-3-O-glucoside. The range of recovery rates of protocatechuic acid, 3,4-
dihydroxyphenylacetic acid, hippuric acid, ferulic acid, 3-(4-hydroxyphenyl)propionic acid, 
cyanidin-3-O-galactoside, cyanidin-3-O-glucoside, cyanidin-3-O-arabinoside, and peonidin-3-O-
galactoside was 70% to 110% from plasma, and 43% to 119% from urine (Table 5.3). The 
intraday relative standard deviation (RSD) of analytes was from 0.83% to 10.83%, and the 
interday RSD was 1.32% to 11.46% (Table 5.7.3).  
5.4.3 Determination of anthocyanins and metabolites in plasma samples  
The retention time (RT), mass to charge ratio (m/z), LOD and LOQ of aronia 
anthocyanins and metabolites are reported in Table 5.2. Protocatechuic acid, hippuric acid, 3-(4-
hydroxyphenyl)propionic acid, cyanidin-3-O-glucoside, and peonidin-3-O-galactoside were 
recovered in plasma after aronia consumption (Figure 5.2 & Figure 5.4). Concentrations of 3,4-
dihydroxyphenylacetic acid, ferulic acid, cyanidin-3-O-galactoside, and cyanidin-3-O-
arabinoside, were not detected. Cyanidin-3-O-glucoside reached a peak concentration of 0.059 ± 
0.024 µg/mL at 1.6 h post-consumption, whereas polyphenol metabolites peaked at 1 h for 
protocatechuic acid, 2.67 h for peonidin-3-O-galactoside, 5.33 h for hippuric acid, and 6.33 h for 
3-(4-hydroxyphenyl)propionic acid (Table 5.5). AUC can be used to describe the absolute 
bioavailability of compounds (Lappin, Rowland et al. 2006). The plasma AUC ranged from 
0.054 ± 0.013 µg×h/mL for protocatechuic acid to 22.4 ± 4.4 µg×h/mL for hippuric acid. Among 
the plasma metabolites, hippuric acid accounted for 85.2% of the total quantitated polyphenols 
by their AUCs, followed by 3-(4-hydroxyphenyl)propionic acid (10.4%), peonidin-3-O-
galactoside (2.39%), cyanidin-3-O-glucoside (1.76%), and protocatechuic acid (0.21%). Thus, 
the microbial phenolic acid catabolites represented for around 95.8% of the total of increased 
polyphenols after aronia consumption. In contrast, anthocyanins accounted for 4.2% of the 
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increase in plasma polyphenols. Creatinine concentrations varied from 15.9 to 258 mg/dL in 
urine samples. 
5.4.4 Determination of anthocyanins and metabolites in urine samples 
Protocatechuic acid, 3,4-dihydroxyphenylacetic acid, hippuric acid, ferulic acid, 3-(4-
hydroxyphenyl)propionic acid, cyanidin-3-O-galactoside, cyanidin-3-O-glucoside, cyanidin-3-O-
arabinoside, and peonidin-3-O-galactoside were recovered in urine samples (Figure 5.3 & 
Figure 5.5). Cyanidin-3-O-galactoside reached a peak concentration of 0.004 ± 0.001 mg/mg 
creatinine at 4.67 h post-consumption. Also, the tmax and Cmax for cyanidin-3-O-glucoside and 
cyanidin-3-O-arabinoside were 6 h and 0.010 ± 0.006 mg/mg creatinine, and 4 h and 0.020 ± 
0.006 m g/mg creatinine, respectively (Table 5.5).  Phenolic acids peaked at 4 h for 
protocatechuic acid, 4.67 h for peonidin-3-O-galactoside, 4.83 h for 3-(4-
hydroxyphenyl)propionic acid, 5.33 h for ferulic acid, and 6.33 h for both 3,4-
dihydroxyphenylacetic acid and hippuric acid. The urine AUC ranged from 0.016 ± 0.005 
mg×h/mg creatinine for cyanidin-3-O-galactoside to 2430 ± 360 µg×h/mg creatinine for hippuric 
acid. Among the urinary metabolites, hippuric acid accounted for 98.5% of the total increase in 
polyphenols after aronia supplementation, followed by ferulic acid (0.80%), 3,4-
dihydroxyphenylacetic acid (0.46%), protocatechuic acid (0.15%), 3-(4-
hydroxyphenyl)propionic acid (0.09%), cyanidin-3-O-glucoside (0.004%), cyanidin-3-O-
arabinoside (0.004%), peonidin-3-O-galactoside (0.002%), and cyanidin-3-O-galactoside 
(0.001%). Thus, the polyphenol microbial catabolites represented nearly all of the increase in 
urinary polyphenols after aronia consumption.  
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5.4.5 Between-subjects differences 
There was large between-subject variation in the pharmacokinetics of aronia polyphenols 
and metabolites (Table 5.5). As a result, plasma anthocyanins were below the limit of detection 
in 3 participants. The Cmax interindividual CV for plasma polyphenols was generally greater than 
urinary polyphenols (20 - 65% vs 17 - 60%) except for hippuric acid, which had 23% and 34% 
CV in the urine and plasma, respectively. Also, anthocyanins had higher Cmax variation than 
phenolic acids in both urine and plasma. The interindividual Cmax range was largest for 3-(4-
hydroxyphenyl)propionic acid in plasma and urine, having 14- and 29-fold differences, 
respectively.  
5.4.6 Correlation Analysis  
The utility of using overnight fasting samples of plasma or urine to estimate polyphenol 
bioavailability and metabolism has not been validated. If the total AUC of polyphenols is not 
correlated with fasting concentrations, we would expect fasting concentrations to be a poor 
reflection of the previous exposure. Therefore, we determined the correlation of AUC values of 
aronia polyphenols and metabolites with the 24 h concentrations after an overnight fast. All 
metabolite concentrations in plasma and urine were significantly lower at 12-24 h post 
consumption compared to the total AUC. The Pearson correlation coefficients between the sum 
of polyphenols and metabolites in fasting plasma or urine and total AUC were 0.9275 (P < 
0.0001) and 0.9828 (P < 0.0001), respectively. When hippuric acid was not included in the sum 
of polyphenols and metabolites, the correlation between fasting plasma and total AUC was -
0.1890 (P = 0.4046). In contrast, overnight urine and total AUC correlation of metabolites and 
polyphenols without hippuric acid was still significant, at 0.9573 (P <0.0001). 
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5.5 Discussion 
The UHPLC-MS methods developed for polyphenol analysis in plasma and urine had 
acceptable reproducibility and sensitivity. Routine RSD was ≤10% without including an internal 
standard in the method. Including a stable isotope standard would be expected to further improve 
precision. The recovery rates after SPE of plasma polyphenols were 10% to 20% higher than 
previously reported, which was around 70% to 90% for other anthocyanin-rich foods (Zhang and 
Zuo 2004, Wiczkowski, Romaszko et al. 2010). However, the SPE recovery of urine polyphenols 
were 10% to 40% less than a previous study on aronia juice consumption (Wiczkowski, 
Romaszko et al. 2010). This difference may be a result of increasing the urine volume used for 
SPE. 
        The LODs of anthocyanins and their metabolites in this study were equivalent to 0.002 to 
0.05 nmol/L and 0.003 to 0.02 nmol/L in the plasma and urine, respectively, and the LOQs were 
equivalent to 0.004 to 0.1 and 0.01 to 0.04 nmol/L in the plasma and urine, respectively. This 
result was consistent with other studies about the lowest detection on anthocyanins and phenolic 
acids measured by HPLC or HPLC-MS, which was within a range of 0.01 to 0.2 nmol/L in 
plasma (Kay, Mazza et al. 2004, Vitaglione, Donnarumma et al. 2007, Wiczkowski, Romaszko 
et al. 2010). These results indicate the sensitivity of the UHPLC-MS is in range of prior studies.  
 The plasma tmax of 1.6 h for cyanidin-3-O-gluoside after aronia extract consumption was in 
the range of 1.3 to 3.1 h, which was reported in previous studies (Wiczkowski, Romaszko et al. 
2010). Plasma cyanidin-3-O-gluoside increased by 30 min post-consumption, which supports the 
hypothesis that anthocyanins can be absorbed though the stomach (Fernandes, de Freitas et al. 
2012). Fernandes, et al. (2012) demonstrated that cultured stomach cells absorbed anthocyanins 
via a saturable transport mechanism without biotransformation. Passamonti, et al. (2002) 
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proposed that bilitranslocase could be a high-affinity anthocyanin transporter in epithelial cells of 
rat gastric mucosa. However, while rodents have stomach bilitranslocase, to the best of our 
knowledge, it has not been identified in human stomach (Battiston, Macagno et al. 1999).  
 In the present study, plasma protocatechuic acid peaked as early as 1 h, which was 
consistent with previous studies that reported tmax values of protocatechuic acid 1-2 h after 
anthocyanin consumption (Vitaglione, Donnarumma et al. 2007, Keane, Bell et al. 2015). The 
aronia supplement in the present study provided 1.2 mg of protocatechuic acid, which may 
contribute to its early tmax. Also, other aronia polyphenols were also metabolized to 
protocatechuic acid, e.g. chlorogenic acid, quercetin, and caffeic acid (Figure 5.7.1). Thus, 
pharmacokinetic parameters of microbial polyphenol catabolites are likely botanical- or 
composition-specific. Generally, the phenolic catabolites had later peaks than cyanidin-3-O-
glucoside, which suggests these metabolites may be generated from colonic metabolism of 
anthocyanins. Since the major aronia anthocyanin, cyanidin-3-O-galactoside, was not detected in 
the plasma, it could be a major source of the colonic catabolites. Urinary colonic polyphenol 
catabolite concentrations peaked later than those in plasma, except for 3-(4-
hydroxyphenyl)propionic acid. The lower concentrations of anthocyanins in both plasma and 
urine samples confirm their extensive metabolism and low bioavailability (Scalbert, Morand et 
al. 2002). 
The aronia supplement provided 45.07 mg anthocyanins, which was similar to the dose 
provided by 250 mL juice in a prior pharmacokinetic study (Wiczkowski, Romaszko et al. 2010). 
The peak plasma concentration of cyanidin-3-O-glucoside and peonidin-3-O-galactoside from 
the aronia supplement was more than 10-fold greater than the previous study of juice, which was 
~1.0 nmol/L. However, plasma peak concentration of cyanidin-3- O-galactoside was ~12.0 
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nmol/L after juice consumption, while this was undetectable after extract consumption. This 
suggests that cyanidin-3-O-galactoside in aronia extract is likely metabolized to peonidin-3-O-
galactoside more quickly than that in juice. 
Participants had significant interindividual variation of polyphenol bioavailability after 
aronia extract consumption. Data linking gender, age, and health status to polyphenol 
bioavailability is very limited. Bioavailability and colonic polyphenol catabolism can be 
influenced by intestinal enzyme activity, intestinal transit time, and colonic microbes (Sterchi, 
Mills et al. 1990). Intestinal lactase-phlorizin hydrolase (LPH) may mediate the bioavailability of 
cyanidin-3-O-glycosides and its activity varies significantly between individuals (Kay, Mazza et 
al. 2004, Kay 2006). Van Duynhoven, et al. (van Duynhoven, Vaughan et al. 2011) also 
proposed that the wide variation of polyphenol metabolism was because a result of the diversity 
of the colonic microbiota. Thus, variable polyphenol bioavailability may result from a number of 
factors. Besides differences in metabolic fate, the total bioavailability of polyphenols varies 
between individuals. According to Czank, et al. (Czank, Cassidy et al. 2013), the recovery of 13C 
in blood, urine, breath, and feces was in the range of 15.1 to 99.3% in 8 patients that consumed 
500 mg 13C labeled cyanidin-3-glucoside. Urpi-Sarda, et al. (Urpi-Sarda, Monagas et al. 2009) 
have indicated that changes in human urinary levels of phenolic acids and flavanols vary from 
0.001 to 59.43 nmol/mg creatinine in 21 subjects who consumed proanthocyanidin-rich cocoa 
powder.  
In this study, we quantitated aronia anthocyanins and polyphenol catabolites. It should be 
noted that other metabolites are produced from aronia polyphenols beyond those measured in the 
present study (Figure 5.1) (Manach, Williamson et al. 2005). A previous study have identified 
22 metabolites of cyanidin-3-O-glucoside using an isotopic approach (Czank, Cassidy et al. 
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2013). The metabolites of anthocyanins generated from intestine and liver include phase I, phase 
II and colonic metabolites (Wu, Cao et al. 2002, Czank, Cassidy et al. 2013, de Ferrars, Czank et 
al. 2014). The phase I metabolites mainly include phloroglucinaldehyde, 3,4-
dihydroxybenzaldehyde, and hydroxybenzoic acid (Czank, Cassidy et al. 2013, de Ferrars, Czank 
et al. 2014). The phase II metabolites are glucuronidated and methylated cyanidins (Wu, Cao et 
al. 2002, Czank, Cassidy et al. 2013, de Ferrars, Czank et al. 2014). Colonic anthocyanin 
metabolites include hydroxybenzoic acid, hippuric acid, phenylpropenoic acids, and ferulic acid 
(Czank, Cassidy et al. 2013, de Ferrars, Czank et al. 2014). Thus, the present study did not 
quantitate all plausible polyphenol metabolites due to the difficulty in obtaining standards. 
Furthermore, the polyphenol catabolites in the present study could be products of multiple 
polyphenol catabolic pathways. For example, hydroxybenzoic acid and ferulic acid are also the 
major metabolites of proanthocyanins (Rios, Gonthier et al. 2003).  
This study was a part of a larger study evaluating aronia berry polyphenol supplementation 
on cardiovascular disease risk. The significant correlation between fasting plasma or urine 
samples with total polyphenol AUC suggested that fasting polyphenol concentrations could be 
used as a marker of compliance and/or catabolic fate of aronia extract polyphenols. However, the 
correlation between plasma polyphenol AUC and fasting concentrations was low without 
including hippuric acid. This may result from that the wide variation in hippuric acid, and fewer 
types of metabolites observed in the plasma. Others have also suggested that urinary polyphenols 
might be a better predictor of polyphenol intake than food frequency questionnaires in analysis 
of association between polyphenol intake and all-cause of mortality in adults (Zamora-Ros, 
Rabassa et al. 2013).  
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5.6 Conclusions 
In conclusion, we developed UHPLC-MS methods to determine bioavailability of aronia 
extract polyphenols and metabolites. The current study indicates that aronia extract anthocyanins 
are extensively metabolized. Total fasting plasma and urine polyphenols 24 h after aronia extract 
consumption correlated with bioavailability so they could be used as a marker of polyphenol 
metabolism in individuals when consuming a low-polyphenol diet. Future work should consider 
the extent of the significant interindividual variation in aronia polyphenol metabolism when 
determining intervention efficacy on health outcomes.  
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5.7 Chapter 5 Tables and Figures 
Table 5.1 Characteristics of participant population. 
Characteristic Male (n = 3) Female (n = 3) 
Age 22.3 ± 1.5 40.3 ± 7.3 
SBP (mmHg) 112.7 ± 2.9 112.0 ± 6.4 
DBP (mmHg) 70.7 ± 2.0 76.3 ± 2.7 
Waist circumference (cm) 81.3 ± 5.5 75.0 ± 3.0 
BMI (kg/m2) 24.9 ± 1.3 24.2 ± 1.4 
Fasting TC (mg/dL) 160.7 ± 17.6 168.7 ± 24.5 
Fasting HDL (mg/dL) 48.7 ± 2.8 65.3 ± 9.1 
Fasting LDL (mg/dL) 92.7 ± 12.0 96.0 ± 12.5 
Fasting TG (mg/dL) 96.7 ± 27.0 63.0 ± 11.5 
Fasting glucose (mg/dL) 93.0 ± 4.6 99.3 ± 1.45 
Data is mean ± SEM. SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total 
cholesterol; TG: Triglyceride. 
 
 
 
 
 
 
  
1
2
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Table 5.2 Optimized MS instrument parameters for UHPLC analysis of polyphenols from plasma and urine. 
Method Standard IV 
(kV) 
DV 
(kV) 
IV 
(kV) 
DLV 
(V) 
Q array DC 
(V) 
Q array RF  
(V) 
1 protocatechuic acid -3.5 3.5 -3.5 -10 -10 20 
3,4-dihydroxyphenylacetic 
acid 
-5 3.5 -5 -70 -10 20 
hippuric acid -5 3.5 -5 -70 -10 20 
ferulic acid 5 3 5 0 20 20 
2 3-(4-hydroxyphenyl)propionic 
acid 
-5 -3.5 -5 -70 -50 30 
3 cyanidin-3-O-galactoside 4 3.5 4 100 0 50 
cyanidin-3-O-glucoside 4 3.5 4 100 0 50 
cyanidin-3-O-arabinoside 4 3.5 4 100 30 40 
peonidin-3-O-galactoside 4 3.5 4 100 30 50 
DV: detector voltage; IV: interface voltage; DLV: desolvation line Voltage; Q array DC: Q array direct current; Q array RF: Q array 
radio frequency. Method 1: formic acid (99.5:0.5, v/v) (A) and methanol (B); Method 2: water (A) and methanol (B); Method 3: 
trifluoroacetic acid (99.9:0.1, v/v) (A) and methanol (B). 
  
1
2
1 
Table 5.3 Polyphenol retention time (RT), m/z ratio, LOD, LOQ and recovery rates of standards of optimized UHPLC-MS methods. 
Standard RT m/z LOD 
(pg/column) 
LOQ 
(pg/column) 
Recovery 
rate 
(Plasma) 
Recovery 
rate 
(Urine) 
Intraday 
RSD 
Interday 
RSD 
protocatechuic acid 3.7 (-)153 4.88 9.77 81% 73% 4.54% 7.29% 
3,4-dihydroxyphenylacetic 
acid 
4.0 (-)167 19.53 39.06 70% 92% 6.02% 5.35% 
hippuric acid 5.4 (-)178 2.44 4.88 101% 104% 7.75% 11.46% 
ferulic acid 17.4 (+)195 29.30 29.06 93% 114% 0.83% 6.42% 
3-(4-hydroxyphenyl)propionic 
acid 
10.5 (-)165 24.4 48.8 72% 119% 1.08& 7.29% 
cyanidin-3-O-galactoside 8.8 (+)449 312.5 625.0 71% 43% 10.83% 9.10% 
cyanidin-3-O-glucoside 9.3 (+)449 195.3 448.3 104% 43% 2.12% 9.98% 
cyanidin-3-O-arabinoside 10.1 (+)419 58.6 73.2 110% 58% 6.34% 5.49% 
peonidin-3-O-galactoside 10.3 (+)463 14.6 24.4 100% 63% 4.89% 1.32% 
RT: retention time; m/z: mass to charge ratio.  
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Table 5.4 Polyphenol composition of aronia supplement. 
Assay Component Chokeberry Supplement 
(mg/500 mg) 
polyphenols by UPLC-
MS 
rutin 2.6 ± 0.0 
neochlorogenic acid 3.5 ± 0.0 
chlorogenic acid 31.9 ± 0.3 
protocatechuic acid 1.2 ± 0.0 
caffeic acid 0.3 ± 0.0 
quercetin-3-galactoside 3.6 ± 0.1 
quercetin-3-glucoside 2.9 ± 0.1 
quercetin 0.8 ± 0.0 
cyanidin-3-galactoside + 
cyanidin-3-glucoside 
32.52 ± 0.7 
cyanidin-3-arabinoside 11.79 ± 0.3 
cyanidn-3-xyloside 0.76 ± 0.0 
proanthocyanidins by 
DMAC 
(+)-catechin equivalents 41.9 ± 0.4 
proanthocyanidins by 
HPLC 
(+)-catechin equivalents 2.6 ± 0.1 
 % monomers 0.2 ± 0.0 (%) 
 % dimers 7.1 ± 0.3 (%) 
 % trimers 32.2 ± 0.7 (%) 
 % 4-mers 24.2 ± 0.5 (%) 
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 % 5-mers 14.9 ± 1.0 (%) 
 % 6-mers 6.5 ± 0.5 (%) 
 % 7-mers 3.1 ±0.3 (%) 
 % 8-mers 1.2 ±0.1 (%) 
 % ≥ 9-mers 10.5 ±1.1 (%) 
total phenol by Folin 
assay 
gallic acid equivalents 306.0 ± 4.11 
Data is mean ± SD of at least duplicate determinations. 
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Table 5.5 Pharmacokinetic parameters of anthocyanins and metabolites in plasma and urine 
samples in n = 6 individuals consuming 500 mg aronia extract.  
 
tmax  Cmax (range) AUC  
Plasma h µg/mL μg×h/mL 
Protocatechuic acid 1.00 ± 0.00 
0.005 ± 0.001 
(0.004-0.007)* 
0.054 ± 0.013 
Hippuric acid 5.33 ± 0.67 
2.169 ± 0.495 
(0.873 to 3.488) 
22.350 ± 4.441 
3-(4-hydroxyphenyl)propionic 
acid 
6.33 ± 1.45 
0.211 ± 0.135 
(0.033-0.475) 
2.725 ± 2.391 
Cyanidin-3-O-glucoside 1.60 ± 0.24 
0.059 ± 0.024 
(0.014-0.180) 
0.462 ± 0.170 
Peonidin-3-O-galacoside 2 67 ± 0.67 
0.075 ± 0.049 
(0.029-0.266) 
0.627 ± 0.198 
Urine h mg/mg creatinine mg×h/mg creatinine 
Protocatechuic acid 4.00 ± 0.52 
0.431 ± 0.075 
(0.208-0.650) 3.682 ± 0.587 
3,4-dihydroxyphenylacetic acid 6.33 ± 2.25 
0.700 ± 0.130 
(0.552-1.238) 11/426 ± 0.881 
Hippuric acid 6.33 ± 2.25 
190.156 ± 42.136 
(59.966-316.070) 2429.852 ± 360.197 
Ferulic acid 5.33 ± 3.50 
1.773 ± 0.609 
(0.323-4.137) 19.770 ± 6.167 
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3-(4-hydroxyphenyl)propionic 
acid 4.83 ± 2.04 
0.477 ± 0.222 
(0.023-0.643) 2.299 ± 0.715 
Cyanidin-3-O-galactoside 4.67 ± 1.03 
0.004 ± 0.001 
(0.002-0.010) 0.016 ± 0.005 
Cyanidin-3-O-glucoside  6.00 ± 3.35 
0.010 ± 0.006 
(0.002-0.004) 0.118 ± 0.070 
Cyanidin-3-O-arabinoside 4.00 ± 1.26 
0.020 ± 0.006 
(0.002-0.038) 0.088 ± 0.031 
Peonidin-3-O-galactoside 4.67 ± 1.03 
0.010 ± 0.002 
(0.003-0.014) 0.053 ± 0.012 
Data is mean ± SEM (n=6). The data were collected from participants whom consumed 500 mg 
of a polyphenol-rich aronia supplement within 24 hour after consumption. 
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Figure 5.1 Proposed metabolic pathway of aronia polyphenols determined in the present study. 
Red lines represent colonic catabolic steps, while blue lines represent tissue metabolism. (Wu, 
Cao et al. 2002, Prior 2003, Wu, Pittman et al. 2004, Monagas, Urpi-Sarda et al. 2010, Stalmach, 
Edwards et al. 2013). 
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Figure 5.2 Plasma concentrations of (A) cyanidin-3-O-glucoside, (B) peonidin-3-O-galactoside, 
(C) protocatechuic acid, (D) 3-(4-hydroxyphenyl)propionic acid, and (E) Hippuric acid, 
0 5 10 15 20 25
0.00
0.04
0.08
0.12
Time point (h)
C
o
n
c
e
n
tr
a
ti
o
n
 (
µ
g
/m
L
)
A
0 5 10 15 20 25
0.00
0.05
0.10
0.15
Time point  (h)
C
o
n
c
e
n
tr
a
ti
o
n
 (
µ
g
/m
L
)
B
0 5 10 15 20 25
0.0000
0.0025
0.0050
0.0075
Time point (h)
C
o
n
c
e
n
tr
a
ti
o
n
 (
µ
g
/m
L
)
C
0 5 10 15 20 25
0.00
0.15
0.30
0.45
Time point (h)
C
o
n
c
e
n
tr
a
ti
o
n
 (
µ
g
/m
L
)
D
0 5 10 15 20 25
0.000
0.001
0.002
0.003
Time point (h)
C
o
n
c
e
n
tr
a
ti
o
n
 (
m
g
/m
L
)
E
 128 
 
following consumption of 500 mg of a polyphenol-rich aronia supplement. Data is mean ± SEM 
of n = 6 participants.  
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Figure 5.3 Cumulative urinary excretion of aronia polyphenols and catabolites following 
consumption of 500 mg of a polyphenol-rich aronia supplement.  
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Figure 5.4 Chromatograms of (A) polyphenol standards and (B) representative plasma samples.
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Figure 5.5 Chromatograms of (A) polyphenol standards and (B) representative urine samples.
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Chapter 6: Aronia berry polyphenol consumption 
reduces plasma LDL and total cholesterol in 
former smokers without lowering biomarkers of 
inflammation or oxidative stress 
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6.1 Abstract 
Background: Former smokers are at increased risk of cardiovascular disease (CVD). Little is 
known about the ability of dietary polyphenols to reduce CVD risk in former smokers. Aronia 
berry is a rich source of anthocyanins, hydroxycinnamic acids, and proanthocyanidins. Upon 
consumption, these polyphenols are extensively metabolized. The significant interindividual 
variation of polyphenol metabolism may modulate the ability of aronia consumption to reduce 
CVD risk. 
Objective: We hypothesized that dietary aronia polyphenols would reduce CVD risk factors and 
improve biomarkers of inflammation and oxidative stress in former smokers. We also tested if 
these effects were associated with interindividual differences in polyphenol metabolism and 
bioavailability. 
Design: A 12-week multiple-dose, randomized, placebo-controlled trial was conducted in 49 
adults (n = 24/placebo, n = 25/aronia) to evaluate if consumption of 500 mg aronia extract per 
day modulates plasma lipids, plasma biomarkers of inflammation, oxidative stress biomarkers in 
plasma and urine, and lipid transport genes of peripheral blood mononuclear cells (PBMCs).  
Results: Aronia consumption reduced fasting plasma total cholesterol (TC) level by 8% during 
the 12-week treatment (P = 0.0140) compared with placebo group, and reduced plasma low-
density lipoprotein cholesterol (LDL-C) level by 7 % and 11% at both 6 wks and 12 wks 
compared with placebo group, respectively (P = 0.0285). Increases in the urinary polyphenol 
metabolites peonidin-3-O-galactoside, 3-(4-hydroxyphenyl)propionic acid, and unmetabolized 
anthocyanin cyanidin-3-O-galactoside were associated with lower plasma TC and LDL-C in the 
aronia group. Participants in the aronia group who showed the largest decreases in TC had 
stronger correlations of urinary peonidin-3-O-galactoside and cyanidin-3-O-galactoside than 
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those who did not respond to the intervention. However, aronia and placebo consumption did not 
change biomarkers of inflammation and oxidative stress. 
Conclusion: Aronia polyphenols reduced total and LDL-C in former smokers but did not 
improve biomarkers of oxidative stress and chronic inflammation. The total cholesterol-lowering 
effect of aronia polyphenols was most closely associated with the tissue and microbial 
metabolism of aronia polyphenols, particularly the formation of peonidin-3-O-galactoside.   
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6.2 Introduction 
Cigarette smoking increases oxidative stress and inflammation, which increases 
cardiovascular disease (CVD) risk through vasomotor dysfunction, leukocyte and platelet 
activation, lipid peroxidation, adhesion and inflammatory molecules activation, and smooth 
muscle proliferation (Ambrose and Barua 2004). In the last decade, smoking cessation has 
increased, and in the United States, former smokers outnumber current smokers (Services 2014). 
Although smoking cessation reduces CVD risk, CVD risk in former smokers remains elevated 
for 10 to 15 years compared with never-smokers (Tilloy, Cottel et al. 2010, Godtfredsen and 
Prescott 2011). Former smokers also have compromised vascular and antioxidant function, 
suggesting the need for additional strategies to further reduce CVD risk (Helmersson, Larsson et 
al. , Jin, Webb-Robertson et al. 2011).  
 Aronia berry consumption may reduce CVD risk by improving dyslipidemia, inhibiting 
inflammation, and reducing oxidative stress (Naruszewicz, Łaniewska et al. 2007, Skoczyńska, 
Jedrychowska et al. 2007, Valcheva-Kuzmanova, Kuzmanov et al. 2007, Jurgoński, Juśkiewicz 
et al. 2008, Porȩba, Skoczyńska et al. 2009, Broncel, Koziróg et al. 2010, Kujawska, Ignatowicz 
et al. 2011, Kim, Ku et al. 2013). Aronia berries has high levels of polyphenols, and its 
anthocyanins, hydroxycinnamic acids, and proanthocyanidins may mediate its putative health 
benefits (Taheri, Connolly et al. 2013). Increased aronia berry polyphenol intake reduces 
biomarkers of CVD risk in some populations. Daily consumption of 300 mg aronia extract for 2 
months decreases blood pressure, total cholesterol (TC), low-density lipoprotein cholesterol 
(LDL-C) and total triglyceride (TG), and increased antioxidant enzyme activity in adults with 
metabolic syndrome (Broncel, Koziróg et al. 2010). Similarly, patients that survived a 
myocardial infarction and were prescribed statins whole also consuming 255 mg aronia extract 
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per day for 6 weeks demonstrated reduced blood pressure, oxidized low-density lipoprotein (ox-
LDL), high-sensitivity C reactive protein (hsCRP) and monocyte chemoattractant protein 1 
(MCP-1) when compared to patients that consumed a placebo (Naruszewicz, Łaniewska et al. 
2007). Other anthocyanin-rich interventions modulate lipids and improve other biomarkers of 
CVD risk in individuals with dyslipidemia or metabolic syndrome (Qin, Xia et al. 2009, Basu, 
Du et al. 2010, Basu, Betts et al. 2011). Therefore, the consumption of aronia berries and other 
dietary anthocyanins appear to be a promising intervention for populations at higher risk of 
CVD.   
 Anthocyanins and polyphenols from aronia and other berries have limited bioavailability 
and are extensively metabolized (Manach, Scalbert et al. 2004). The interindividual variability of 
polyphenol pharmacokinetics is considerable (Manach, Williamson et al. 2005). Interindividual 
variability in polyphenol metabolism is due in part to genetic polymorphisms in xenobiotic 
metabolizing enzymes and transporters, as well as variation in gut microbial catabolism 
(Scheline 1999, Barnes 2008). The extent to which individual differences in polyphenol 
metabolism are associated with the efficacy of dietary polyphenol interventions for reducing 
CVD risk is largely unknown. Therefore, the primary objective of this study was to determine 
the ability of aronia polyphenols to reduce plasma lipids and biomarkers of oxidative stress and 
inflammation in former smokers, while the secondary objective was to determine the extent in 
which aronia polyphenol bioavailability is associated with changes in CVD risk biomarkers.  
6.3 Materials and methods  
6.3.1 Participants 
Interested participants were recruited from Storrs, CT area from July 2012 to May 2015. 
Participants were pre-screened by phone, and then visited the University of Connecticut 
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Nutritional Sciences Department to provide informed consent and subsequent eligibility 
screening. The screening consisted of a standard medical history questionnaire and determination 
of height, weight, BMI, waist circumference, blood pressure, and a routine laboratory analysis of 
a fasting blood sample for blood sugar and TC.  The inclusion criteria were: former smokers who 
had previously smoked ≥3 cigarettes/day for at least 1 year and ceased for at least 6 months; 
healthy male or female between 18-65 years of age; premenopausal status for women; serum TC 
<240 mg/dL and serum TG <150 mg/dL; resting blood pressure <140/90 mm Hg; stable body 
weight (± 5 lb) during the prior 2 months with a BMI between 18.5 kg/m2 and 39 kg/m2; 
willingness to maintain a normal exercise level (<7 h/wk) and avoid exercise 24 h prior to blood 
sampling; and willingness to ingest an aronia berry supplement or placebo daily for 12 wks. The 
exclusion criteria of this study were: previous diagnosis of CVD, diabetes, or arthritis (except for 
osteo-arthritis); current treatment for cancer; women with perimenopausal or menopausal 
symptoms or prescribed estrogen replacement therapy; adherence to a slimming or vegetarian 
diet; current consumption of vitamin, mineral, or botanical supplements; and consumption of 
alcohol exceeding the definition of moderate drinking (2 drinks/day or a total of 12/week for 
men or 1 drink/day or a total of 7/week for women). All participants consented to the study. The 
research protocol was approved by the University of Connecticut Institutional Review Board as 
protocol #H11-311, and listed at ClinicalTrials.gov as NCT01541826. 
6.3.2 Study design  
The participants were advised to consume a low polyphenol diet for a minimum of 4 weeks 
before the intervention and were randomly assigned to consume 500 mg of aronia berry extract 
or the placebo. The supplements were opaque, color-matched, and provided 250 mg of extract or 
placebo per capsule. The participants and study personnel were blinded to the composition of the 
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intervention material. The aronia extract provided 45.07 mg anthocyanins, 35.73 mg 
hydroxycinnamic acids, and 41.9 mg proanthocyanidins per 500 mg dose. The placebo was 
composed of rice powder with 0.2% beet juice concentrate. The extract and placebo passed 
quality control measures of microbial pathogens, heavy metals, pesticides, and residual solvents. 
The compositions of the aforementioned intervention materials are further described in Table 6.1 
and Table 5.4. The polyphenol content of placebo and supplement changed less than 10% over 
the course of the study.  
Participants completed a three-day dietary record during the run-in period prior to the 
intervention. At the start of the intervention and again at week 12, participants completed an 
overnight fast, and baseline blood and urine samples were collected the following morning. 
Study personnel subsequently determined height, weight, and blood pressure. At week 6, 
participants were again asked to fast overnight for 12 h prior to arriving at the study center for 
anthropometric measurements and collection of fasting blood samples. All participants were 
advised to consume a low polyphenol diet, moderate alcohol consumption, and maintain their 
normal physical activity throughout the course of intervention.  
6.3.3 Preparation of biological samples  
Blood samples (80 mL) were drawn from a brachial vein into EDTA vacutainer tubes (BD, 
Franklin Lakes, NJ, USA) to recover plasma and peripheral blood mononuclear cells (PBMCs). 
Another 10 mL blood sample was drawn from a brachial vein into evacuated glass tubes (BD, 
Franklin Lakes, NJ, USA) to recover serum. The blood samples were immediately placed on ice, 
and centrifuged at 1,500 ×g for 15 min at 4 °C to recover plasma. For serum collection, the blood 
samples were allowed to clot at room temperature for 25 min and then centrifuged at 1000 ×g for 
15 min at 4 °C. Plasma and urine aliquots for polyphenol analysis were acidified using 0.5% HCl 
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and centrifuged at 2,500 ×g for 15 min at 4 °C. The supernatants were collected and stored at -80 
°C until analysis. PBMCs were isolated from whole blood samples using Ficoll-Paque premium 
(GE Healthcare, Pittsburgh, PA, USA) by density gradient centrifugation. Whole blood samples 
were diluted 1:1 with sterile PBS, and the diluted blood samples were layered over 2:1 with 
Ficoll-Paque premium, and centrifuged at 700 ×g for 20 min to separate the PBMCs. The buffy 
coat-containing PBMCs were collected, washed twice with PBS, and the cells were resuspended 
in ice-cold FBS. The cell suspensions were diluted 1:1 with cryopreservation media (fetal bovine 
serum, 20% dimethyl sulfoxide) to a final concentration of 107 cells/mL and frozen in CoolCell 
containers (BioCision, LLC, Larkspur, CA, USA) at −80 °C for 24 h. The plasma were then 
transferred to liquid nitrogen for storage.   
6.3.4 Anthropometric measurements 
In a quiet location, participants were seated for at least 10 min in a chair with their back 
supported, feet on the floor, legs uncrossed, having an empty bladder, and the upper arm 
supported at heart level (Pickering, Hall et al. 2005). Before all visits, participants were asked to 
refrain from exercise or ingesting caffeine the day of the measurement. Blood pressure (BP) was 
measured in the left arm using an Omron HEM-780 automatic BP monitor (Omron Healthcare, 
Inc., Bannockburn, IL, 60015) three times with one minute intervals between measurements. If 
the readings were within 5 mmHg, the readings were averaged and recorded as resting systolic 
and diastolic blood pressure. If a difference of > 5 mmHg between readings occurred, the 
measurements were repeated until three readings were within 5 mmHg. Body weight and height 
were measured on a digital physician scale (Detecto 758C, Cardinal Scale Manufacturing 
Company). Waist circumference was determined by placing a measuring tape evenly around a 
bare abdomen at hipbone level. 
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6.3.5 Plasma lipid analysis 
As previously described, plasma lipid concentrations were determined enzymatically using 
Cholesterol Reagent (Pointe Scientific, Canton, MI) and a L-Type TG M kit (Wako Chemical, 
Richmond, VA) for TC and TG, respectively (Kim, Ku et al. 2013). High-density lipoprotein 
cholesterol (HDL-C) was measured after precipitation of apolipoprotein B-containing lipoprotein 
in plasma, and non-HDL-C was calculated by subtraction of HDL-C from TC. Precinorm L 
(Roche, Indianapolis, IN) was used as a control. The Friedeman LDL formula was used to 
determine LDL-C concentration (Equation 1).  
         Equation 1:   LDL-C = TC – HDL – TG/5  
6.3.6 Analysis of inflammatory biomarkers 
Inflammatory biomarkers were measured in plasma samples by ELISA. Plasma adiponectin 
(eBioscience, San Diego, CA), interleukin-6 (IL-6) (eBioscience, San Diego, CA), interleukin-1β 
(IL-1β) (eBioscience, San Diego, CA), MCP-1 (eBioscience, San Diego, CA), tumor necrosis 
factors-α  (TNF-α) (eBioscience, San Diego, CA), and C-reactive protein (CRP) (eBioscience, 
San Diego, CA) were determined as described by the respective manufacturers’ protocols. 
6.3.7 Analysis of biomarkers related to oxidative status  
         Biomarkers of oxidative stress and total antioxidant activity were measured in both plasma 
and urine to investigate the antioxidant effects of aronia polyphenol supplementation. Assay kits 
were used following manufacturers' instructions to measure plasma oxidized LDL by 
immunoassay (MyBiosource, San Diego, CA), catalase activity (Cayman Chemical, Ann Arbor, 
MI), glutathione peroxidase (GSH-PX) activity (Cayman Chemical, Ann Arbor, MI), and 
superoxide dismutase (SOD) activity (Cayman Chemical, Ann Arbor, MI). Plasma total 
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antioxidant capacity was measured using the 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic 
acid) (ABTS) radical scavenging assay and expressed as mg vitamin C equivalent (VCE)/mL as 
previously described (Wang, Yang et al.). Urinary 8-isoprostanes were also measured by 
immunoassay (Cayman Chemical, Ann Arbor, MI) and the amount was normalized with urinary 
creatinine. 
6.3.8 Analysis of plasma biomarkers of vascular reactivity 
Concentrations of cell adhesion molecules including inter-cellular adhesion molecule-1 
(ICAM-1), vascular adhesion molecule-1 (VCAM-1), and P-selectin in serum were measured 
using assay kits for Bio-Plex Magpix multiplex reader with xPotent software (Luminex, Austin, 
TX). 
6.3.9 Gene expression analysis by quantitative realtime PCR (qRT-PCR) 
Cryopreserved PBMCs were thawed and slowly added to 15 mL of phosphate-buffered 
saline (PBS), and then 0.25 mL of 1 mg/mL DNAse were added to prevent PBMC clumping. 
Pelleted PBMCs were obtained by centrifugation at 300 ×g for 6 min. Total RNA was isolated 
from pelleted PBMCs using TRIzol reagent (Invitrogen, Grand Island, NY, USA) and qRT-PCR 
analysis of gene expression was conducted as previously described using the SYBR Green 
procedure and CFX96 realtime PCR detection system (Bio-Rad, Hercules, CA) (Park, 
Rasmussen et al. 2008, Rasmussen, Blobaum et al. 2008). Primer sequences were designed 
according to GeneBank database using the Beacon Designer software (Premier Biosoft, Palo 
Alto, CA) (Rasmussen, Blobaum et al. 2008). GAPDH was used as an internal control. 
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6.3.10 Western blot analysis 
Protein was extracted from pelleted PBMCs as previously described (Rasmussen, Blobaum 
et al. 2008). Western blot analysis was performed using antibodies against 3-hydroxy-3-methyl-
glutaryl coenzyme A reductase (HMGR) and -actin (Sigma, St. Louis, MO) as previously 
described (Rasmussen, Blobaum et al. 2008). The blots were developed using a horseradish 
peroxidase system (Pierce), and densitometry analysis was performed using a Chemidoc XRS+ 
(Bio-Rad) and Image Lab software (Bio-Rad). -Actin was used as a loading control. 
6.3.11 Urinary creatinine analysis 
The urine creatinine was measured by a urinary creatinine colorimetric assay (Cayman 
Chemical, Ann Arbor, MI). Creatinine concentrations varied from 15.26 to 573.92 mg/dL in 
urine samples. 
6.3.12 Plasma and urinary polyphenol analysis 
Polyphenols were isolated from plasma and urine by solid phase extraction (SPE) and 
quantitated by UHPLC-MS as we previously described in Chapter 5. Briefly, plasma and urine 
samples were applied to HyperSep C18 SPE cartridges (Thermo Scientific, Waltham, MS) 
attached to a vacuum manifold. The eluate was collected with 0.5% formic acid in methanol 
(v:v) and dried under nitrogen gas. Dried residue was reconstituted with methanol. UHPLC–MS 
analysis was conducted using a Shimadzu Nexera UHPLC equipped with LCMS-2020 mass 
spectrometer. Separate chromatographic methods were used to detect 3,4-dihydroxybenzoic acid, 
3,4-dihydroxyphenylacetic acid, hippuric acid, and ferulic acid; 3-(4-hydroxyphenyl)propionic 
acid; and cyanidin-3-O-glucoside, cyanidin-3-O-galactoside, cyanidin-3-O-arabinoside, and 
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peonidin-3-O-galactoside. Limits of detection (LOD), limits of quantification (LOQ), and intra- 
and inter-day variance have been listed in Chapter 5.  
6.3.13 Statistics 
Changes in plasma lipids and anthropometric markers after supplementation were log-
transformed and analyzed by a repeated measures MANOVA model using JMP® Pro 11 (SAS 
Institute, Inc., Cary, NC). All other data were analyzed using SAS (9.4, SAS Institute, Inc., Cary, 
NC). Baseline differences between the placebo and treatment groups were analyzed by two 
sample t-test and chi square test. Group differences in biomarkers over time were analyzed by 
repeated measures ANOVA and assuming 100% compliance. For these data, a univariate 
approach was applied when the sphericity assumption was violated. A multivariate approach was 
applied when the sphericity assumption was not violated (Austin). A log transformation was 
applied when the normal assumption was violated. Principle component analysis and Pearson 
correlation were used to measure the association of changes in urinary polyphenol and plasma 
lipids. Data was expressed as mean ± standard error of mean. 
6.4 Results 
6.4.1 Participant characteristics 
After informed consent, 56 participants were enrolled and randomized (26 men and 30 
women) and 49 participants completed the study (Figure 6.1). The reasons for drop-out included 
not responding to communication from study personnel (n = 2 placebo, and n = 3 supplement), 
weight gain (n = 1 placebo), and headache (n = 1 placebo). Participant characteristics are listed 
in Table 6.2. There were no significant differences between the two groups, other than the 
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average years of smoking in the aronia group that was five years less than that of the placebo 
group.  
6.4.2 Anthropometric measurements 
Participant waist circumferences were 85.57 ± 2.87 cm for the aronia group and 86.16 ± 
4.86 cm for the placebo group at baseline (P = 0.9163) (Table 6.2). Over the course of the study 
participant waist circumferences were reduced with the aronia and placebo groups having 1 and 
5% lower waist circumference, respectively, at week 12 (P = 0.0075) (Table 6.4). At baseline, 
systolic blood pressures were not different between groups, at 117 ± 3 and 121 ± 3 mmHg in the 
aronia and placebo groups, respectively (P = 0.3643). However, the placebo group had lower 
diastolic pressure than the aronia group at week 6 (74.8 ± 1.8 vs 80.2 ± 2.2 mmHg) (P = 0.0331) 
which had persisted through week 12. The BMI of both groups were not different at baseline, but 
the placebo group mean BMI decreased from 27.0 ± 0.9 to 26.8 ± 0.9 over the course of the 
study (P = 0.0354). 
6.4.3 Plasma lipids 
Participants had borderline high TC at baseline with 220.11 ± 12.59 mg/dL for the aronia 
group and 203.41 ± 7.25 mg/dL for the placebo group (P = 0.2037). Aronia polyphenol 
consumption reduced TC by 8 % at 12 wks, compared to no significant change in the placebo 
group (P = 0.0140) (Table 6.3). The mean LDL-C for each group was above optimal, with 
175.42 ± 10.80 and 158.26 ± 6.07 mg/dL for the aronia and placebo group, respectively (P = 
0.1289). The aronia group had 7 and 11% less LDL-C at both 6 and 12 wks from baseline, with 
no significant changes to LDL-C in the placebo group (P = 0.0285). Participants had low TG 
with 89.58 ± 9.08 mg/dL for the aronia group and 82.08 ± 7.62 mg/dL for the placebo group (P = 
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0.4858), and low HDL with 26.77 ± 1.52 mg/dL for the aronia group and 28.75 ± 1.25 mg/dL for 
the placebo group (P = 0.2715). Neither intervention significantly changed HDL-C or TG from 
baseline values. 
6.4.4 Expression of hepatic genes involved in lipid metabolism 
LDL receptor (LDLR) and HMGR mRNA expression of PBMCs were not different 
between the placebo and aronia groups at baseline or 12 wk (Table 6.5). However, aronia 
supplement consumption reduced LDLR protein in PBMCs 56 % from baseline at 12 wk (P = 
0.0036). In contrast, LDLR protein of PBMCs in the placebo group was unchanged from 
baseline at 12 wk. 
6.4.5 Other biomarkers relevant to CVD risk 
Plasma cytokines (IL-6, IL-1β, and TNF-α), CRP, adiponectin, vascular adhesion 
molecules (sICAM and sVCAM), chemokines (MCP-1), antioxidant enzyme activity (CAT, 
GSH-Px, and SOD), and markers of lipid oxidation (urinary 8-isoprostanes and oxLDL) were 
determined at baseline, 6, and 12 wk in both groups (Table 6.5). None of these biomarkers 
significantly changed in either group at 6 and 12 wk.   
6.4.6 Urinary and plasma polyphenols  
Analysis of dietary records did not reveal differences of polyphenol intake between the 
groups at any time point (Table A.6.1). Aronia polyphenols and their key intermediates were 
determined in plasma and urine to evaluate the relative enrichment and metabolism of the 
supplemental polyphenols in participants. The baseline level of peonidin-3-O-galactoside and 
sum of anthocyanins in aronia group were 6.2 μg/mg creatine and 0.332 mg/mg creatine, 7-8 
times higher than that in placebo group (P = 0.0461 and P = 0.0441) (Table 6.6). At 12 wk, 
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protocatechuic acid, 3,4-dihydroxyphenylacetic acid, hippuric and ferulic acid were detected in 
all individuals in both groups without differences at the baseline. However, at least 25% of 
participants did not accumulate urinary 3-(4-hydroxyphenyl)propionic acid, cyanidin-3-O-
glucoside, cyanidin-3-O-galactoside, cyanidin-3-O-arabinoside or peonidin-3-O-galactoside in 
significant quantities, as all were below the LOD. At 12 wk, the change from baseline of total 
urinary polyphenol excretion was not significantly different for either intervention. However, the 
polyphenol profiles of the aronia and placebo group could be distinguished by canonical 
discriminate analysis with 80% confidence (Figure A.6.1). At baseline and 12 wk, fasting 
plasma polyphenols were lower than the LOD for most of the participants in both placebo and 
aronia groups, except for hippuric acid (Table 6.7). The range of plasma polyphenol and 
metabolite concentrations for the aronia group was similar to those of the placebo group. 
6.4.7 Association of urinary polyphenols and lipids changes in aronia group 
A multivariate approach was used to determine the association of urinary polyphenols to 
changes in plasma lipids at 12 wk from baseline. In the aronia group, changes of urinary 
polyphenol and its metabolites were associated with the changes of lipid in the plasma (Figure 
6.2). Cohen’s standard was used to determine the strength of the correlation between the 
difference of plasma lipids and urinary polyphenols at 12 wk from baseline (Δ), where 
correlation coefficients between 0.10 and 0.29, 0.30 and 0.49, and greater than 0.50 represented 
small, medium and large associations, respectively. Peonidin-3-O-galactoside Δ had a medium 
inverse association with plasma TC Δ and LDL-C Δ (P-value = 0.0645 and P-value = 0.1104, 
respectively). Cyanidin-3-O-galactoside Δ and 3-(4-hydroxyphenyl)propionic acid Δ both had 
small inverse associations with plasma TC Δ (P-value = 0.1912 and P-value =0.4993, 
respectively) and LDL-C Δ (P-value = 0.2586 and P-value = 0.4176, respectively). A strong 
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positive association was observed between 3,4-dihydroxyphenylacetic acid Δ and plasma HDL-C 
Δ. A medium positive association was observed between protocatechuic acid Δ and plasma 
HDL-C Δ. Hippuric acid Δ and ferulic acid Δ also had small positive associations with plasma 
HDL-C Δ. Cyanidin-3-O-glucoside Δ was strongly inversely associated with plasma TG Δ. 
Small inverse associations were also observed between plasma TG Δ and urinary polyphenol 
metabolites including ferulic acid Δ, cyanidin-3-O-galactoside Δ, cyanidin-3-O-arabinoside Δ, 
and peonidin-3-O-galactoside Δ. In contrast, the placebo group did not have medium or large 
associations between urinary polyphenols Δ and plasma lipids Δ. 
6.4.8 Analysis by respondent to total cholesterol 
To further examine participant response to aronia consumption, we also classified 
participants as responders or non-responders to the intervention. An aronia responder was 
defined as a participant who lost more than 10 mg TC/dL from baseline at 12 wk, and an aronia 
non-responder was a participant who lost less than 10 mg TC/dL. Aronia responders (n = 14) had 
higher baseline TC at baseline (248.09 ± 17.06 vs 188.96 ± 13.12 mg/dL, P = 0.0117) as well as 
a slightly higher urinary peonidin-3-O-galactoside Δ (0.01577 ± 0.00890 vs -0.00400 ± 0.00222, 
P = 0.0998). Aronia responders had a medium association of peonidin-3-O-galactoside Δ and 
plasma TC Δ, whereas these were not associated in non-responders (Figure 6.3). In addition, 
responders consuming aronia extract had distinct polyphenol metabolite profiles from non-
responder. Particularly, responders had more closely correlated peonidin-3-O-galactoside Δ and 
cyandin-3-O-galactoside Δ than non-responders (Figure 6.4).  
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6.5 Discussion 
In the present study, consumption of 500 mg of an anthocyanin-rich aronia berry extract 
daily for 12 weeks did not change plasma biomarkers of chronic inflammation in former smokers 
(Table 6.5). This contrasts prior studies that have characterized the mechanism by which 
anthocyanins may inhibit chronic inflammation. Increased anthocyanin consumption or direct 
application of anthocyanins to cells reduces NF-κB activation, thereby inhibiting the expression 
of pro-inflammatory chemokines and cytokines (Blanco-Colio, Valderrama et al. 2000, Kim, 
Tsoy et al. 2006, Karlsen, Retterstøl et al. 2007, Xia, Ling et al. 2007, Martin, Taheri et al. 
2014). Anthocyanins can also inhibit the pathogenesis of atherosclerosis and plaque formation by 
reducing IL-6, IL-8, MCP-1 and ICAM-1 induced by TNF-α and CD40 in human endothelial 
cells (Atalay, Gordillo et al. 2003, García-Alonso, Rimbach et al. 2004, Xia, Ling et al. 2007). 
Anthocyanin pretreatment of cultured human umbilical vein endothelial cells inhibited VCAM-1, 
nuclear GATA-4, nuclear GATA-6 and nuclear interferon regulatory transcription factor-1 (IRF-
1) expression in human, which suggests a role of the Jak/STAT pathway in preventing monocyte 
adhesion and subsequent inflammation (Nizamutdinova, Kim et al. 2009). Large doses of 
anthocyanin-rich foods or extracts reduce biomarkers of inflammation in healthy individuals. 
Daily consumption of 280 g cherries reduced plasma CRP after 4 weeks of intervention (Kelley, 
Rasooly et al. 2006). Additionally, a single 12 g dose of an anthocyanin-rich extract from red 
wine grape decreased plasma level of MCP-1 24 h after intake (Garcia-Alonso, Minihane et al. 
2009). 
Aronia berry consumption has an inconsistent anti-inflammatory effect among participants 
with increased CVD risk. Participants with metabolic syndrome that consumed a 300 mg dose of 
aronia berry extract per day did not have significant changes in CRP from a baseline of 2.62 ± 
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2.5 mg/dL after 8 weeks (Broncel, Koziróg et al. 2010). However, participants who had suffered 
myocardial infraction and consumed 255 mg of aronia berry extract and statins daily for 6 weeks, 
had 23% lower CRP from a baseline of 4.48 ± 2.56 mg/L (Naruszewicz, Łaniewska et al. 2007). 
In the same study, aronia consumption reduced MCP-1 by 23% from a baseline of 305.9 ± 87.5 
pg/mL (Naruszewicz, Łaniewska et al. 2007). The former smokers in the present study had 
baseline levels of CRP and MCP-1 that were at least 70% lower than the population of 
participants that suffered a myocardial infarction (7). Thus, aronia consumption may only have 
an anti-inflammatory effect in populations with relatively higher levels of chronic inflammation.   
Aronia berry extract consumption did not modulate markers of antioxidant function and 
oxidative stress in former smokers. However, over 8 wk, aronia berry extract consumption 
modulates the serum antioxidant capacity of participants with metabolic syndrome by reducing 
erythrocyte CAT activity and increasing erythrocyte SOD and GSH-Px activities (Broncel, 
Koziróg et al. 2010). Blueberry anthocyanins (1.2 g) consumed with high-fat meals for 7 days 
improves serum antioxidant capacity (oxygen radical absorbance capacity) of healthy male 
individuals compared with placebo consumption, with the change positively correlated to serum 
anthocyanin content (Mazza, Kay et al. 2002). Anthocyanins may directly protect membrane 
fatty acids of endothelial cells from oxidation and DNA cleavage induced by increased 
inflammation (Youdim, McDonald et al. 2002, Acquaviva, Russo et al. 2003). The 500 mg dose 
of the anthocyanin-rich aronia extract used in the present study did not appear to sufficiently 
enrich plasma to exert antioxidant activity, as peak concentrations were 0.004 to 3.488 µg/mL. In 
contrast, a lower dose of aronia berry extract reduces plasma ox-LDL and urinary 8-isoprostanes 
in participants that suffered from myocardial infarction (Naruszewicz, Łaniewska et al. 2007). 
The ox-LDL and 8-isoprostanes reported by Naruszewicz, et al (Naruszewicz, Łaniewska et al. 
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2007) are not comparable to the present study due to significant differences in analytical 
methods. However, when compared to a report using similar methods, urinary isoprostanes of 
former smokers in the present study was 3-fold lower than that of participants with coronary 
artery disease (Kim, Hyun et al. 2008, Noriega, Pennanen et al. 2009). Former smokers in the 
present study had less oxidative stress and more favorable plasma lipid profiles (lower plasma 
LDL-C, TG, and TC and higher HDL-C) than participants in other trials where aronia intake 
improved antioxidant function (Naruszewicz, Łaniewska et al. 2007, Broncel, Koziróg et al. 
2010).  
Consumption of anthocyanin-rich foods also lowered TC, LDL-C, and TG in previous 
studies (Qin, Xia et al. 2009, Basu, Du et al. 2010, Broncel, Koziróg et al. 2010, Basu, Betts et 
al. 2011). Low CVD risk is defined as TC less than 200 mg/dL, LDL-C between 100 to 120 
mg/dL, and HDL-C more than 40 mg/dL (Services). The former smokers in the present study 
had increased risk of CVD due to greater than optimal levels of TC and LDL-C. Aronia extract 
consumption lowered plasma LDL-C level at 6 and 12 wks, and TC at 12 wk. Responders to the 
aronia intervention had higher baseline TC than non-responders, suggesting that individuals with 
hypercholesterolemia may benefit the most from increased polyphenol consumption. Our prior 
pre-clinical work suggests that aronia berry polyphenols reduce TC through mechanisms 
independent of the modulation of hepatic mRNA expression of lipid-metabolizing genes, and 
possibly by intestinal mechanism of cholesterol efflux (Kim, Ku et al. 2013, Martin, Taheri et al. 
2014). In the present study, LDLR protein of PBMCs was reduced by aronia extract consumption 
without a corresponding change of LDLR mRNA. Post-translational regulation of LDLR protein 
by proprotein convertase subtilisin/kexin type 9 (PCSK9) might explain this observation (Park, 
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Moon et al. 2004), but further studies are needed to identify how aronia polyphenols modulate 
LDLR expression.  
Aronia berry consumption reduced blood pressure, waist circumference, and BMI of 
participant with metabolic syndrome or abdominal obesity (Kardum, Petrovi et al. 2014, Sikora, 
Broncel et al. 2014). These parameters were not affected by aronia consumption in the present 
study. The mean blood pressure of the aronia group met the criteria of prehypertension (120-
139/80-89 mm Hg) (Association). However, in trials where aronia reduced blood pressure, 
participants had higher blood pressure (127.6 ± 16.9/83.5 ± 9.9 to 136.8 ± 10.9/86.8 ± 16.0 
mmHg), larger waist circumference (95.0 ± 9.4 cm to 104.8 ± 10.1 cm) and greater BMI (30.9 ± 
3.7 kg/m2 to 36.1 ± 4.4 kg/m2) (Kardum, Petrovi et al. 2014, Sikora, Broncel et al. 2014). It was 
suggested that aronia juice and polyphenols could reduce the blood pressure of spontaneously 
hypertensive rat model (Hellström, Shikov et al. 2010). The observed effect might result from of 
the angiotensin converting enzyme (ACE)-inhibitory activity of cyanidin-3-O-glucoside, 
proanthocyanidin oligomers and phenolic metabolites of aronia polyphenols (Ottaviani, Actis-
Goretta et al. 2006, Hellström, Shikov et al. 2010, Hidalgo, Martin-Santamaria et al. 2012).  
Under well-controlled dietary conditions, the dose of aronia polyphenols consumed in the 
present study could increase transient accumulation and excretion of polyphenols. However, the 
same dose did not significantly enrich aronia polyphenols and microbial metabolites in these 
biofluids after 12 wk consumption. Given the low abundance in plasma, urinary excretion of 
polyphenols and metabolites are a better indicator of polyphenol bioavailability than plasma 
concentrations (Tresserra-Rimbau, Rimm et al. 2014).  
Although polyphenol-rich aronia berries may have atheroprotective effects, compounds or 
metabolites may be associated with these effects are unknown. Within the aronia group, greater 
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reductions of plasma TC and LDL-C were associated with increases in urinary cyanidin-3-O-
galactoside, peonidin-3-O-galactoside, and 3-(4-hydroxyphenyl)propionic acid. Thus, aronia 
polyphenol metabolites peonidin-3-O-galactoside and 3-(4-hydroxyphenyl)propionic acid and 
parent compounds (cyanidin-3-O-galactoside) were associated with the cholesterol-lowering 
mechanism of aronia berry. A precursor of 3,4-dihydroxyphenylacetic acid and ferulic acid, 3-(4-
hydroxyphenyl)propionic acid can also be derived from microbial metabolism of aronia 
anthocyanins, chlorogenic acid, or proanthocyanidins. 3-(4-Hydroxyphenyl)propionic acid 
catabolites have the potential to reduce plasma TC and LDL-C levels in rodents (Lee, Park et al. 
2007). Thus, 3-(4-hydroxyphenyl)propionic acid might be a functional precursor to cholesterol-
modulating compounds. A large inverse association was found between cyanidin-3-O-glucoside 
and plasma TG levels in the aronia group, which was also observed in another study that 
suggested cyanidin-3-O-glucoside could improve TG metabolism by the activation of lipoprotein 
lipase (LPL) activity in plasma and skeletal muscle but suppression of LPL activity in visceral 
adipose (Wei, Wang et al. 2011). Comparative data on anthocyanin structure-function activity 
and mechanisms of lipid metabolism are lacking. However, even minor structural differences can 
alter anthocyanin anti-inflammatory activity in vitro (Martin, Taheri et al. 2014). 
There were several limitations of this study.  First, participants did not synchronize daily 
consumption of the intervention. The interindividual variation of fasting urinary and plasma 
polyphenol concentrations could result from the time of consumption and do not solely reflect 
bioavailability. Furthermore, participants did not strictly adhere to low-polyphenol diets, as 
anthocyanins were detected at the baseline. Therefore, consumption of other polyphenol-
containing foods might significantly affect polyphenol excretion. 
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6.6 Conclusions 
Consumption of 500 mg aronia berry extract for 12 wks improved biomarkers of CVD risk 
in former smokers by reducing LDL-C by 10% and TC by 8%. However, this intervention did 
not change CRP, 8-isoprostane, and other biomarkers of chronic inflammation and oxidative 
stress. Regular consumption of aronia extract in high dose may be impractical, and given the 
apparently lower baseline markers of inflammatory and oxidative stress, have limited benefits. 
Increased excretion of peonidin-3-O-galactoside, and to a lesser extent, cyanidin-3-O-galactoside 
and 3-(4-hydroxyphenyl)propionic acid were most associated with reductions in TC and LDL-C, 
which suggested host and microbial metabolism have a role in the cholesterol-lowering 
mechanism of aronia berry extract consumption. These specific associations could arise from 
structure-function differences between polyphenols and metabolites and may begin to explain 
why polyphenol-interventions are more effective in some individuals with metabolic pathways 
favoring production of these compounds. 
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6.7 Chapter 6 Tables and Figures 
Table 6.1 Non-polyphenol contents analysis in aronia berry supplement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assay Aronia berry 
Supplement (mg/500 
mg) 
Total sugar 7.5  
Total Sugar Alcohol 4.1 
Vitamin C < 0.005 
Minerals < 0.4 
Vitamin B < 0.02 
Organic Acids < 4.9 
Sterol < 0.005 
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Table 6.2 Baseline characteristics of study population 
Measurement Placebo 
(n=24) 
Aronia 
(n=25) 
P Value 
 
Age 37.37 ± 3.02 32.6 ± 2.57 0.2337 
Gender (%Male) 46% 52% 0.6660 
Average years of Smoking 14.85 ± 2.43 8.96 ± 1.34 0.0404 
Average Num. of Cigarettes/d 
     3-5 Cigarettes/d 
     6-10 Cigarettes/d 
     11-15 Cigarettes/d 
     16-20 Cigarettes/d 
     >20 Cigarettes/d 
 
2 
4 
4 
11 
3 
 
4 
7 
4 
6 
4 
 
0.5447 
Height (cm) 172.97 ± 1.88 171.44 ± 1.66 0.5447 
Weight (kg) 81.64 ± 3.47 77.18 ± 4.15 0.4151 
BMI (kg/m2)    27.04 ± 0.93 25.64 ± 1.15 0.3429 
Waist Circumference (cm) 85.57 ± 2.87 86.16 ± 4.86 0.9163 
Blood Pressure (mmHg) 
      Systole 
     Diastole 
 
121.00 ± 2.95 
76.00 ± 2.12 
 
116.96 ± 3.29 
75.28 ± 2.41 
 
0.3643 
0.8224 
Total Cholesterol (mg/dL) 203.41 ± 7.25 220.11 ± 12.59 0.2037 
HDL-C (mg/dL) 28.75 ± 1.25 26.77 ± 1.52 0.2715 
Triglycerides (mg/dL) 82.08 ± 7.62 89.58 ± 9.08 0.4858 
LDL-C (mg/dL) 158.26 ± 6.07 175.42 ± 10.80 0.1289 
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TC/HDL Ratio  7.27 ± 0.31 8.54 ± 0.53 0.0284* 
Data was expressed as mean ± standard error of mean and analyzed by t-test. 
*P < 0.05.  
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Table 6.3 Changes in plasma lipids in former smokers after daily consumption of 500 mg aronia 
extract or a placebo 
 
Biomarker Week Δ baseline (mg/dL) P-value RM-MANOVA 
  Aronia (n = 
25) 
Placebo (n = 
24) 
Group Time Time*Gro
up 
Total 
Cholesterol 
6 1.4 ± 2.5 -0.1 ± 4.6 0.2300 0.0016* 0.0140* 
 12 -17.9 ± 7.6 -1.3 ± 6.4    
LDL-C 6 -12.6 ± 5.4 0.9 ± 4.2 0.0285* 0.1046 0.4547 
 12 -18.5 ± 8.0 -0.4 ± 5.9    
HDL-C 6 0.2 ± 0.8 -0.9 ±1.0  0.4181 0.8881 0.9153 
 12 0.2 ± 0.8 -0.7 ± 1.4    
TG 6 1.0 ± 5.9 -0.6 ± 2.7 0.7534 0.2326 0.8699 
 12 2.0 ± 8.5 -1.0 ± 5.9    
Data was expressed as mean ± standard error of mean, transformed and analyzed by repeated 
measures MANOVA. 
*P < 0.05.  
TG, triglycerides 
  
1
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Table 6.4 Changes in anthropometric measures following of consumption of placebo or 500 mg aronia extract/d for 12 wk 
Marker Week Δ baseline  P-value RM-MANOVA 
  Aronia (n = 
25) 
Placebo (n = 24) Group Time Time*Grou
p 
Weight 
(kg) 
6  0.5 ± 0.3 0.7 ± 0.6  0.7364  0.0775  0.1842  
12 0.5 ± 0.5  -0.1 ± 0.6        
BMI 
(kg/m2) 
6 0.3 ± 0.4  0.2 ± 0.2  0.3800  0.0354*  0.0464*  
12 0.5 ± 0.4  -0.2 ± 0.3        
Waist 
circumference 
(cm) 
6 0.0 ± 1.2  1.5 ± 1.1  0.8832   
0.0075* 
0.0619  
12 -0.8 ± 1.0  -1.4 ± 0.7        
Blood pressure            
Systole 6 2.8 ± 1.7  -0.8 ± 1.5  0.3606   0.5179 0.5002  
(mmHg) 12 1.2 ± 2.4  0.2 ± 2.9     
Diastole 6 5.0 ± 1.3 -1.2 ± 2.4 0.0331* 0.6855 0.1661 
(mmHg) 12 2.0 ± 1.5 -1.1 ± 1.7    
Data were expressed as mean ± standard error of mean, transformed and analyzed by repeated measures MANOVA. *P-value < 0.05.  
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Table 6.5 Changes in peripheral blood mononuclear cell gene and protein expression, and biomarkers of inflammation and antioxidant 
function following of consumption of placebo or 500 mg aronia extract per day for 12 wk 
 Placebo (n=24) Aronia (n=25) P 
value Baseline 6 wk 12 wk Baseline 6 wk 12 wk 
HMGR 
mRNA (fold 
change relate 
to baseline) 
0.90 ± 0.06 ND 1.16 ± 0.28 0.91 ± 0.06 ND 0.79 ± 0.12 0.3781 
LDLR mRNA 
(fold change 
relate to 
baseline) 
0.90 ± 0.07 ND 0.93 ± 0.22 0.84 ± 0.07 ND 0.88 ± 0.26 0.9666 
LDLR protein 
(fold change 
relate to 
baseline) 
1.71 ± 0.33 ND 2.47 ± 0.80 1.45 ± 0.58 ND 0.64 ± 0.07 0.0036
* 
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Adiponectin 
(µg/mL) 
13.21 ± 1.92 14.15 ± 2.01 12.45 ± 1.64 12.75 ± 1.54 13.82 ± 1.68 13.24 ± 1.47 0.9994 
IL-1β (pg/mL) 9.33 ± 2.43 9.50 ± 2.73 10.08 ± 3.04 16.20 ± 8.55 17.03 ± 9.67 14.74 ± 7.38 0.4438 
IL-6 (pg/mL) 1.94 ± 0.34 1.87 ± 0.38 1.76 ± 0.29 4.68 ± 1.34 5.16 ± 1.54 5.34 ± 1.52 0.0782 
MCP-1 
(pg/mL) 
97.01 ± 5.78 96.41 ± 5.24 90.93 ± 5.32 132.76 ± 31.15 166.85 ± 42.74 140.99 ± 26.78 0.0679 
TNF-α  
(pg/mL) 
4.36 ± 1.83 4.70 ± 1.89 4.86 ± 1.85 5.90 ± 1.63 6.44 ± 1.83 6.10 ± 1.72 0.5977 
CRP (pg/mL) 2.54 ± 0.60 2.18 ± 0.42 2.24 ± 0.38 2.01 ± 0.34 2.32 ± 0.39 2.29 ± 0.49 0.7222 
sICAM 
(ng/mL) 
97.06 ± 7.19 97.63 ± 7.16 100.12 ± 7.70 96.59 ± 5.40 99.42 ± 5.68 97.52 ± 5.82 0.4613 
sVCAM  
(ng/mL) 
585.43 ± 22.55 603.93 ± 22.86 604.11 ± 25.53 601.09 ± 31.04 621.97 ± 30.91 599.35 ± 27.24 0.5902 
P-selectin 
(ng/mL) 
129.95 ± 13.39 110.66 ± 10.92 130.82 ± 11.41 123.76 ± 11.77 126.60 ± 11.75 144.61 ± 16.75 0.1321 
OxLDL 209.55 ± 3.70 214.26 ± 3.44 209.16 ± 3.97 207.66 ± 3.24 211.43 ± 3.42 206.57 ± 4.41 0.5701 
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(ng/mL) 
TAC  (µg 
VCE/mL) 
210.46 ± 4.51 215.70 ± 4.00 214.49 3.28 221.20 ± 4.51 225.87 ± 4.66 224.31 ± 4.90 0.0775 
CAT 
(nmol/min/mL
) 
41.71 ± 1.36 36.53 ± 1.17 41.65 ± 2.28 41.07 ± 2.13 38.68 ± 1.52 41.20 ± 1.84 0.2552 
GSH-Px 
(nmol/min/mL
) 
2554. 35 ± 
139.90 
2561.51 ± 
133.91 
2468.65 ± 
110.19 
2554.37 ± 
143.63 
2497.00 ± 
163.72 
2654.65 ± 
186.52 
0.8323 
SOD (U/mL) 1186.69 ± 54.27 1192.81 ± 51.87 1158.84 ± 58.25 1181.85 ± 40.92 1160.11 ± 43.85 1160.19 ± 39.76 0.8479 
Isoprostane 
(ng/mmol 
creatinine) 
71.01 ± 8.09 ND 81.59 ± 7.81 58.60 ± 7.00 ND 68.42 ± 8.98 0.1715 
Data was expressed as mean ± standard error of mean, transformed and analyzed by repeated measures ANOVA. 
*P-value < 0.05.  
ND: Not determined.  
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Abbreviations: HMGR: 3-hydroxy-3-methyl-glutaryl-CoA reductase; IL1β, Interleukin 1 beta; IL6, Interleukin 6; MCP1, monocyte 
chemoattractant protein 1; LDLR: Low-Density Lipoprotein (LDL) Receptor; OxLDL, oxidized low density lipoprotein; TAC, total 
antioxidant capacity; TNF-α, tumor necrosis factor alpha; CAT, catalase; CRP, C-reactive protein; GSH-Px, glutathione peroxidase; 
sICAM, soluble intercellular adhesion molecule 1; sVCAM, soluble vascular cell adhesion molecule1; SOD, superoxide dismutase.  
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Table 6.6 Overnight urinary polyphenols and metabolites at baseline and 12 weeks following daily consumption of 500 mg aronia 
berry extract or placebo. 
Polyphenol/Metabolite 
Placebo (mg/mg creatinine) Supplement (mg/mg creatinine) 
Baseline 12 wk Baseline 12 wk 
mean  Q1 Q2 Q3 mean Q1 Q2 Q3 
protocatechuic acid 1.89 ± 0.41 0.94 1.38 2.08 1.41 ± 0.20 0.64 1.20 2.03 
3,4-dihydroxyphenylacetic acid 4.85 ± 0.92 2.36 5.04 7.45 4.93 ± 0.81 2.18 4.56 9.09 
hippuric acid 161 ± 22 104 133 234 208 ± 40 62 138 292 
ferulic acid 5.81 ± 4.57 0.242 0.684 1.20 1.71 ± 0.48 0.233 0.709 3.571 
3-(4-hydroxyphenyl)propionic 
acid 
5.56 ± 1.28 ND** 3.91 9.95 4.93 ± 0.14 ND 3.36 9.68 
cyanidin-3-O-glucoside 0.036 ± 0.017 ND ND 0.055 0.170 ± 0.094 ND 0.00907 0.1993 
cyanidin-3-O-galactoside 0.004 ± 0.003 ND ND 0.014 0.0175 ± 0.0081 ND 0.00466 0.0341 
cyanidin-3-O-arabinoside 0.0090 ± 0.0057 ND ND 0.011 0.138 ± 0.073 ND ND 0.053 
peonidin-3-O-galactoside 0.000796 ± 
0.000547 
ND ND ND 0.006159 ± 0.002571* 
ND 
0.00075
6 0.0106 
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Sum anthocyanins 0.051 ± 0.022 ND 0.014 0.091 0.332 ± 0.136* 0.028 0.134 0.442 
Data are mean ± standard error of mean of n = 24 placebo, n = 25 aronia extract with non-missing value.  
*P < 0.05 by 2-tailed paired t-test vs 4 wk control group.  
**ND: less than LOD and not detectable, assumed to be 0 for calculation of mean 
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Table 6.7 Fasting plasma polyphenols and metabolites at baseline, 6 weeks, and 12 weeks following daily consumption of 500 mg 
aronia berry extract or placebo. 
Polyphenol/Metabolite 
Placebo (mg/mL plasma) Supplement (mg/mL plasma) 
Baseline 6 wk 12 wk Baseline 6 wk 12 wk 
range  (number of detections lower than the LOD) 
protocatechuic acid 
0.0017-0.0042 
 (22) 
0.0010-0.0016 
(22) 
0.0015-0.0053 
(18) 
0.0024 
(24) 
0.0016-0.0038 
(21) 
0.0028-0.0091 
(22) 
3,4-dihydroxyphenylacetic acid 
0.0571 
(23) 
0.0540 
(23) 
0.0407 
(23) 
0.0191 
(23) 
0.0156-0.0335 
(23) 
- 
(25) 
hippuric acid 
0.0968-2.0232 
(0) 
0.0643-2.2765 
(0) 
0.0319-2.3277 
(0) 
0.0362-1.3358 
(0) 
0.0694-3.0580 
(0) 
0.0636-1.2587 
(0) 
ferulic acid 
0.0028-0.0190 
(8) 
0.0025-0.0477 
(7) 
0.0024-0.0300 
(8) 
0.0039-0.1368 
(13) 
0.0035-0.0372 
(14) 
0.0030-0.0224 
(15) 
3-(4-hydroxyphenyl)propionic 
acid 
0.1237-0.1806 
(20) 
0.2107-0.2536 
(22) 
0.1782-0.2059 
(21) 
0.1468-0.1581 
(23) 
0.1347-0.2470 
(22) 
0.2311 
(24) 
cyanidin-3-O-glucoside - - - - - - 
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(24) (24) (24) (25) (25) (24) 
cyanidin-3-O-galactoside 
- 
(24) 
- 
(24) 
0.0095-0.0153 
(22) 
0.0025-0.0316 
(22) 
0.0002-0.0065 
(23) 
- 
(24) 
cyanidin-3-O-arabinoside 
- 
(24) 
- 
(24) 
- 
(24) 
- 
(25) 
0.0069 
(24) 
- 
(24) 
peonidin-3-O-galactoside 
- 
(24) 
0.0001-0.0009 
(21) 
- 
(24) 
0.0005 
(24) 
0.0003 
(24) 
- 
(24) 
Sum anthocyanins 
- 
(24) 
0.0001-0.0009 
(21) 
0.0095-0.0153 
(22) 
0.0005-0.0316 
(21) 
0.0002-0.0009 
(22) 
- 
(24) 
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Figure 6.1 Flowchart of enrollment.   
Assessed for eligibility (n=68)	
Excluded  (n=12)	
¨			Not meeting inclusion criteria (n=12)	
¨			Declined to participate (n=0)	
¨			Other reasons (n=0)	
Analysed (n=24) 
¨	Excluded from analysis (Other reasons) (n=0)	
Lost to follow-up (no contact) (n=2)	
Discontinued intervention (negative effect) (n=2)	
Allocated to placebo (n= 28)	
¨	Received allocated intervention (n=28)	
¨	Did not receive allocated intervention (Other 
reasons) (n=0)	
Lost to follow-up (no contact) (n=3)	
Discontinued intervention (Other reasons) (n=0)	
Allocated to supplement (n=28)	
¨	Received allocated intervention (n=28)	
¨	Did not receive allocated intervention (Other 
reasons) (n=0)	
Analysed (n=25) 
¨	Excluded from analysis (Other reasons) (n=0)	
		
Allocation	
Analysis	
Follow-Up	
Randomized (n=56)	
Enrollment	
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Figure 6.2 Principle component analysis correlation of urinary polyphenol and lipid changes A) 
loading plot and B) correlation coefficients of participants in the aronia extract supplemented 
group.   
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Figure 6.3 Principle component analysis correlation of urinary polyphenol and lipid changes A) 
loading plot and B) correlation coefficients of participants in the placebo group.   
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Figure 6.4 Principle component analysis of urinary polyphenol change in aronia supplement 
group A) responder and B) non-responder.   
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The bioefficacy of polyphenols is often assessed by in vitro cell models. In these studies, 
cells are treated with either polyphenol aglycones or polyphenol-rich extracts derived from plants 
and foods. However, after consumption, human plasma and tissues are not exposed to these 
forms of polyphenols. Table 7.1 indicates the potential metabolic fates of polyphenols in 
humans. Based on human studies, only phenolic acids and flavonoids are present as parent 
compounds in human fluids in significant quantities after consumption. Polyphenols mainly exist 
as metabolites in the human body after consumption (Shahrzad and Bitsch 1998, Shahrzad, 
Aoyagi et al. 2001, Holt, Lazarus et al. 2002, Rechner, Kuhnle et al. 2002, Scalbert, Morand et 
al. 2002, Setchell, Brown et al. 2002, Olthof, Hollman et al. 2003, Rios, Gonthier et al. 2003, 
Sano, Yamakoshi et al. 2003, Talavéra, Felgines et al. 2003, Walle, Hsieh et al. 2004, Seeram, 
Henning et al. 2006, Fernandes, de Freitas et al. 2012, Czank, Cassidy et al. 2013). Thus, the 
overall hypothesis for this study was that polyphenol metabolites contribute more to bioactivity 
than their dietary polyphenol parent compounds. The rationale for this hypothesis is that 1) few 
dietary polyphenols are absorbed intact; 2) for those that are absorbed intact, the rate of first-pass 
and microbial metabolism leads to a much larger pool of metabolites than parent polyphenols; 3) 
chronic polyphenol consumption will reduce biomarkers of chronic disease and polyphenol 
metabolites would be most closely associated with efficacy.  
 
 
 
 
 
 
 
 
 
 
Table 7.1 Metabolic fates of polyphenols (Shahrzad and Bitsch 1998, Shahrzad, Aoyagi et al. 
2001, Holt, Lazarus et al. 2002, Setchell, Brown et al. 2002, Bowey, Adlercreutz et al. 2003, Lu, 
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Meng et al. 2003, Olthof, Hollman et al. 2003, Rios, Gonthier et al. 2003, Sano, Yamakoshi et al. 
2003, Walle, Hsieh et al. 2004, Seeram, Henning et al. 2006, Czank, Cassidy et al. 2013). 
 
Classes Location Metabolites 
Phenolic acids Small intestine NE1 
Colon parental compounds, phenolic acids 
Liver parental compounds, phenolic acids 
Flavonoids Small intestine parental compounds, flavonoid glucuronide conjugates, 
flavonoid sulfate conjugates, flavonoid methyl conjugates 
Colon flavonoid aglycones, phenolic acids 
Liver parental compounds, flavonoid glucuronide conjugates, 
flavonoid sulfate conjugates, flavonoid methyl conjugates 
Stilbenes Small intestine stilbene glucuronide conjugates, stilbene sulfate conjugates 
Colon stilbene reductive products 
Liver stilbene glucuronide conjugates, stilbene sulfate conjugates 
Lignans Small intestine lignan glucuronide conjugates 
Colon lignan reductive products 
Liver lignan glucuronide conjugates 
Hydrolysable tannins Small intestine NE 
Colon tannic acid, hydrolysable tannin reductive products 
Liver tannic acid, tannic acid methyl conjugates, tannic acid 
glucuronide conjugates 
Condensed tannins Small intestine PAC dimers 
Colon PAC dimers, phenolic acids 
Liver NE 
1NE: No evidence 
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In order to develop a more accurate assessment of the potential pool of dietary metabolized 
polyphenols, we characterized tannins and stilbenes in almond (Prunus dulcis). Almonds 
contribute to dietary polyphenol intake, and are ranked as one of the top 40 richest food sources 
of polyphenols (Perez-Jimenez, Neveu, Vos, & Scalbert, 2010). A prior study identified more 
almond flavonoids and phenolic acids than reported in prior studies (Bolling, Chen et al. 2011). 
This study demonstrated the need to more thoroughly characterize specific polyphenol classes in 
almonds and other foods. Accurate compositional data are needed to understand polyphenol 
bioactivity and metabolism. Almond phenolic acids and flavonoids have been well-characterized 
(Table 7.2) (Milbury, Chen et al. 2006, Bolling, Dolnikowski et al. 2010). Eighteen flavonoids 
and two phenolic acids, a total of 25.04 mg/100 mg, were reported, which were catechin, 
epicatechin, isorhamnetin, isorhamnetin-3-O-rutinoside, isorhamnetin-3-O-glucoside, 
isorhamnetin-3-O-galactoside, quercetin, quercetin-3-O-galactoside, quercetin-3-O-rutinoside, 
quercetin-3-O-glucoside, kaempferol, kaempferol-3-O-rutinoside, kaempferol-3-O-galactoside, 
kaempferol-3-O-glucoside, dihydroxykaempferol, eriodictyol, naringenin, naringenin-7-O-
glucoside, procatechuic acid, and vanillic acid. These two polyphenol classes would be expected 
to contribute a minor portion of parent compounds and a major portion of phase II metabolites 
and microbial catabolites in humans after consumption (Table 7.1). Almond also has lignan 
polyphenols (Table 7.2) (Smeds, Eklund et al. 2007). However, lignans are extensively 
metabolized, and parent compounds are not observed after consumption (Table 7.1). Although, 
proanthocyanidins (PACs) in almond has also been determined (Gu, Kelm et al. 2004), almond 
PAC content may be underestimated because solvent extraction does not completely liberate 
polyphenols covalently bound to cell walls (Arranz, Saura-Calixto et al. 2009). Furthermore, 
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almond stilbenes and hydrolysable tannins have not been determined previously, and may 
significantly contribute to almond polyphenol content.  
The studies undertaken in Chapters 3 and 4 expanded the knowledge of the polyphenol 
content of almonds. In Chapter 3, bound PACs were recovered from almonds that contributed 3-
21% of the total PAC content among three almond varieties. Also, a significant quantity of 
hydrolysable tannins, ellagitannins (27.4 mg/100 mg almond, ellagic acid equivalents) and 
gallotannins (54.7 mg/100 mg almond, gallic acid equivalents), were characterized in almond. In 
Chapter 4, we report the presence of stilbenes (8.33-9.55 µg/100 g almond) in almond. Polydatin 
(resveratrol-3-glucoside) was the most abundant stilbene in almond, and piceatannol or 
oxyresveratrol were also tentatively identified in almond. To our knowledge, these were the first 
reports of both hydrolysable tannins and stilbenes are in almond. Thus, this research has 
redefined almond polyphenol abundance, with proanthocyanidins being the most abundant class 
followed by hydrolysable tannins, flavonoids, lignans, phenolic acids, and stilbenes.  
Hydrolysable tannins and bound PACs have limited bioavailability and only their microbial 
catabolites are absorbed. Stilbenes circulate mainly as phase II metabolites.  (Table 7.1). Only 
dimers of extractable PACs can be absorbed as their intact form in the small intestine and colon 
(Holt, Lazarus et al. 2002, Sano, Yamakoshi et al. 2003). Extractable PACs have degree of 
polymerization more than 2 are metabolized in colon and absorbed as phenolic acids (Rios, 
Gonthier et al. 2003). The metabolic fate of bound PACs is still unknown, but if liberated in 
digestion, these would also be subjected to extensive microbial catabolism. Hydrolysable tannins 
are metabolized by colon to corresponding phenolic acids and colonic metabolites, such as 
urolithins (Seeram, Henning et al. 2006). Similar, only daughter compounds of stilbenes were 
found in human plasma (Walle, Hsieh et al. 2004). Thus, PACs, stilbenes and hydrolysable 
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tannins constitute of the pool of parent polyphenols compounds with limited or no 
bioavailability. 
Chapter 3 and 4 largely support the hypothesis that few almond polyphenols remain 
unmetabolized after absorption. Although the polyphenol databanks such as USDA databank and 
Phenol-explore provide comprehensive database on polyphenol contents in food (Neveu, Perez-
Jiménez et al. 2010, Bhagwat, Haytowitz et al. 2013), these studies developed a more 
comprehensive understanding of the almond polyphenol profile. Many nuts, berries, and other 
polyphenol-rich foods have not been well characterized. Utilizing a similar analytical approach 
can likely improve the compositional data for other foods. 
Next, we hypothesized thatplasma and urinary polyphenol metabolite concentrations would 
be greater than bioavailable unmetabolized polyphenols in adults that consumed a polyphenol-
rich aronia berry extract,. This hypothesis was strongly supported by data presented in Chapter 5. 
The polyphenol profile in aronia berry supplements is listed in Table 5.4, which contained 36.9 
mg/500 mg phenolic acid (neochlorogenic acid, chlorogenic acid, protocatechuic acid, and 
caffeic acid), 9.9 mg/500 mg flavonoids (quercetin, quercetin-3-glucoside, quercetin-3-
galactoside, and quercetin-3-rutinoside), 45.07 mg/500 mg anthocyanins (cyanindin-3-glucoside, 
cyanidin-3-galactoside, cyanidin-3-arabinoside, and cyanidin-3-xyloside), and 41.9 mg/500 mg 
PACs. Previous studies suggested quercetin aglycone and glycoside consumption mainly 
generated daughter compounds such as quercetin-3-glucuronide, methyl-quercetin-3-glucuronide 
and quercetin-3-sulfate in plasma (Day, Mellon et al. 2001, Sesink, O’Leary et al. 2001). 
Chlorogenic acid ingested by humans is hydrolyzed into caffeic acid and quinic acid (Plumb, 
Garcia-Conesa et al. 1999). Only 1.7 % of ingested chlorogenic acid was recovered in urine 
unmetabolized (Olthof, Hollman et al. 2003). Caffeic acid is an intermediate metabolite of many 
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polyphenols, including chlorogenic acid (Table 5.1) (Stalmach, Mullen et al. 2009). 
Protocatechuic acid is an abundant metabolite of anthocyanins (Vitaglione, Donnarumma et al. 
2007). Anthocyanins are extensively metabolized to phenolic acids, phase I metabolites and 
conjugated anthocyanins, and more than 99% of the bioavailable portion of anthocyanins are 
metabolites (Czank, Cassidy et al. 2013). However, it is unclear the polyphenol metabolism 
profile in human consumed polyphenol rich food. Thus, in this study, polyphenol metabolism 
and pharmacokinetics were determined in adults that consumed an anthocyanin and PAC -rich 
aronia berry extract. 
In Chapter 5, after former smokers consumed a 500 mg dose of aronia berry extract, 
polyphenol metabolites constituted at least 99% of the total polyphenol pool measured in plasma 
and urine. This is likely because the aronia extract had abundant condensed tannins and 
anthocyanins, which are highly metabolized (Sano, Yamakoshi et al. 2003, Czank, Cassidy et al. 
2013). This result suggested plasma and urinary polyphenol metabolite concentrations would be 
greater than bioavailable unmetabolized polyphenols in adults consumed aronia berries extract. 
The Cmax of hippuric acid was the highest among the studied compounds, followed by 3-(4-
hydroxyphenyl)propionic acid peonidin-3-glucoside, cyanidin-3-glucoside, and protocatechuic 
acid in the plasma, subjected the concentration of polyphenol metabolites is higher than that of 
the parent compounds. Studies utilizing isotopically-labelled polyphenols are needed to more 
specifically track the metabolic fate of polyphenols. Also, this method can be applied to other 
types of polyphenol rich food.   
Our hypothesis for Objective 3 was that chronic consumption of polyphenols would reduce 
biomarkers of CVD risk and that increases in polyphenol metabolites would be more associated 
with modulating these biomarkers than unmetabolized polyphenols. This hypothesis was 
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partially supported by the results of the study described in Chapter 6. The aronia supplement 
significantly reduced fasting plasma total cholesterol in former smokers after the 12-week 
treatment, and reduced plasma LDL-C level by 6 weeks of consumption.  Peonidin-3-O-
galactoside, a phase II metabolite of cyanidin-3-O-galactoside, was associated with lower plasma 
total cholesterol and LDL-C in the aronia supplemented group. It is presently unclear why 
peonidin-3-O-galactoside has more bioactivity than cyanidin-3-O-galactoside, and further studies 
are needed to resolve its potential cholesterol-lowering mechanism. Despite changes in 
polyphenol excretion after supplementation, the increase of total urinary polyphenols from 
baseline was not significantly different between the placebo and aronia-supplemented groups. 
This implies that the bioavailability of aronia polyphenols was insufficient to lead to  significant 
polyphenol accumulation beyond the background diet. Also, aronia berry supplement 
consumption did not change biomarkers of inflammation and oxidative stress, which might be a 
function of the participant population having lower oxidative stress and more favorable plasma 
lipid profiles (lower plasma LDL-C, TG, and total cholesterol and higher HDL-C) than 
participants in other trials where aronia intake improved antioxidant function (Naruszewicz, 
Łaniewska et al. 2007, Broncel, Koziróg et al. 2010). Future studies should consider examining 
the specific function of polyphenol metabolites.  
Thus, this dissertation supports the central hypothesis that the sum of polyphenol 
metabolites is more responsible than polyphenol parental compounds for in vivo bioactivity. 
Also, despite efforts to databank polyphenol values, there is still a strong need to utilize 
analytical chemistry to define the polyphenol composition of foods. The polyphenol contents of 
foods may be more abundant than previously reported. Large interindividual differences were 
observed for polyphenol metabolism in Chapter 5, which is informs the new field of personalized 
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nutrition, as individuals have apparently unique polyphenol profiles after consuming aronia 
berry. Colonic polyphenol metabolism and peonidin-3-galactoside were related to cholesterol-
lowering activity of aronia berry polyphenols in former smokers. Although we cannot suggest a 
causal relationship for these compounds, studies of these compounds should be pursued to 
identify their intrinsic cholesterol-lowering activities and mechanisms.  
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A.1 Appendix Materials for Chapter 3 
 
Figure A.4.1 Chromatogram of blanch water  
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Figure A.4.3 Chromatogram of almond sample under different condition 
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A.2 Appendix Materials for Chapter 6 
Table A.6.1 Baseline characteristics of nutrients intake 
 
Nutrient Placebo           Aronia             P-Value 
Macronutrients   
    Energy (kcal/d) 2225.6 ± 734.8 1952.7 ± 525.8         0.146 
    Carbohydrate (g/d) 237.9 ± 9.1 241.1 ± 8.5               0.791 
    Protein (g/d)     89.2 ± 3.3 90.3 ± 3.1               0.812 
    Fat (g/d) 
    Fiber (g/d) 
Micronutrients 
   Sodium (mg/d) 
   Calcium (mg/d) 
   Iron (mg/d) 
   Vitamin D (mg/d) 
   Vitamin E (α-tocopherol mg/d) 
   Vitamin C 
   Vitamin A (retinol equiv mcg/d) 
Polyhenols  
    Isoflavones (mg/d) 
    Flavanols (mg/d) 
    Flavones (mg/d) 
    Flavanones (mg/d) 
87.8 ± 4.0 
23.5 ± 1.6 
 
3490.3 ± 156.1 
946.5 ± 58.2 
16.9 ± 1.3 
5.0 ± 0.9 
10.6 ± 1.1 
80.9 ± 12.9 
3278.0 ± 738.0 
 
3.86 ± 2.7 
73.9 ± 20.0 
54.1 ± 29.1 
28.8 ± 11.4 
77.6 ± 29.5             0.553 
21.0 ± 1.5               0.282 
 
3479.7 ± 146.2         0.961 
1066.8 ± 53.2           0.139 
16.9 ± 1.2               0.974 
7.1 ± 0.8               0.109 
10.8 ± 1.1               0.904 
90.9 ± 12.1             0.579 
2688.5 ± 691.3         0.566 
 
8.5 ± 2.6                0.233 
81.7 ± 18.7              0.779 
50.3 ± 27.2              0.924 
22.4 ± 10.7              0.686 
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    Flavan-3ols (mg/d) 
    Anthocyanins (mg/d) 
    Proanthocyanins (mg/d) 
20.6 ± 7.4 
18.2 ± 5.2 
221.8 ± 162.4 
26.0 ± 6.9                 0.601 
26.6 ± 4.8                 0.247 
417.9  ± 152.1            0.388 
Data are mean ± standard error of mean of n = 24 placebo, n = 25 aronia extract with non-
missing value.  
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Figure A.6.1 canonical discriminate analysis based on respondent 
 
